var title_f25_50_26400="Side lying position PI";
var content_f25_50_26400=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71497&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Side-lying position for breastfeeding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The side-lying hold allows the mother to nurse while lying down. When using this position, there should be no excess bedding around the infant. The side-lying hold should not be used on a waterbed, a couch, or a recliner because this poses a suffocation hazard to the infant.",
"    <br/>",
"    To nurse from the left breast, the woman lies on her left side. The baby's head and body lie parallel to the woman's body, with the baby's mouth close to and facing the woman's left breast. The woman may prefer to have a pillow under her head, with her left hand between her head and the pillow. The mother's free hand (the right hand in this example) supports and guides the breast to the infant's wide-open mouth. The thumb on the free hand may be placed on top of the areola and the breast supported with the cupped fingers. Care should be taken to position the hand away from the nipple so that the thumb and fingers do not interfere with latching.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26400=[""].join("\n");
var outline_f25_50_26400=null;
var title_f25_50_26401="Normal gallbladder EUS";
var content_f25_50_26401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radial endoscopic ultrasound image of a normal gallbladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 317px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE9AUIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDE0yK1QQolraSjI86Ux5wPXB60l82nzufMtICkf922Cn8x0qa1Ty7VYpPklmXBjbhvy61noC0kiIC0Y+8wGQvpk9ucUAZki293c/ubMYHAB4/Gug0nTdMtpVm1CJLidRnyniDqo/vYPftn3rLZha3AcAu/QIOSc+1bFhbyTP591mHK4Mcg2kjI7GgCbV7iymLNpujWhLDa7G0XAHbH61U0zSrZG82+t7XyjyV+yLxVe8uWW8KxMEtIvmwTgHPpRbi61KR2R/8AR0xj0Gc/4UAaGo2tm8Zb7PaiAcLmEJx+FQR6TZ3Vvi3tEESnJKqQM9/6VZtFmuJxbsii3QctJwM/U1BqWpYVoll8hEO3hvlb6H1oAz3gsUMiNbIzKMHBzTLC70+1RhJp9q5HEZZcn8ajE1u8m6BWjA5ZnGN1XbDTn1iZ3s1jht4/43OA3rz9c0AULyD+05UZraJA/wA2AcAZ9Pas6XTTb3B226tjP3TmuxbTltpI1jHnSSDO48xp7Z6YqaLToVDNJNEnJBYuAoPfmgDAOj/aMkwWmO/yGtLRtMsLaPK2ltOOodoyCPercmsaVb9JG9uayRfSyyNK8yrAR8sZcA/Qe9AG3NaaVBGzzxWiI4+ciPcQPp3rmrm6sbaSRrPTraUA8ObUKeeOo571PJPdg74LCNx1DySZ/wD11ZsLmFpFa6t8SDPEYyOhoAr2sEd2vmHTrZOOog3foazrqxtBMfNgiUdvLtFBzXWiC+dTJazGCIjGWUkc9qWw0K+lbfNBNcjOf+PZgAfXOP8AOaAON/slZuMFVHTdEI/5daZNoTpt2Rb0Od2f8/WvQrjR5Ecl1h+UZ2k8iqqTmUPCfI2rgEhhkdaAOETR4w422mH9xin3OlXayAeShi2jgH616Bc6fpiRIz3e59vPzjjnpWbm1SRo4cv8ufU/54oA4eeyjiTc1oC3fFU5P9UCEKL/AHcdK6PVZGVnCI4Hpg1j4upYmUKgXsG4NAGGh/fPz/Ef50h5LYBPJ6Vpi1lRQHjiyBgk0zZGTiKRIm75YDmgCuSOeRUFp/rHz6UTqWxtUt9BmgH5xjkg5xQBY27uCOtH2UP8vrUclwQpB4OO9TW10IwGkHyDr/IUAVQnlXAXGB60+8IJXBB57HNTTx/afmRgy9dgOT+VVzD5Z4HPpQBIih1AJAx6mmzR7NuOQfTmmeXu5YYxyMinwzH5kAOOKAGBM/P3Xil3l4iTwQcVY+zMx+R1Ge2ahmjaNvmO7jqOn0oAqHrUqfcHIpjgsxI5HqKbtP8AdP5UAKwO5uO9NqdOFUewqFvvH60AJRRRQB6tc/v3Ro2+cJgEdjWPqbyyxmG1zHyN7D6g/wBK32MVraQGQgXPliUrjOR9en4Vzmo3pluQtqmUP3z0x+dAD2/0ZUkfDuPWr9vLJcfvZXMasNoz6/5FZ39mrebJvOYBSCRg1rrNFIEQgIV6LjrQA17J0ikZGVjIMDNTW8s1laiJkUtN/dxxj/8AapLrzRGoEnlqOvGd1U52WG1kkUN5jY2nru6/l260AFxqMthbyR8s8rbh7DGMfpWdFbfaE3XUwRGYkE+vpWisLy2Q+0R4d/mBJ7UWunW4dfMnOAfugE80AJpGgXV1qgRYpGtY8MXGMMMZrq9SuIdPKW9hDiJuCwH+femx302mWWLcqCwx0zWSgvLx3lnmCljlVAz/ACoAtrcvHMosoHkdOGJ5BNaFvoGpX0nnas6wwt8wjXGSDyOlR+HrW8WdmRgjZ5cgHJ9cVvW8N3cStliSGPJYLnn3oA5S90qCOYRwRC4cclVx/WqS2qLds3kn5+FTGQpPQ1097o0Vhia8uCh6EfeJ9uM1O+rWMNoILGxES9A7cn8utAHJ2ul6heXDK2EhB6dMitK+0waaYVeLO/GTxxSPcXZnaTzdsQ5IA7UPZ6hqbL/rAB91gM/pQBvi5gQwwWwRiVz0OOKfNcTIqiZ9qZ4VAc5/zmr3hfwxeXeEvDtCdSSAf516Np+gWlu6KkRllA5zGcAcc5xj0oA8Vndr27MUNrdMR1YKQOfrWvZeDb4wvMrAxnBZcYI64/rXsVzpL7gfMto1H3RtANZU2pw28pt7m4gYd/4cf40AeWT+HrYwOA7RlWwwfufUVXexg06MBI/Pc87h2Hp+leqXg8PXCqrzxGVugGar32gWL22bcL93OMigDxHxG0B3Yg2AgfN74rlJbVfK3xzDPcelel+NNJWKHCqNx6DIrz9Z7VYWjeEs44J6ZoAwp3fG0fNjjPrUZtjgErgkZq7KYRI38PJ+XBOPaqdyI/MCeawY9BtNAEdykajMLBl9RVGOKTzWbYdvXNWZJFWHaxwfpUFrI7gIOS3y/nQBDMjMflUmpbbaThhu9RU7RtEwMowo64Of5UkCKNzL+FAAjl5fKVfL77v6U64YLiJlw4Oc+3+TUDRiWXazsncEAnn04qzBaGQFZyQQMg4zmgBkSBtwb04qN4GhO9lITuasQ2UsMjseUIGORVuVVKqJeEOff0oAzg7eYhj5Xb1H1qvM7iXZKCueRnuKlmJSX93/AKsdDUVw6zKGU5ccdKAFeJk6D5fWmUoM7Hp8mODuFDDBIoAaWUHkioijEnCnk0j/AHm+tTjqB3IFAEAUkZAOKKtBzgZTB9MjiigDsJ7mS7XzmJBC7VHtUdjFmPzpB8rZA9auW8OYI4wuS3AI6UkTJ9iSEgq+/GT060AP0+YQvukVxGO+3v2q28MU959rkLRkLgDHB5H+FSRf6XdJbBP3KYZgBySOmK0dRtYnY+ZiK3RMqD1Ldv0zQBi3t79oV4o+NgyC3GayY2uHlSNpMLzyvI/GrkCxXV4YY8gZ6npW3Y6VCl2sTMrIeWI9umP1oAhsrW+uF2Rr5sY4yeD+HtVuRItBdXmhE07/AMI5wP8AINdBNr1lpEHlQIVnxhSwGMfnWJbxNqlwbmchm3fp1/rQA668y6KOIxGjYwDxitDT7aKFg3Lv/EF5Aq2Ld7kRqVVY+gJq9JbraqttYI0txJxKw+6p/n0xQBJDdw2kTO5RQ3NZWoa3LM/l2y89iOhqvc6b9l1NU/eXEoOJE/h3d8e2avQWflLmKBjM7HC4zjnpQA1ECuZbxzeT9NhqrBoWo3t15ht2WIcjrn8sV6F4Q8EXLSfa7wR7/UkgH6ZFdzdyaXoEavcuAxOVBIoA8o0rwM11JG1xLKvzcjFd7pfhe1sbX5rsR7cHceorI8U/EuxtYZ44JYV+U85y1eR+JvifI6y/ZpZZHPQBcA8igD21vFmkaLJcK80UpyMFiBXNan8Vw1w32GaCOMDAzg180aprNzqEjtPvYMc7VPNUleZYgCuBngk0AfQ1z4/ad2Z7mOR36YbpVabW7O4WOS5W3kcZ6yY9OlfP0ssvGGIx/dNC3E3V5ZSR93BoA95v9Y0z7MWit4UlXgEyc/hUWm+Kb5BhZY/I935z/nFeFTXUkm0yzOGHC89q1tI1R2YQF3KDnP8An6UAewarfC8gW6eRWYAhlBz7DFeWajcCS6kEQZWLfxDArpdFu7L7O/mSOrc5V/rWDrMK3DPLasoUHOTnmgChHG9vLuYq0jckZyM1PcW+YixC+aeR6VRtRIZg0jKQK0Ly4RHVHVgCB83GOlAGVPaysDhR0PeqtkGwrBGGPmwRg1tLdSOD5ZVuO1Q25kDoZo8kEfd+tAD7YLKV81WAJ5JFW0sgXBjUNHznH0p8qTxp5yImxRnDZx+NIYpGhjuS7jccYj+6PrQBVuIRArShOR8oB963vDluLq2IuI9r4+U9j7Zpn9n215sa3eQz4+4/f1NbOhm8sLpIp7UNCvzE9uo6e/8A9egDM1PSpIo5CEGAPWuZlSRVAkGOuM16jrJtp3NxaSFMjDxy44+mM15rr0jyXQ8sYRc/0/woAyZ4mA/h/OqYypKlWPfIGRVwyE/KwOTUb3DWq+Wy7kY7sj34/pQBAd4Py4xTQ/OGBBHU44qwUErFo+Fx0NJHiVvKfAC8ZoArshJJGMH3qaONntWQY84/dJPH50OgSZ4lPCDIPtToJQmCQTnB4oAaSCSR3oqPcB3ooA9O09Macsg4kx8vHQ0lrBAIM3LDKODux6nGMVNYeX9likdysMfLHHao4o1vPNC5MeQQD3wc/wBKANqM2dpG8oGydyNqnnjvWLrZuNRQrBnCHeR7YI/qKl2G+vIwoy6DH4d607kxwKLa3GHP35O+30x9cUAYkVklnBkkCXaGJxRZ34WUEklunWodbuleYQoWJxjdjrT/AAzpE8t+vmqTF97ce1AF37M0zmR1ErM3y5HQeldlp1i9rZJNNEBk42gY4wOa04LW0js4GMWCWxnFJqWo+ZOEjgd4o1CfL0JGf8RQBXtLaO7ukRUdsnkK2MfpXZ2+lRWYQHBRhym3DD6t3/KqvguNbqYzi0MKngZOTxx/Su0hit28ySfO2H77kUAcnH4ak1i/PlReRbRsVEjDJwOnpmtxU0Pwtbx7wkk6nlz1z3rm/H3xN0vR9Pe3s5m3LlCU4IxxxXhviXx7ea6yR28nldNrBtx9ieKAPVfGPxWaOMx21zHbqR/yyO4/nXi2seNNV1Vzb/a2dQuDIx3ZGOa5rL4AVSo6cndxTJnWAeXBEMHjduoALq5UzAzyyNNn5SDjmoPMkmVsTuyjrGRnd/nr+FT7YcoHj3yscLnjmtC1tDFC0sabX4wcZxzQBjIJFYEIw7cirk8c8iJGF3Hdn6cGtURO4HmyZGc7doFXo4V++ODjAGKAOb+wSo6qwzu/SnTWTQqTJxj261p3S3qy+aYl2Dp81JNi7h5cg9xjOKAMUbVKglAW55XNP8phIjqRj1C4qytpiZG271UYJPFabRpcQgRx7AOOOeaANnQp7MwFJo1EmOpNN1GwZbKW4jZBCWwo/wA++aoWVk0jIFdVYHucZraa2WSKWC5OEyD8pyOgoA5Z7ZhBkHlRjp973qFo7kwhZ7fzc42kSBeO3Y12I02KRITHIqxqoCg9xjjNRP4fNwjNFMucnjOBQBxFosyQh4FIP93rWnFBdsEY/ICQOVzjmty1s1tLrCL5x/usNv8AjXWf2at1b7ljWNRzkc0Ac9YRCW3EE7qdwwRjGat6PYMsTRHZ5aNnJGc/hWfPZyHUfLLMqBuMDrXTaNaL5R3jyiOjE5zQBo2Gjwz24aOIGUEfdGDjvUGr2MlqC3mYGMbSvT36+1dLo1sEtspcgHPVRk4/OsrxXcxKJYiS4K8OBzn6UAeZXly/2t0ViAerZ/pVATweZJFLyz42t6468fiKdqWQuyFXZ2Y5LDGBUFratDNE91EpUA4Ynp0oAyp0AuG3EptOB8uc+9JcKj2vHJBPJGK17+Eyh57NwY1+VgV79f5YrMbdI/lTHbxncB/SgCnZvyUx7ZzRLAVlbbIOvXb/APXqdIBGNu45yecVDNKsUgVyT70AR8rIxJydmz/69JMPJjXHz/KOBx2pXIMg2nKtyDTgrbC5Gdp4BoAb5btyGUg852//AF6KjWBEUII3wox/rD/hRQB6FA8lxdW1rCF2Pu3DnHBrbeLyo1ig2iQjBxWUbT+z2R4y32iYFEyc7S3NakFqYLYyMW3nqSfegCzptv8AYbdyCGdurNyR9MVDM7BiQqlieSfSrNikbRtLMXyAR97AqFFM0yiGJsluSemP84oA0bOztWthLcxDcOQV7n3zW9oy2808aIGRSCCVxxVCeJoLONEAYscAEZxWxpyi20/ywoMs2MkDkYz09PvUAamoXUHlRW1vGrLD8pZupbPt/hWl4a8MCbffX6IIN5yMkHoP0qtp2gyXEIuLs+VDGfXBbvSeIvGFqlk8QkMUMCYABxkjPP8AKgDodT1rSvD0LyR+WkJHyg/r39c15L4++KkS2b2enTbXuOOM/wCNeb+NPHDa83lQErEG28DHTiuTmkYyqYwrBepYZNAGxPPJI4N5K0hf5m3dMn0qtKYobgGIAd6qTXQlCh1JCjAK8ZprneQzZ4H6UAW7p/L/ANUFYf7VO0zT2vlGNyg8Z4yKXTLS4nlIlAIHoMV1mk6fizMsrCMhSxAOO2aAMJYI7XMUkYYr0fHIq8lxGLdgqZ6dfrUyW8kk8oJRkbhcjn86mt4RI+2KA/L1B/i+lAGXw7jAIP8ASpopDLOYoEJAXduYe4H9a2f7LuHRiLYgY6g4ret9DitdOhdfmlkH3e4Prn046UAcjLZXLxHkkdwf6VnGBl/drC5b1X+tenRaIJrNCzbZQTnnHFUrvSEgiZnlVT2x3oA4CDTLvdu2FV9D3q48fkqBhUPoR+tasM0sTvsYSAN/Eua1Uez1BQWt9sijDE9OP/10Ac2tkJkDjOT/ABLVvTdPujKyBJJIz0LHrWrNcWKmOKFWifOCDyK1be0mjIkt3Yg9DnigDOh09VlWKVCoHB55p2q6XJbJCloBiU4yx5H5YrZntrnYk0gG5lDZx1zTGJuLy3jztCYPPrQBh2tmBdm5+Ysf4Tjb/j+tT3lxIYlWByi/xjuF74/CtO1tiBncvrWZJay3KzTgfOGxheBj6UASadLbSgrIGJHRu9WzOLseTHGoHsDzjn+lZ0CSWyMdoJx0xXVaRpwjszczyxqSODj7ueOn44oAl8PwxCzlJYrKAcc8VyGt3cltM8jqHQNj5evf9K6O6SW1sZ5oz+7zjfnjn2rze/1jzBNGwbcTjIoAr3OrrdXD5hCKOhIqjdwTXCfLI/l/xcjI+lQPbSlISsnyFz161qhNkKqrZLdaAM+0tg1sywyS5V8MpIwTjr0pupadLKY5Ih8iqFbHXIz/AI1uw2ZtIklVkJduR+FJb3sUFxKJo2aFmKhR1z/nFAHMSxF5yIwduAOeucc1JLozXNuGKHjoR3rqTpiM4lVGCOcjmtB0FtZkKo2KOMjJoA8xltGgYearhU4GO9TB0GI/4SM5711Gput3boiIgYAAkrXISxASvnO5SRwaALRhOTkUVY8/1I/KigD0kWTzy/bZRnYdyr0/lWvfWqpppaYhWIG0fiKNFuE1EIjAR+TGGA/56Gr2tWMl6InJLQx8Mp6Ht/MigDLi09TZQxl/mk+br1xW9psEVlaFZdrPjjiqUunvti2fKycKR2Fa8en4t1kudzFjsz39f6UAUd6ySI0Aw5OGPXj6HgfhXYeGNDEt9HNcMFtwN0mTwT2+nfpWXpukW6zBmQrH3Zh92k8Y+L7XR9IltrCVJCxAZs9Mf/rNAFj4j+KbWOFrK0nCRRnaWXGPpXzr408Uz6jK1pCxMScZCqM9e+Ki8S+I7m6uZoMZgZt5Cnjd6/WueRmwxLHJNADhtEQKEZ7rinQRuIuBt3dQeafp9ur3LttFW7hHLqiMVbvigCtASsiRcbQAMYFXrCxM9wVlXdHk8dOPwqNLKT7QpOSe9dTplktraNNNJl+oJ6gUAW7K1jsGJunBb16VUuZ2vXkhibaiKfnHQ8Ul/KtxxN8+eOak0u0SY/Y4/NVz8mfrxQAsUTQpFsyWzw/p/SumjiW5tYyoCuo5YcVPa6NEkcKO4AU/Ofal3QWqyxRJ5meAB1JoAfAiOPJnlLR4yRnbnHuOa0BrFtaW+xLfzDGvyjJNZFjpVzenAinVkyGYDkntWvYeG9SSYsY0MZXA3dc5FAFJNTa4HneSw3nHl5I2+9VQ9zNdMnkMV7AjNdtp3hiRbhZJSgLcELWnDpEcd8wVgMY7UAee22kXlzd5FqBgYBPGP8a0IfD0ke6KeKVjkv8Au+nPv+Fd68At5/3qiRCv3j29qzZYtm8RsSzHIIPQelAHP2fh2G4+ae3LMvTeSpH5EVqpbR2sCo8GQgx1Pr9aaZL+zyySyeV9aadTmlQbwWB7GgCS6Kz26Ki4UKAB6DFVYdIimEzSEG4VQUYMRt/AHB/Goxcy/asKmFJ6VoWtxC1z5ciLHK3BbuaAOWW0k84LCSqfn/OluZlsiUg3tG7cjbnNad6ZrR/Ot48xn0qrHdkSAXAleKQ7MOOOeP60AMlWIpBNGgWTOcZJz+dXbbZBZzG6RgGAwcnjkdulRQWP2i9jkSQlI23BewrV1KaN4liWNWKjketAHM+JJ47fS1jSZ1MvJz0+tefX1s6lYxIrK6bw+0ct6dPQmu68Zobyxt4nRVGM5bpx2rgxKyhLeSMNEjblCdjyP6mgDOXeGEMoOVOc9M1qLFBHCWdio/u5J3fj2x7etNlVJ3ciNgygHLU9VVESSfc23OMe9AAXSJUMUjSqTkIeqmp0gdphI5DBvm6Dj2qK8tdsAvbIMH6YxyfetTQyu4Lc/vdwyQ3YmgC9b3KG0FqI8zZJQ+nNNug14r26DyTHw2ed/Ge9XUs1huY2iUrcDkHsAannhRb5TLHHuQjfjoTjNAHHajYPFbEKMMnFcw1ohnwz9eT9e9eoatbxXcly0TBEYFwo6DNebatYuJwFzD/tL396AAWKEDKf+PGikSS62L+8c8dfWigD0zTpBaQwOirvEYIIHOa6TTpbiZVtJN/BDOSTkjtn15xXK7jdXShPvGMACuq8LWM7awA5+XjPNAHT6Josl1cSZYuAwwCc4H0rX1+70vR7VhcRgsBgKqjhvX9D+daOoXw0+GUAAbcdBXiPxH8Rfa7adxkfNj9DQBq+KPHO6NobWZY0CZ2r8ufrjrXiGua1c380sckmBn5djEZ+v6VW1C53ThsnlRVXzBJyB09qAF8wMoCgAgYYj+I+p9adFEWbI4HpTKtWEUzyExjK9PxoAsWkLLPhSR04BxVma1kkmYIzKQeoJB6UsCukeJB84Jz+dWI4QzxtGT5h680AXNL0yVhGXd2bA5ZiSa0bq3eCM28pLFuQHOf51PEGtdOYL/r5Bub2J61XViI7VmOSG5yaAC1jtH1K3RklYEfdY5z+FdRp9sFvCwwrZ+ZlGD9c1W0zRjm1t/4gOveti6Jjijt1GHBGPc0AJdTmQmG1VWboSR1+vrXReGfB8jPHdXnyKSTkduDj9a1vBvh5TCs8uPMc8fWu2uolsLAySD5EAz+JA/maAM2K0itf3MbBNwyzrwWx6kdahdoVZgMO2OcjNZ66vcmdhZFQTnBYZ4pLa2u5r5JJJAzP8u0CgAFxtnbGR9OKL24CGNo8ByDkjqenWtSx8LXMiuTKE8xjnPpVy80iws4VW8mLtH0x29f6UAcs11cTIVkifk4G04z9a19M0iS5wDDsUjqRzUl5qdnFFGtlgoB82R3z/hUM3iQWqD6ZoA0X8LM9qFWQuMngnPesT/hFriG8KoN+88KRkD6DtSw/EaOFzEVBxz+dSTfEXT3kRXUwyd5OxoAp694RvoIxcW7MCOSqnAz+FcjIlzHd7pBvccZJyQa9Z0jxdpupR/ZxcBnIxux1qrqej2Gq3Crbk7h1wMZPegDg7eaF5WSeVlUDhM8flVmDTjf2jvwVVC2OoGBTtY8N3+nXQ8y1+02o53A4IrW01/JIuxggnd7Hn0oA5DSYn0/VlWSRmSR8BS2R+VX9fjZZY5LSNQ+M7VXGeOc49s11mt6NDdRRXlp/r2+Zh2FZrWC3Fjbhz+9RiKAOS8VWT3ul2sixpuAwUCjB/CvO4NNuIbqQiMLwegx3Fe5+NbfydJtFGMlQOK8xtraSO8eJDlsFjnnjIoA568WHy18yZlfnoxGaymeX5/LZmiRSSC2R7cfnVrxPBcfbyQBwadZyTGGMsF2oCDx1z/8AqoAbYa3ixi86JCo+XLKDV1o0Vlurd2VSoO1TgZ9cVh38BgLG3wVlO9gex6f0q7o7uX8uQfNjPtigDpdK1KfUAYNpZo+STycdq07Ih74Qzxph1OMqDn3rlIpbix162dR+46/X1rsjcJexvLAP3jc9Onb+lAEVxBFbIYdiFiMBioyR9a5HxbYC3uotm2TKg7W5HT0rprWa5jugjAEr8vPNW9Zh+0ovQNgc470AeZLAQoAOAB0zRXZLplrtGyzTZjj5u1FAF3RVa6vI4YSTEiDIHPFeq+E7ZUuJLuYFVgQld3G7gjjP1rmfhfoiyXRnkRvJRRubHAOOmau+PdVGlaVsinWNQw43DP3h0oA5z4ieKoYxOFYJ5zAswI4xng14Vq+oi6mJDM53Z5X2NXfFesLqV43llxHnJDcAn1rCBB6EGgBfML8YIxQT6n86XBIJx06+1IVV4XJIwMc5+tABkeoq5Ywu4ZlZQOmCabDaqLQSNx6Z71JaEIm6T5VLEAngHpQBc02FvnST/ln82e3PNXtJYvfO/lIQx+8T17VYtrYDTZHPDzHAB6kDip7Gy8uYooJCYzx04z/WgDRkZVJL7LcHkMrDJ96sC33p8pLkr1HJPHWsq7lke4WFUiIX5Vz3Ara0NpTavMEbcmV4HpxQB0cH/Hsytxg8g9vrXReDdBRZprzoMEtgenasjT7cXzhE+dpuZAvJX616fpFitikER4ikTMhPRT6H0NAFmCYwWq7HKRAfNz2rldduZL/U4n+0b4osgqfoQP1Irp9akKQFLOBpBjG5VyB9TXL3MFwCBHFGN5GTjpyDQA2zmla5WBQwz3IIArtPC2ktBbziU4QvvHYZ9f51V0nTVigkutaAijVgQCME4qrqXiW91Im30NEjhXgu3Ujpgfn+lAHRalq9nYxqLi+WFRnGxgxb2rj7vxr4dMxC2t1Oy9SgIB+tUf7BhYmbVLorJ1KMcVPDHpNvhILCeUv32E7sen50AL/wm2ig7TocgB5ywzUsPiLwrejy7myNs5P3lXoPr+dNMtgnynSpwvf92ahnt9EuY/niaAnjngUAWn8M6DrKP/Z10szj7qu45rifEXgyewaRyuxs/dUcdO1bdz4akB8/Qr1keL5iiHJ/IVe0bxldWxFj4nsmkt2+WOdkIIH+0T75oA8e1CK8sGb9+w54Qr09sVZ8N+Lr3Sbry57r90efQCvVvF3hO01bTzf6V+9U/OGj+bGee1eM+IdCa1Q743B55K4oA910Pxd52miC/ZJVYcMjAg/QjrTZIc/6TphBTq4T5iV79PavE/Cetvp9w9nc/Lbyf6mRuFi9iegru/DeuT6Vqi207hI+GAY7dyjqR6jFAHb6PfhJyJPl5+YHg10c0MCRpOh5YZ3Z/rXP3empdW0Wp2hEkbnLFPmH5itXR5Ev7NoGZeCABnqQQf6UAZXjp3u7GAsjgKvJKmvMp0EVnvBzskD7R34Pb8a931mzjn0iZJFJYJwvf8q8R1GRIb+O3aFl6jkYxQBg+LbWDUrc3saHzCgViR1x2zXOafqCQ2AtX5D/AKY//XXdRWLCxuYbnMcWSyb+K8wv1NvqpRQfKBPz/wAP50AbOpoLrTwbfKzRfKM+nX+tYmES4SZQNyqFb6gn/Gumhjje1BR1bK54Oa5qVCbiRYxuwedvOKANG4ujcWcN1g7rcnAxz1rZ0Z5Jx5iunzjIGRmuatPNYokQaQZIZEGSvPcV1+m2H2fyZBGyJjIyMd6ANLTZktJmN0jkkk42nmuv1KzE1tDJa5UMit9MgHmuV1GSNgssciNIi5wDkit/TNSE+mqkjqCQOCfagDCfTblXZSTwcdDRVn+21b5vNTnn7wooA9C8CaadP8MzXMhK7gjZPf5a8P8Aihr0k8jxbsqr4/WvffEN7/Zvw6jdBt3xovHPYV8j+KdRN3dyEsSvmHORQBhzMX3M3UmmRfeP0pZHUrgH9KbGQrHPpQBZT/Vy+4pbezklhLMCsYPPI5qtI/y4Tk1ZhuWFuUB9M0AaMMs7wCJEVFB2jPf3rV8i5tUiWeNNsnIzjv3qlYqHgGCN4bPPHFbM5ivEjbzcGMBMEHqP/wBdAE88BtUt7Z5FklHzcejcj+ddJpEUa+b5seHb178Vy8UbyXqzq3mBNoYZ5GBjpXUXk7MFQL5bsu4cY4oAzbu1iXVwGwpZiQOvf2rpNPRHzbrD5YPU+vvWHo8X2jUsXByU5B68V3NjaJeSSuilUgUNIcY4x2Hf8KAI9AVre93hTt7GvVtNQvprvdDYQpIzzzj2rhPDoJO2KISH34/nXa3Ejw6cwH3UyG5oAgaYi6jXG5CefpV/QNOjud15cIRGGJUEcGsWCKa5vYoojhmI5z0HrXX6iXt7Xy1cJEqY4HJPSgDmNZ1E6xceXbsUtYiQW7HHesx7hy4sdHiDbj8044/DnBzkj8qS6kKulpYgtuz5h6Y+metdGkGneEdFN5d5eQDI4yxbGcD8qAKth4TVAZNQmlGBukLEYI9Kkudd8M6Sg8pUldegRCT+tcTrGv3eqo2oarcmx09RlIAeSPp1rhbnxtp3nbdE0qW7YZDPg9e3X8aAPYG+IXh92AkspVP+1EBV6x1bwxribQI4pC21cjBzx/jXhn/CZeIJHG/w/bmID7su0MR7U+z8d6VLKIdY0VtOlLYEyA7f0/HmgD3HUfDM1upudMuSXHJB5BArDmMWpQy295Egujx5gGBn2rL0HxDcaIEuLOY6hpshw3z52ZP513WqWNtr+mi/siBMBu+Ujk+hoA4DStQvfCmrrZXm6axc4BJyMdqtePdAgurBL20TdBKdwYY4J5xUstsNTsLm2lX/AEuJNxJ4IHse/wCFT/D+6+12tzoF6xdkG+PeDnH/AOqgDwnV7R4CwVCGXr7VsaffPqOlw3KjdLbfK7jrjvXQeN9LS0vZ4yu125UHv+NcX4buVtPEQjYkQTkK6EcAk4/rQB6p8PvFcls8mnTqbi3kGI06ZY9hmu3nhh03U1aCOTyLrDRsGGM9SPyBrxPV4pLS9DxHyiPnUg16j4dvF1Tw1ArStJcwDdnB49efpmgD0aFY5mcMrDzBxuOc15B450trfUHmRDw/XI9DXpnha+a4t0D8qc7WPXiuX+KFk8jAxqQhIYkeu00AcDaXC3cEkbsPMA+7XnfjKz8gERjDtuJ9sY/xrq9NdbO/y7sQ52nAJ71F8QrdYxa+WoPmFi5PGFG3/GgDj/ClncykCSYktyq56j/9dT6ggtbgRFCrSNgE9zTLK8i03VxLDJugONnB/lXX3NtBrE9pcqoG04I6dP8A9dAGdpXht7dTcSkoh/iJFbsVs8EY53qo6ZH1pmutNsOmAFS2ChXnIIz+HWopJE0iwQSSuzbccqTQA97qNmuAE5VMEelVtEuZob6OMKZEYAgelZ+nX0dxqrhmwJU3MMetXLa5ktNQ3W6LJt4GSB0+tAGoVtHJZWG08jg9Pyop8lzH5j+XH8mTt4xx2ooA6zx/qaw6FFaSFtn2eMgAd9v1r5c1OZJppim7iQ9RXvHxnne3sImUnmGNBj12jmvn6XkkdwxLe9AEdFFFABUkbBUfOeSP601VLZ5xT1iY5UEZ6/lQBv6UqOiyOW2L8uB19a1JYIY8bS+089P/AK9Z2kRn7GvT5juH8q1bhS0akc44xQBbsC6wSQ26oHJz5jHBrVe4VmgM0oMqxEOT3OT/AExWRpcg85uD0FMvrny7xZsIY4/kZcHcc8/TvQB1XhdopBPNhm3LhcD+ddppN8V01ykTBiAr5XrjjjmuO8OSxDTmkto2Dk4xxjPt7V0kU9x5YVIyAFGR6nFAHoXgS1gew+dW831xxVnxI6w208IYb2JIx06VY8IotrYMSN2eBiqniu1V7JJIgdyjJP0oAm8Co0pmu5ADGo2rnrmr3im6MbMmThVyak8IRiPw+mByzcmsjxtIZFuBHlWLJFk+oYEn8hQAvgiz+1O15MAVRjjNc94v1gX+s3MlxtbTdOBcAnqw447H7x712Vof7K8GzzDlhEzfL64rwv4g3L2PheKFGJfUGDEj3DcH/PagDFVL34ga0Xmmkt9IjckbvlVV6c4z6VPf+NfD3hQGy8OadFe3kOVM5ICqR0zzznJ7dqk8b3r+FPh/ZWFkNkl3H+9xwcYB/rXi6lE+7HtyASe5PvQB6Z/wubxMhw/2KRGOTG1uvHsG61t6V428PeMv+Jd4ksYLGV/uS8BSe3Oc/pXi7tuIwKdH/q3+SNn48tmz8jetAHsURu/h9rkUcis+j3p27B8wUHuM469a9W8E6mmk6zBBA7HTLsfKG7MTxj2rzHw9cjxf8NLqG/YyXeng7Hfk9T+npVvwXey3nhSMTb/OsZwiN6DOf60AeweKrM6frNvew4AmYq3p+NczqrtpHie01GHAds7tnIIrtdb/AOJl4NtZ5P8AWMivuPrt5/lXDeIjv8MW9xz5gHBP0oAufF+xS5tre9RQvmIHX17dfzrwfWQ8d/BcfdkWVHOOnDA19C+Ix9v+H9hOfvLF5Zz39/0rwXxSgWMkcFgQD6HHBoA67VlS70WCYZy8W3PfNaPwk1RvtEtlKSUZiv6Guf0y8S48K2JySXUgA+1V/h3O1v4kkGeEkycd85FAHu2jyCDUJ7RmKlXUqR0x3ra8Yx+bpMqqgZ9pI9e9chqazf255tsflfa2B2rotRuJfs0ciOpZcbgewwef5UAeGBfsMsjzKfNL8qR0xVPxPcyaqNwB8sLhc8EdM5/Kur8a2xnH2qCMs24hyvQj2rmzC8NuwkA7ZXHJzmgDlvD2jRT6j5bFm5yc9BXbGCLT7ZtrENG2c9sf48VNo1lDpqi5kib98cqB16VR1OZZ5ZYTuZC3AHUH/OKANnTg8kyandqoVV79eOB/KuM8T6xFe30oUkAt0IAHQe9dD4i1L7J4fgjfKjBHH1ryy/lj80yqsjJnIII5oA2LBFj1pXZ/ldcDac1qpdqt7IrFl2dSw7e1cjplx5mpJN5gEanhG+8B6elbeoJJcXTt/DIo2460Abp1hzzxRXLKkpUHz4P++6KAO9+OV+otreAp8/lxN97/AGfpXiEg++3r2/GvUPjy7nW4WIwuyL5e33a8tZ8qRjrQAyitrwl4Z1PxXq39n6PCryhDLI7sEjiQdXdj0AyK3Lv4d3sd5ptvY61oGqG+uls0ewvPNVJGzjf8oIHB5waAONh6tVu02+Yd3cYrp9f+HWr6FpOo6i13pV9Bp0wt70Wd15j2zltoDqQCPm4rj4nJlXtQB1enJu8mFNvyryxPv6VuW8KxyOsrAnbngVz2iIJLpN4yBxnPSush8qKYoIwylc5J6UAYlpMILiTjcM8HOKuRP50NxGyqpZgykjJHFQahbKZ4zExCbsnAq0YQ138pIiXHzAdeBQB0GiyoNLgEKMJoyFkwOGYdT7c/Wutt5n2Fn+XIz69q5jSLkratFb7QobcGxya6LQCZJmW875NAHq/h+MjSN+fmz9zH9aPFh/4lsDRgIHIDKOcA07RDLDHOrxpiPgAHrTPEo8zT42U5J/h7CgDR8OYXQotnzDPPtXO+MAQsh67pVfHpyBitjwjxpcsIbeynPNUPF0LC2SaMF2Y8qeAORQBY1VTJ4CuhEdxEJNeC/ErCaRoMjHci7QT02tz/APXr33wvtv8Aw/cWxf5nVkI9MivGPFmjSXnhzUdNYE39tJuiQjqADz+tAHK/HJS1joVwz/uWixvA4OFHFeTSOJCJAu0MMBc56V7XbLD4+8A/2ZFxqVmvlqG6Bxwck9M4rx6/sbi0vJLe9tpbaWL5GjYYxjvz2NAFKpIyQvK/L/ez39KR4nUgkDy/XcM1b0nTbzV72CysYZJZZH+VFGfqT6CgD0/4NoyeGfE1wT+7ZAADxjHH9K0vhxIf+EZ1ZnXcJLoFG6Z6D+lN18QeEPBcehxSA6lcthwnqxzj8M4re8LaRLbaRpOlCPFxM4eQD+H5if5YoA9YmYw/D2yMg5WBOCeuV/8Ar1xfiIeX4Ot88njj8K7bxpttdCtNPVsk7UB78DFcL4wkMdraWJHzFRjHXp6UAbbSbfhlZCQZY8YzXg/jJvKtixG7YduM4zXv3ieFLLw1aWjORjJ5GK+e/Gk29DEqgsxyPc9hQBtaVGtv4Q05xGWKlh1x1o+G8iSeLpg6FuT8mevynv8Ar+FXbpfsXhTT4FAZyvmc8YPpU3wqaE6xNMYUEzE/MTwODQB6al46a95e35WXaBnpnvXSTwfZ7Fy77yW2McY4IJ/oK5JWE+vmfKAIwUKhzk9q6DxRqgsLHyJowZpWHCn7o2nn+X50AZd7ZwRSCPzlaI4YLs9e3WofFGgQtCs1tEPugnjp6f1rnbnUBdzwIjSK4bjI4au9F2bjTfInURMQoJU555x1oA5r+zjcWFpFJF82SA3oAM9K5ObTxBFNemL1IXPT8a9CVJ4p4YT0UFsn1PGK47xYsttpLWTvhixbeOuD/k0AcP4gilvoLaF/maTJI/uisDVtNS3sIYxxgEMcfdOTxXQ3jSxrHIvzOi4Ge/FY9yJ7jR5IZwN8j7w+eR7YoAwdO09Yyztzz6YzV0yzSXiR+Z5YwApA3Y9KeZmisv3sargYyDmqVrcC0uRcT4kA+YKeOO1ADi0GTsSy29sRnGPzoq7HFZmNT5QGQDjFFAGx8dJo5r1HXGdsS8fSvJ69B+I7teW8M8nLbwCRwMDgVwTooUkUAdt8K/EOm6PPrmna5NJa2Gs6fJYvdxxlzblujFRyV65A56V2Ta54L0mTwaYLjRm1HT9TjkvLzTbGaMG3UYDMWXLMeCQM814nRQB7n478beHb/wAM+KrM6va6qdRuhPp8Flp0lq0Lbyd8zlVEh2kDncSR+NeI24BfPpTY1DE5qSIBJk/uH739KAOo8OtI0rhQu1RnODnNb00ywxq8iyYcY3g/KD6VgaHeJamSPHzS8qTz8uMfzFaguS6NDKwcdQAOAP8AGgCW5DWsK4eOVG53DPf8atWZDacSxAjYYDH72c/l+lZFsPkCHO1SSB+OadeCWSPykOIhKpYD6CgDo/DrtZzCCcFkHy5H3v8AP4V2EF7bNqtqTvUEbSFx0H4da5zTp4opVkcAt15qxbXDtqquNvyksvy+9AHvXhy2ktreaSeQyLJ1JOaqPexyRTggnZwo/wAaZ4WuWOieUWJfPfmqRmaK9kiITDHONvegC54PvBDfzRSZBlbC59a3dThEiyJwQnJB64PHH51yN/KYJI5EwpBByBiuohkGpWwubeUGXZsdfX8KAOY8P3h0PWXtrg5ilfKN7d81L460GUXi65pu6VsYlj6rtxnOAM9h3703V7CSLako+dfuE9cVa0HXXs9tpdo7x85z2HrQB4lrOgXVpd/234Sm3ZcvPYno7DnoMHrnvUFx4n8O+JF8vxhpwg1BRtllKlXGenPI7ele56r4Oju5WvdBuUgd8sy4yCf6VwOu+GJWcx6z4fZy+czwru34xySOnX9aAOGi8N/Dt4ixvy8Cn7qDc2fr0/Sph4o0Pw7utvB+lPLeyLhXEZEi54z1x2rYTwP4bd1CaResw6rsYHNdNo3he4jkSLRNC+yDvPOvzfme1AHEaHoEsl2db8TSKs45gt/7ze4OTn6EV7L8P9EkhEmt6mskUkikxxPj92o49Pb9an0nwtbaeXutfuIbiUEMqYGEx6etVPE3iGTUilpYb0jJw7CgCprN4+s6y0qEC0tGJzzk4P8AKsrw7aSeKPGv2plP2G1zyB1OffNP1GT7KYdLtFMt1cRhS69Acd66q1gg8H+FGEz/AOlSqCdvBJIoA5P4n6sskrLGU2w/dx3z68/4V4dLHJqvim0tUAMayI7EdeGH6V13jDVxIztIwJblsCs34e6c7LfazdqRIAfL7DZjnj1x3oA0/ExYyw2aAF1jwoA7+9dP4E0pNP8AD8096qxyykYY9ByPx9qz9B02XVdY+0PgLnCkjoK71oFv1Fl5RNvb7eBxk5A6/rQBF4N09ZLmR542WJm3mVegx6ZrP8T6gt5qV1tYkwnbGR0K+/v+VdBr8b6FpLwIW3uuRg8AVwkfzW3myOoJGR67sj/69ACabaT6le20UbKsu4kk9h7V6CYbeSxhhM7farZsvtIwT2zx04NcEI7izu4p4mGGQ9OMVf8AC8N1cJd3EznJddvPX72f6UAegXMH9ob1hIFyYfMyPugjjH6eteS+JJLuW4KzmIhPlJAPYn3r0PTLqeystRlc7RsIUkc5xXj/AIl1GQWJeNx9pLneSMj8qAHXbxRI5mDE7Rt2dM471yOq3inYXLK3cJwv61tabqbDS76S5CybV+Qbeh71ya3S3ITz1wGztGMEc0AWFmgdJPNMhXZv6j/CsJZw1wVwzQHJyeorcu1CwoEA2bAr/lVVUSC2J2Db2+lAGx50SfLsT5eOlFYZlySWvIyT1Ij60UAbviyS1uLC5RIxtQrsG48Ejnvz+NedyE7nHYf411uvna+xeEaMMwHQkdDXJSffk/z3oAjooooAkh6tSyn5Me9JD1aldSzLg/KOooA1rElwhbkquB7CrtoZN7sqg9sk1lR3ARQFO3HpU0c+5TtJDE9QaANm2ufLGZiC+TlRVl74DGyIhXOWHXJrCs7d/tHmOxIPqa6e0ktVgxPDG7kfKWHIoAv2d1BJauZlcsv14/KtLT3LESA/Nt4OOgrGtL9VT7Opw544qfSrt4rphM7MoJ4J4oA938LTqNKM3/LTqT/9bpVcSyXl6bhn2KeQMCsjw/eMuh3GHYbTxz0FXhKLtCbf5FAyAvGKANLV4wLZHL7zjJHrUXhPUDpl1iRSsbk5Gc9j61TS4NxE8LEtMg+Vj1Bp1zBKEVndiAOc0Aeh31pBqtss0G1pQPkYscD8Aa4e7H71rfVDJHOG+UhcAfljNXfDmrSxoQ+INucKTgNW9JPpmsgJdqqT7cZI7fWgDkob3UdLl3W58+Ls4OMfgOv41p2njqPJFwMMMZEgx+WBUGoeFNWtpWk0e5ikt+ojJxu9qxLo6hCyjUtDlZ+ceXHx7/0oA7BvHFhsyuz/AL6/+tWdd+Owx22UbSysMBUGQPfNc39tiIKL4duAT/0yqxYLqUjEaboksJJ/1jpjmgCa4fUtQYnUSsVuPmBLfMfbPWq/22UEWOj2pYv8rSgbvx5z+lbEHg7UtRZZdbvfs8KnPlxt1+ta73OjeGoGWxWN7gcFs8/iaAKmhaLB4dsm1PU38y5Yb9jHlSe1ef8AjjxMb2TeZSSGO3IHAzwOlSeNfFstwGHnoSrHHzdOe1eVXl1d6pemCzLvKcng96AIXjn17WPssSnyhjL9q9JitCYodJsBs2ocyDnP50zwv4eWxgNnAjtqPRpcfJj6128Gm2ujRoyKktw3yDI5XPFADNO0u3trKGHhbhuC248/rXVaAi7j5EStJ0ZiTg4rjGNw92JNpCoc59K7LTxHp+lttmMjTAZ5+7zQBg+MdUW8me3WMmcDHTIx3riPsZuY1tTERMXzuyRgc9s49K7q4kghhkNwq5ZhhiOa5W+ku7aSe7gOF2FQSfoePyoA4rxfrklrctZwyMVgXaCAOvetb4fa804SyjdlmJB5wc9fWvO9be7kubi4IXYWz8vr3Neh/BrQJLvUF1CSJcRKDkj1z/hQB3fjjVjp3h9Y3GZGbJOAK8IutSOoahLCn7pM53ep9Oa9X+Kt2sdkiSncznIz6ZIrxeINLcuIowUEhY/pQBszIbLQ55OgY4B61zZVJ5VLO3mL6KBitnXb+SfTIbWOEImTkjvzVKGC4tLVHwWLsArd8UATBHntzAxIdh98jGfeo9etRp2n2qTSCR3AB7cY9q2msZXtknlym19pbviuO8QXbXupjzHYQRMVAzxwcZ/SgCM3wB4gAHpiioyi/wDPY/nRQBpanNvgBIySMbjyfzrl5Pvyf571tX//AB+j/rnWJJ9+T/PegBlFFFAACR0JFSxE4bJPaoqkh6N+FAElSQv5bbieKjpol2Sge2aANmO9ElrKE4II5HGK1LRGZUcksEAzk5rmTy6Tep/lxXQ2d15tts9BQBoxfZ5JmlyFZju44xn0rWskU36SlVKBRkFeG47+tYFlNsiZf7vFb3h+E/NF3ky3580Aei6bOLa0KMBtPVex/CrVlf7JHWIYIBwq8c/SqcAtoA1sc8VXIdkCr/qyMQ/738P64oA2LG7DXoB+SZm+XjGT/WumiVb+2P2SVZmT764zivK9btNRsIGktU8wMP3q+o9KteEdSkvmEE032ZwSNo9gT/SgDqdRkliuALhmEasCeTxWklxDebGsppJJ+mzeSMfT8qzdRnaBF/tO284dFcGq9lBa/ao7m2lO8HJj9B6/nj86AOntNVvLS5Fs8pjmPVCxwB7Ctp/FTwHy5DEWHUmuaMv2y5Z/7iise8kBmkP9wj/P6UAd5/wmB2MVjjfHdT0qnc+N5kQ7YUBrmoNQiEKiQcgcVY+0W08AH+1/hQBT1rxrPPG24lSewbFcVqeu3U8ZEZ3seoZs16ZDo9jcljImxiP9b+FRwaPpFlIWeb7Q3dcUAeLPpmo6zdxRiNUiYZcrgYNegeFfBosV2WyI7Hkz7QZAfZuo/Ou1F3pi/LbWpDDjHpVPUPEYhnS2trX7OTjLZ6+9AF1Y4vD+meUpMt50/ec/zqhDBNaKTdXCSXtwNyrJ8236Z6fhWfp0fnTnUrq67cVVnv8A7Tg/aMk9vX2oAk8Q6u9pAYLaWP7RINpGOlY1n43u2uEtZPLIGQQBycKT/Sk1rQpJIvMhk2Syj5W/un1rldF0q4v9V+y2ib2DHfL6YBP9MfjQB3uu6pLe6fahEUFiGJHfFY/jG+22VtEk0ivtDeWrkKxweoBwetbsls8QhEyb3T5dtc34jgkmvUW5h8uAHKn/AGvT8iaAOMkkja0kMwVZDwUA459q9i+Eqy2EFvY3IZY5F3FuhI7c/jXmd/YW5ljT++cV33hr7Pp1usRJJMZ6n0//AF0AYnxg8u51J47ZmMdsuSM/7Rrl9A0y2k0x7pkfzXkYgLwMYX/69X/GFzbzW5HPU/zqHSB5Gl5T/UZJ/HAz/SgDIubRpVlTy9kYYbSRyPWuk07QPtbwRL80cQHBGR69PxrDhlWe6aSPO0nH5Cuv029+y2Kyf88h/U0AZfxCEGlaWtqh/fSqGwBjB9q8nu7b98nmLnIBO4da67xfqJ1bU2eb/Vu5YfQmsmz0jOortP8Aop+9zQBz/wDZl13XmivRBo8rjeqyANyAbPpRQBxnii0+w6q6YIVo8AkYBrnJ/vV3XxDsJ7WZPtCtlYwCSOhPSuGfmNiOcf40AQ0UUUAFOj++KbTgDsYqMkY4oAuSBhFzErZHV+KrRZ3n5QnsvSpzM0sSh+CowAahQEA59aAJHcxuXXk47c1YtLkuFZhyfWqwB2lsHaOp9KuWpVQA0TFh14oA2LMhwph+WQjk+9dr4LdZZCskijBwSWAGa4vT1JbIUgHpxXc+G4mkt90YhjQnG5uATQB0UyXD3RFq2D1IHX8q0dGlF0Zba8YqCpUMeOoxxWZp4dZDOZlEmOhNTRyrGHlviBKFJjKfdL44H54oA3LRZ0E0dt5VxDEMlHcZYemKzblbJrtZI42tJUzu2jvjFZH9sTWkjNCQHfueg+ta2j3clzIovok/eZwe54J4oA1EeS8sXS+Mcq9FkDAsKzbbSmsoX8td0THgKM8/5zWpdaLJFMk1vMGgI5RTnGe9Z0lxKl+bcTDy0TeDngtkDH15NAFuz1dbQxxTDBY42ngj8K1vOtZN7BS7nHK87frjpXH31qZXkllmVJGHBY4xU1i/l2jL9o3OuPmQ53df8/jQBtXV6bRwk8e61cbmyfmB6dKLW8tskhmeM/d3cEH0rlLr7VcOB+9wOPmBrQitnFuNkgL+gPNAG5Fcks8dzP8AP7HIwen6VDtUZ28qP4jWFjUY5cBMKehYdanvRcRWu6/u4oVccRhsMPwoAvzXk8+YLVsmP5ODnpxVDyrqfchznJB471nQXotoMRsUyPld+Cw9avWRubzGxih9T396AJ7qb7VCbdhnHPIrKRgGVhyQQRjmtK6spHASOXy5P+ehOAauWFtbrHIrR7mAK5/untQBBNeM8dvGpCux2jPFTWUr2BNnYvtUfOxz8pJ647Vi3FxFDfE3LBUiOeTyfpVO6824kU2TTAkjb6e/6ZoA76GI39woVl8jaTIM9/WuY8TXpa9cLKq+QvlglgAy+3r0FSy+I10Oz+zso+1OhHPU561yWuatHNaLJsBlIwV7igDPOoJPqUSBmQqxJZRkH8a7q5gL6erwy7+Oc/p/WvK9Lv1+2kyRFVyOSOOteqQzRXGgSFI5CQo2mMZ9aAOB1l2ZHjnZQ27IBIBxTYdUDaekcoyisR+grGvS5vJRJvyGwA45Ap9sU2bJGVcnPJoA6TT5Yi4u7bAEXCqDz7/rWjq5jewQpt8wjJb8ay9BjW3bLLui6gjoal1W482aSNEKp1VcdsCgDm9R3BMOcnuexq74OaaS7+WRQQDt554qjq7KYBhh09a1PAc9uPE9hI4VYEwHU/qaAPdLfwpZRQRxgKNihcfQUVhyeOrQyNmeEHJ43iigDhPixZ+ZaxSqpLFY93t8teLzBo5XQggGvoHx3N52mYKLu2R/yrw/W3VZpI2QB2PBH1zQBlUUUUAFSRMADk4qOigCcEHoc0tNgUspxjr609gVODQBLCjSW8yIMtkHGcVaiVi/AqG2DLGjJ3J3fnWvaojYZeh9sUAXtCgllm2bOD05HT869DgtSLO3eNfKaP70fr71xnhjdHqf72OTy93ylVJyK9EKGa1zbDHtJ8n86AJ4hbxDc9u6r67gf5VnXeoLJPsVMqvIqsdPvJ7eIx3md/IycZq9pdm5vgXiJKsGx265oA5TXNQlScIsLDecA4rrtLuI20yN0fN0oG1MEE+vJGOmT1qfXxbQxxTTRRD5sDnPNQxIlyqPCCqDgsBwM8daALTXc9ym62u8FeoIPFJJfFokS4K4DDEijJJweOOfWnJpqWkm2SVQroTw2eawpJEjuWRZzuHI4yKALGp20rfvYpWdG68EY/Orui25MLmK4j3jGVY49fWqA1O5ZXhuWh8sAbCWAOajnso5Iog8pRZMksrdMY/xoA6KVbx0Y7Ygy8DDKc+/BqhbzSSymK4fY+eoU4x9fzotRZxPCkVxIQqYPBOTmlu2fYTGf3OcYIwc9/6UAakGmL5jSC5Em0AgA+1UbxbidpmJXap+VG7cCsWW/l094zEGG842Dk1pXV3JdQRLLHLG6jjah5+tAGdBZC7vcXD7P4iPQfhW/JA1tGotQX+UAEcZ496y7f8Ac3sbTlV3xgAZ747+lS3TSh9i30e7sAwOPagC295NM6rFbli3I5Az+ZqK2N3E0xliIBcEHcpyPXg1A0EyXUHlXsbBB82GFQ6ldy+aBASMkAZ4xQBDcRebfgyRswJ+703e1SWmn3Vt5hNyn2duTHjJHcc/XFaOk2sl5ExllGVHOeKg1S7Nnbyog3YwM/iKAOI1+T7Zf+YJyVj4JwRj9Kw9TnN2qWyNtVmA8z8DxXQ6mGm3JCgJY5OOtZgsEZFV/wDWK+7CcnoR/WgCLS7FI7m3tAfNKNudsdQa9ott0GhssUARAo5Yfe61yPhDTba1u0u7hW2tgMWWu88Sag01t9nt4lWNVOCDjOcf4UAeIeIbZpria4mKxqh2gj8+g+tZGkWoubth5uVAyDgj+dbXiGAgyASDJbJBNP8ADti13cKGCqirksrZyaAKsEtxa3LAbmRe3Sn3GopLdeYWAJXBHoa6LUreKeORYkwQAM4x0FcNqlj9kj3O53HsDk0AVrmdmkKPwM8c5pbC7exJkjH74HKr61Wt0cyxtJ9wgEHvj6VMYHknJQDbk9TigDZXJUF5iHPUe9FQk4JBZc9+RRQB2viW9S7sUMTcNGjAN14HtXmOtQCVDIuAScDP1/8A1121zD5UIyGYGH5cdq5HVUKQEZyVJbAHWgDmMdfbikqUxNsDHgPyPamMm0ZyDQA2iinKm7POMUACuVGBU0e50yAWOcYXqPeo/KOeCPWrWkTrC7uYyWJ2/hQBf06HaQjuh78E/wCFa/2aSIh0jZ42+7sGay7OOMuz7Wxn19a9G8PtBaQRw3EfmKy/Kw6Dnvn60AT+ErYyQQzAsNiLuQj5gcVsatKbmVYrfKrjBB4P6Vas7UQRNc2S706ttqhduHuA1r8kx+Yo3XNAFWaeVIbcJkbOv/1qs6fq0thqBHniQMNwHZh6Vj3Ud+mqlJcJH6kHFS3UrzKfs0KyPEChKj7x9qANy6vI7+zdb2GLg7vlPGKggk2r5UUmy2P3gOnHI/UCsvy54rYSbkkH8adCn1qxFdXQdrdI4mGBkYxn6UAWLm/t4j+9kM5HH7vkD65xVaPUYDISsCnAzz1pbuKG3Hl3EBi3/MQepP1rGcRCQtG2wnjB9KALV3f+bK2LJZAfu4/hPrU2nXyypJHNgMmNvmcAZznGM+gqKGRYULoynj5uO1FlLbNfLIGQu38JGRQBbsfnvdytGSoxmMkqPrkDmr5uZ5LgBZIPKHByx6/lTX1p1uPLS0hA24/drjPuc1Sks4Lgu7Xcfmk52o23Htz3oA2rgpcSqPLRQoGJc+1RXF6LRpRPcF8/cZBnPA9cViWKvDKVjZ329i2RWs19BLbEXduvnoPlA/h+tAFFIUvXaS5lYHOQR1qNIbWKN2j5kDHlzx1qzaxJfIFhw0zjL4OACetZ2rJfwQtFH5BIJUHH4UAaOlK1s3mmIMvoTzU8+rS3UpWKyAxyWPQe9Y1rqryTR2iKzGXgOBwK1JrO3sFNrLdmN/uydWIXoentQBbm1FLO287zY1nUbtrE4Y+lZuo6/wD2igjW22qfvuBx6jH41YextBCrbTLbjku/ce1a13bxGyjjtrdEtmxvbHOMg0AUNG0C3lsJbm5m8iTICMf4weuKwtRgitb7y7YjzScb17j0/l+VdTqN9BHZICQUgwsUfcA9c153qGqzXWqI0ERAVsjjofU+1AHaRX3lWaWtw7Kzn+IAAY/GlOvCXU47KBjJHtwW7Dp1rmb9pJ1+0XZLPGMqF4zWhoF7Fdo5aFYpUwFYe+c5/IUAS+IrOBZQI4TJlcsx6A56VF4ce1huH8xkhAXoT3qvqOovbmRC6upOTisp7+CODdLHuUtngjOaAN6S6LtO8GBAOjPwD69M964+WOS/1KZ4Sr/NyMnHQdKvvfvqEKwW5AhbgAfrXReE9GjsTuZQe59qAOUk06WOOUyR4ZiSvoPrWQ8M2cRlQ2cfMSOfyr0XxfcxlhBaAPL0O3+E+lcrrFnLbRIxjLMygnbxyRQBzABwMrL+X/16KvRy70VxJGAwBooA9DsLqzvbVdgDukOWQnH61ga9YQzBzbKN5H3fT8ag8icRQT2WEYKA6g9RVy9LajYQz2J8u6j4dB91vX36ZoA4ue08y18t/wB1JGeB13fyxWHcCRHKOm0DvnrWxqzSvMSpZSp+Y+/pVCdftA853YN02Dp9aAKNSQ9G/CmONpx1pUfbnjOaAJlkRJl3nt0q1GiySbozwe2KpxtGzBpQMDir1vNGkqvbruj6Hdxz3/pQBrWEPmL9nBxITnOK73RWihtyL2NiEGMiuY0xfObzo0QNj+Vb2i6nNb3jxXNuZIicHI4HHagDqtIv0htvP0ptiYzIj/NuP9PpzWRqU3n3JltzsuHyd45wTz0plxNBJdyCxdoxvOI+AG571DYwNBdGRySSxOD0HNAHQtcJf2vlzYST/np1z+HH86o6O0emyuHYHLhwSO46Cs21aWeYgxypBg4dR83+FRXEUyWo81JjHjiTHzfX0oAuXunSHUftYjaRpm+XEmAPwwafbXEX9oYvU8lDwSHzjAyOw7gVkafqk1ixjaSedX4BlGPL9xirq2y3O64nn2x/xE84zx/M0AbmuTRX1vHGs4mUMpBEfOB261g3dlG1zuiwzbcCPOCelVIXjsppnhvmZFOE+Xkg9ahubm1uZkM8LOS2N6MQQfWgCHUrwQmOCSCWFyxB/iBFaNnLZ2kKTIW8wDlTH1/HNLbCC3u0eRHkhXnfIcmrmrxw38e+0mWEYPBXr/nFAGRf6hdTyRzQxjk7M5xgdfTnrTVu1tLjb9iE0h5LE/8A1qpfZL+FgXuEkiRt2AME+1Wpr2e6+a2t3Qjg4HcUAbKXDR229YvLlbPyqOB6VVhu5AGaSzlmdmClydgPv0NZiahePcm3VpPMAHMi4XpV2a1vpohHdyxiPOcxuRQBvrGsdsUFq29h1WbaV/Tms+W3Uri5LxDpndu/wp1hMVIjEq7UG0ZOeBV28txNF5jOzQ45Pf8ACgCnd3kkSQvbWaIy8ZDZ/pWnpkaQO80yLIw5LO2d4HbGO9MnuLaKD5l87J/5Z81Jc6nYm0SOKzMbg/xkg0ASzanFeTKtwoECHJReBin3urwyRrBbt5adNnXPP4fWsfTp1ubl42tSobhT2P1qdltEZiwAmX7qjoe38qAINUuoVIhtlEk7clicYHfj/wCvWPfXEEFu6sV80cjC4J9qfcWkyXRuFxs6E9wDVG4a2+0+cwaa3+6xPUHr/SgBsrzw2qvIvmq4zg/Lj+dVNPu5Eucom3f/AA7+mPw96b4j19LoLFaQLHAgwHJOWrlobyaG6R1csoJzntQB1epwytuZ5NpPIGM/1rI2ySsIsb1ByecVNda0JVQIob5cMSTwag0x5p9RY2y5baMqeg68/WgC0JhYXCJENmMHGc4zzXQzeIJrXR3lA8yWRgoXdt46Z6GsSaJISr3fPJ+Y9fpVa/kNxdQ+UuLePpjv7mgDvPCscAga61Agv1yf4z6+1Qa1J/aKsbYDaCQO/esNLuR44oYSpG0DBOO1SNqbWdo0EMaEk5LEnIPegCtute9zMT68f4UVkG3nJyY1BPbJooA3ZgYpFS1kbe6ZAc5GfwxxTNNnGxkUlGjJJx/EahuPOW7gKnkIMcVFqMgjZJoR8wGGx3yMf1oAd4jNr9mjkUEBx820jr+VcSkm6R1jBwOea7a2gtL2BYZFdX6glziob3w15Fv5sDDaWx69j/hQBxLZ3nePpilRVbP3hir4RoLsrLHlDwTitCTTUmaMoQFYHaAfpQBheUu4Hnjt2q/alZE8vAXBz8vFR3tlPb3Aj+8rDOcdOaktLd45g+8HjpigDZ0KeSKVgzYA7V11jqAmtHjVowVHUjn+dchDC2GkClVI6UyGR/nQMQrdcdaAOhX7WbtJI0DKv8Q/i9+tbdzqkaoFlX94VGQn0rkdPungieIyP5a/KOecD3qzY6nCt6HZCxXu3I4oA6+1vrqCc3L+Xs/u7Tt/LP8AWpBqkt6D5QGxxt2kdAfT3qJo7i404RLCDID60/TVjIaLUGFnLjBwOlAGTqFtqRWYCBdhHy8f/XrNF3cWyGNhIkpGBz8vvx9M/jXpcvh/7fp4Ol34kIHOTXBa/o97Z3JWaNnAP3weBQBmTXuUjti54+bdIAQfrjFXbaS3kjKB9sgGQVqjdXMUcGJ7Riw6N0rR0a78y2Ei28bsDwNoGPegCWIhFXdK0rg/df7oqORNRd2azdQx/hQfL+Oadq9w7xBvs4jc5+ZRj9KzI7uC3iDWlzL9ubqDyB+HSgDXkXU1hH2tIS+OCynIHtzRptxcRB3M1uByNrKSf51AlzfS2/8Apaq+7kvuxj8Kqtb7UMtqPMbPzZbP4UAXY7hppijeW0WfvqpB9+c1egjRmdGGYU+6c8+vP45rJsLm3YmOTMLj+HritW2ZTtAlVov4jgDNAGnpqW6qxaKPA6HHUe9PkmL3ACtH7W6qdzD86j+0aRFbbGuCrkcDcTirOl6xb6cAyWaTT/wu3zHHbrQAXWl6gFC2Vi5UHrGcfzrJvop7S4a5v5Y9v3lDDLZHI6Vd1vxTdD7krp/uDb/KsbR5ob+4aS9R5W/2nOB+FAF3+12Fszb4FXGR8hz/ADqk93G0byJIGl7AjiruppBKqnyl2R8gDismJzPIbeO227jw+OmOf6UAPtpbi5hkFwwTvheBj8c1hXt0gMkdsSNoyc9D/nNaWsSTIRFbkKpGG+XJ/OqFvYReUy7W3HkncaAOaZbu9l2DYMnjg4H61dttJWIsZmYlcb8EY9scfWrVxC1krfOpR+AAORj3pyjzbdQM7f4uevp/WgCe30z7QR9kjXy+jF+Tn9K6jRtBaK2bcoQ7idy8HoKgsJYrazRkyWBwIwM5981vwG8aH94ipuGQvtQBxninRpZHjfzD5APAU8+/61FJamO0Tydu1h82/kj6YrfvLea4zCU5Q5zu9ea5rWXngLxQyqpPDDAPagCjcKqEbZZAV4yGA/pSQys8bMxBI/Ws6Zpw6xlgQODxVm6drOAbTuDAEjHtQBq8/wB40Vl/2hdd4kzRQB113ayh0lRd2yLO31rKvAywSN5W1+OPXkf/AF66uDdNp6TRu0bIvY5JHpmstHXUUuFliRZE4Eqj5uvr+n40AYqxG5sWkibaykZAqJtcWC0MMuXkzgA9jzzUXnvaTyRRFgpznBxmufu+botjnOaALTaibl3jlH3eegHWnrcPGFkiBdYuNg75/wD1Uy0tEuUnJOx1UHevWo7Gdracxff3EfMevH/66AO10XTrbXocKVhlxgpk8n1rIvvDd9YXDtFyiHJI5P5GrmmM1m4urVvKmH8S8E/jWlHrst4TLLEok+4WU4yBzz780AYIu/MtCqIxcZBVhg1m2LsHmF1HIpJ+XjgV097HCrC9SMrM/DYbg446fhTI79Z90ctrA2zgEqM0AY6tbhNsjSE/xHHU96rQ7hckRz7V5wMDgflWjfMqSKYkVSeuRkflUdvb2zS7mgUsTkmgDe03xC9vcHfulJ6H/wDVVy7vJZL6GZlLErukOAd3rXN2UAILKxU46iug0nUT5CmWGOV1H33GTQBrDUGhg8y0nkjkxkJgAMfQ1hT+NJGMsN7bSBl7gZDc1eu75Z0ZXtYcEdNorA1XdaxtmSSRH/hZuF57UAX5PFOiXGmyR3KMJCwwQOQai0NotzFbrETAkA4B6iuLvp47cedHbxiTcFyR61r6IqXTb3XDBc5Xg9RQB0msXqwqvlBmwT05rMN6koUyBo2Ofm8tef0rctIoxG5CnIAzk5zUJeGcOk1tG+z7pIHGevb2FAGUlraTKXa8dnzgBmI/QUojaJT5E8aMe7ZJ/wAKhs9Pgn1BtyDAOACM4rca2+yRbYmGOvK/59KAMG1+1rdNGzCVfVVGDn8M1pFXgLBwY4zTWungYz4DN0wenFULrWpr+48qWNRHn7vagB13NYsQI9zyp8vGeMVYsJ5BIHeRosdGPYVa0nT7XzNyQqjHklRireoaejgjKjt9ygCne/bJD+92N69KsWH2gxSNZrHGpU53HnGPeo3VYCN6ib/rpzVG6vcXDAwxtjoWGcH1oA17GWebzVuXWEIPvcfNVk6tHZQOkbBmI6gCs/T7eK+MclwpZQfu54NZetyraylLeGJBnrt5H40APbUQTIZo90h5BPHH4VUuNWaO23wxfOW2kjnjBP8AQVSlnkaNnLHcB61m293cTzJAJSgZ+SOuKAB7ySe4CNli5xj0ratCISsRbcD94VS1W2i0508lcyt1kP3qbBlYzKzM0j4+ZjkjH/66AO70u4W3KrBbrI7chTnFaUySLGzXbqkxGQEbgL2H865rQb2VCPmJz71d1OT91IUXyzjJ2nGTQBTuZ2EL+VK29iQWz1rmrqGXP3C2OhyaWLUJnwBhQGPA78mtJ2c2bzCRhuGQoPCduP5/jQBjLBJkPLMfUAgfL7dKZezCMAr1HfrTXaUoDJJ5hIz84zVJwbzchYx4yMrQBWWNVUKAwAGB87f40VcZF3H5V6+lFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The gallbladder (GB) comes into view when the transducer is in the antrum. It appears as an anechoic structure with a three-layered wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lyndon V. Hernandez, MD and Manoop S. Bhutani, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26401=[""].join("\n");
var outline_f25_50_26401=null;
var title_f25_50_26402="Patient information: CPR for children (The Basics)";
var content_f25_50_26402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16564\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/46/21218\">",
"         Infant CPR: 2-thumb method",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/50/20256\">",
"          Child CPR: 2-handed chest compressions",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/43/22192\">",
"           One-handed chest compressions",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/61/40914\">",
"            Infant CPR: 2-finger method",
"           </a>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/45/40658\">",
"         Patient information: Head injury in children and adolescents (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/39/34419\">",
"         Patient information: Sudden cardiac arrest (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: CPR for children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cpr-for-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9508807\">",
"      <span class=\"h1\">",
"       What is CPR?",
"      </span>",
"      &nbsp;&mdash;&nbsp;CPR stands for &ldquo;cardiopulmonary resuscitation.&rdquo; It is a way to get blood and oxygen moving throughout the body of someone whose heart has stopped working.",
"      <br/>",
"     </p>",
"     <p>",
"      CPR can save a person&rsquo;s life. It can keep the brain and other organs from being damaged by lack of oxygen. You do CPR until the heart can be shocked back into action or until it becomes clear the person cannot be saved.",
"     </p>",
"     <p>",
"      The instructions for doing CPR on adults are different from the instructions for doing CPR on children and infants. This article is about doing CPR on children and infants. In this context:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        &ldquo;",
"        <strong>",
"         Child",
"        </strong>",
"        &rdquo; means any child who is 1 year old or older and who has not yet started puberty. (Puberty is the time in life when a child&rsquo;s body changes into the body of an adult. In girls, these changes typically start at about age 10 or 11. In boys, they typically start at about age 12 or 13.)",
"       </li>",
"       <li>",
"        &ldquo;",
"        <strong>",
"         Infant",
"        </strong>",
"        &rdquo; means any baby younger than 1 year.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9508822\">",
"      <span class=\"h1\">",
"       How do I know if a child or infant needs CPR?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you see a child or infant who is passed out, tap him or her firmly and ask, &ldquo;Are you OK?&rdquo; If the child or infant does not respond to your voice or touch, is not breathing, or is breathing abnormally (gasping),",
"      <strong>",
"       call 9-1-1",
"      </strong>",
"      . Then start CPR. &nbsp;",
"     </p>",
"     <p>",
"      The person who needs CPR is often called the &ldquo;victim.&rdquo; The person who does CPR is often called the &ldquo;rescuer.&rdquo; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9508837\">",
"      <span class=\"h1\">",
"       How do I do CPR?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can do CPR even if you have never done it before and have never been trained. All you have to do is press HARD AND FAST on the center of the victim&rsquo;s chest. You can still help if you&rsquo;re not sure how to do CPR. When you call 911, you can ask the person who answers what to do.",
"     </p>",
"     <p>",
"      Pressing on the chest for CPR is called doing &ldquo;compressions.&rdquo; Compressions squeeze the victim&rsquo;s heart and get blood moving again. &nbsp;",
"     </p>",
"     <p>",
"      <strong>",
"       If the victim is",
"      </strong>",
"      <strong>",
"       a child",
"      </strong>",
"      , you can do compressions using either the 2-hand or the 1-hand method. No matter how you do compressions, between compressions lift all pressure off the victim&rsquo;s chest, so that his or her chest goes back to where it was.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         2-hand method:",
"        </strong>",
"        First make sure the victim is on a flat, solid surface. Then kneel over the victim, stack your hands on top of one another with both palms facing down, and lock your fingers together. Holding your arms straight, press on the center of the victim&rsquo;s chest with the heel of your bottom hand (",
"        <a class=\"graphic graphic_picture graphicRef53623 \" href=\"UTD.htm?19/50/20256\">",
"         picture 1",
"        </a>",
"        ). Use your body weight, rather than the strength of your arms, to press on the chest. Make sure the victim&rsquo;s chest drops down at least 2 inches under your weight with each push.",
"       </li>",
"       <li>",
"        <strong>",
"         1-hand method:",
"        </strong>",
"        First make sure the victim is on a flat, solid surface. Then kneel over the victim, and place the heel of one hand on the center of the victim&rsquo;s chest. Holding your arm straight, press on the center of the victim&rsquo;s chest with the heel of your bottom hand (",
"        <a class=\"graphic graphic_picture graphicRef55732 \" href=\"UTD.htm?21/43/22192\">",
"         picture 2",
"        </a>",
"        ). Use your body weight, rather than the strength of your arm, to press on the chest. Make sure the victim&rsquo;s chest drops down at least 2 inches under your weight with each push.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <strong>",
"       If the victim is",
"      </strong>",
"      <strong>",
"       an infant",
"      </strong>",
"      , you can do compressions using either the 2-finger or the 2-thumb method.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         2-finger method:",
"        </strong>",
"        Lay the victim on a solid flat surface. Then put the fingertips of the index and middle fingers of one hand on the center of the infant&rsquo;s chest and start compressions (",
"        <a class=\"graphic graphic_picture graphicRef61268 \" href=\"UTD.htm?39/61/40914\">",
"         picture 3",
"        </a>",
"        ). Make sure his or her chest drops down at least 1&frac12; inches under your pressure with each push.",
"       </li>",
"       <li>",
"        <strong>",
"         2-thumb method:",
"        </strong>",
"        Hold the victim with both hands, placing both thumbs on the center of the chest. Press both thumbs on the center of the infant&rsquo;s chest and start compressions (",
"        <a class=\"graphic graphic_figure graphicRef52104 \" href=\"UTD.htm?20/46/21218\">",
"         figure 1",
"        </a>",
"        ). Make sure his or her chest drops down at least 1&frac12; inches under your pressure with each push.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9508852\">",
"      <span class=\"h1\">",
"       What do I do besides compressions?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Follow 3 main steps, which are easy to remember based on the letters C-A-B:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        &ldquo;C&rdquo; stands for &ldquo;Do chest",
"        <strong>",
"         compressions&rdquo;",
"        </strong>",
"        &ndash; For this part, you do 30 compressions using one of the methods described above.",
"       </li>",
"       <li>",
"        &ldquo;A&rdquo; stands for &ldquo;Check the",
"        <strong>",
"         airway&rdquo;",
"        </strong>",
"        &ndash; For this part, you check the position of the victim&rsquo;s head and jaw to make sure the victim can breathe. If the victim&rsquo;s airway is closed, you can try moving the victim&rsquo;s head or jaw to get his or her airway open. &nbsp;",
"       </li>",
"       <li>",
"        &ldquo;B&rdquo; stands for &ldquo;Do rescue",
"        <strong>",
"         breathing&rdquo;",
"        </strong>",
"        &ndash; For this part, you blow 2 breaths into to victim&rsquo;s mouth or mouth and nose. If the victim is a small child or an infant, you might need to form a seal over the victim&rsquo;s mouth and nose. If the victim is a larger child, you can instead pinch the victim&rsquo;s nose shut and breathe into his or her mouth. Rescue breathing gets some new air&mdash;with more oxygen&mdash;into the victim&rsquo;s lungs. After giving 2 breaths, you keep repeating the cycle&mdash;of 30 compressions and 2 rescue breaths&mdash;until an ambulance comes or someone else takes over.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9508867\">",
"      <span class=\"h1\">",
"       Have the guidelines on how to do CPR changed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The American Heart Association (AHA) changed the guidelines about how to do CPR in 2010. When doing CPR, rescuers are now told to do compressions first, then check the airway and do rescue breathing. (The order of these steps used to be different.) &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9508882\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=see_link\">",
"       Patient information: Head injury in children and adolescents (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       Patient information: Sudden cardiac arrest (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?25/50/26402?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16564 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-EA0AF42627-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26402=[""].join("\n");
var outline_f25_50_26402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9508807\">",
"      What is CPR?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9508822\">",
"      How do I know if a child or infant needs CPR?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9508837\">",
"      How do I do CPR?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9508852\">",
"      What do I do besides compressions?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9508867\">",
"      Have the guidelines on how to do CPR changed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9508882\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16564\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/46/21218\">",
"      Infant CPR: 2-thumb method",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/50/20256\">",
"       Child CPR: 2-handed chest compressions",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/43/22192\">",
"        One-handed chest compressions",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/61/40914\">",
"         Infant CPR: 2-finger method",
"        </a>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/45/40658?source=related_link\">",
"      Patient information: Head injury in children and adolescents (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_50_26403="Modified hair apposition";
var content_f25_50_26403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Modified hair apposition of scalp wounds",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 684px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Grasp 5-15 hairs on either side of the wound with hemostats or forceps.",
"    <br>",
"     (B) Twist the hairs once until the wound edges appose.",
"     <br>",
"      (C) Place one drop of glue on the twist. Do not get glue in the wound.",
"      <br>",
"       (D) Repeat the procedure until the laceration is closed.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26403=[""].join("\n");
var outline_f25_50_26403=null;
var title_f25_50_26404="Contact dermatitis nickel 2";
var content_f25_50_26404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Contact dermatitis due to nickel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nickel in earrings caused this dermatitis on the ear lobe and neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26404=[""].join("\n");
var outline_f25_50_26404=null;
var title_f25_50_26405="Meloxicam: Patient drug information";
var content_f25_50_26405=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Meloxicam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=see_link\">",
"     see \"Meloxicam: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/18/2344?source=see_link\">",
"     see \"Meloxicam: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mobic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Meloxicam&reg;;",
"     </li>",
"     <li>",
"      Auro-Meloxicam;",
"     </li>",
"     <li>",
"      Ava-Meloxicam;",
"     </li>",
"     <li>",
"      CO Meloxicam;",
"     </li>",
"     <li>",
"      Dom-Meloxicam;",
"     </li>",
"     <li>",
"      Mobicox&reg;;",
"     </li>",
"     <li>",
"      Mobic&reg;;",
"     </li>",
"     <li>",
"      Mylan-Meloxicam;",
"     </li>",
"     <li>",
"      Novo-Meloxicam;",
"     </li>",
"     <li>",
"      PHL-Meloxicam;",
"     </li>",
"     <li>",
"      PMS-Meloxicam;",
"     </li>",
"     <li>",
"      ratio-Meloxicam;",
"     </li>",
"     <li>",
"      Teva-Meloxicam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702458",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to meloxicam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2980799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 30 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10836 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26405=[""].join("\n");
var outline_f25_50_26405=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191887\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191888\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029906\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029908\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029907\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029912\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029913\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029915\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029910\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029911\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029916\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029917\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/38/35432?source=related_link\">",
"      Meloxicam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/18/2344?source=related_link\">",
"      Meloxicam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_50_26406="NSAIDs: Adverse effects on the distal small bowel and colon";
var content_f25_50_26406=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   NSAIDs: Adverse effects on the distal small bowel and colon",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26406/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26406/contributors\">",
"     Louis-Michel Wong Kee Song, MD, FRCP(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26406/contributors\">",
"     Norman E Marcon, MD, FRCP(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26406/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26406/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26406/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26406/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/50/26406/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distal small bowel and colon are susceptible to the deleterious effects of nonsteroidal antiinflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The ileocecal region is a potential site for a variety of NSAID-induced injuries including erosions, ulcers, strictures, perforation, and the formation of diaphragms, which can lead to bowel obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. NSAIDs can also lead to colitis resembling inflammatory bowel disease (IBD), exacerbate preexisting IBD, or complicate diverticular disease (ie, perforation or bleeding) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The elderly and those on long-term NSAID therapy appeared to be at highest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/9\">",
"     9",
"    </a>",
"    ]. There may also be an association between NSAID use and collagenous colitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27530?source=see_link\">",
"     \"Lymphocytic and collagenous colitis (microscopic colitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STUDIES OF NSAID INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies using different methodologies have evaluated the potential deleterious effects of nonsteroidal antiinflammatory drugs (NSAIDs) on the small bowel and colon. Considered together, they suggest that NSAID-related intestinal injury is common. However, the proportion of patients who develop clinically important NSAID-induced enteropathy remains relatively small.",
"   </p>",
"   <p>",
"    The following summarizes the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About two-thirds of NSAID users demonstrate intestinal inflammation by indirect methods of 111-Indium-labeled leukocyte scintigraphy and 111-Indium fecal excretion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case-control study, patients with small or large bowel perforation or bleeding were more than twice as likely to be NSAID users [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An autopsy study evaluated 713 patients, 249 of whom had used NSAIDs in the six months prior to death [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/2\">",
"       2",
"      </a>",
"      ]. Nonspecific small intestinal ulceration (defined as ulcers &gt;3 mm in diameter) was much more common in those who had taken NSAIDs (8.4 versus 0.6 percent in nonusers). Three of the 21 patients with small intestinal ulcers died from perforation of an intestinal ulcer.",
"     </li>",
"     <li>",
"      A study involving double balloon enteroscopy found that 50 percent of NSAID-users had small bowel mucosal breaks compared with only 5 percent in controls [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At least six studies have used video capsule endoscopy (VCE) to assess small bowel injury associated with NSAIDs, two of which [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/12,13\">",
"       12,13",
"      </a>",
"      ] had a randomized design [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/12-17\">",
"       12-17",
"      </a>",
"      ]. A common finding is the observation that small bowel mucosal abnormalities are relatively common in healthy individuals. In one study, for example, 7 percent of placebo treated patients developed such findings during the course of the study, and an additional 14 percent of healthy subjects who had been screened for the study were excluded because of baseline mucosal abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     COX-2 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the relative safety of COX-2 inhibitors versus nonselective NSAIDs have shown mixed results. Considered together, they suggest that COX-2 inhibitors are not fully protective against clinically important lower gastrointestinal events and may not be more protective than some nonselective NSAIDs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By far the largest study included 34,701 patients with osteoarthritis or rheumatoid arthritis who were older than 50 who were randomly assigned to etoricoxib (60 or 90 mg daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      (150 mg daily) for an average of 18 months [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/18\">",
"       18",
"      </a>",
"      ]. Major lower GI clinical events (such as gross or occult rectal bleeding with hemodynamic instability without an upper gastrointestinal cause) occurred in a similar proportion of patients (0.32 versus 0.38 per 1000 patient years, respectively). On multivariable analysis, risk factors included a prior lower GI event (HR 4.06) or age &ge;65 (HR 1.98).",
"     </li>",
"     <li>",
"      By contrast, an earlier post-hoc analysis of a large outcome study found a 54 percent reduction in the risk of lower gastrointestinal events with rofecoxib compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/19\">",
"       19",
"      </a>",
"      ]. A possible explanation for the difference is that naproxen is a more potent inhibitor of platelet function than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      , thus increasing the rate of lower GI events in the comparator group.",
"     </li>",
"     <li>",
"      Other studies have compared COX-2 inhibitors to combination therapy with a PPI plus a nonselective NSAID. One trial included 120 healthy volunteers who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"       celecoxib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"       naproxen",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      , or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/12\">",
"       12",
"      </a>",
"      ]. After two weeks, all patients underwent VCE. Significantly more mucosal breaks were observed in the",
"      <span class=\"nowrap\">",
"       naproxen/omeprazole",
"      </span>",
"      group compared with the celecoxib group. The proportion of patients with mucosal breaks was correspondingly higher (55 versus 16 and 7 percent in the",
"      <span class=\"nowrap\">",
"       naproxen/omeprazole,",
"      </span>",
"      celecoxib, and placebo groups, respectively). Similar conclusions were reached in a second controlled trial that compared lumiracoxib to the combination of naproxen plus omeprazole or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/13\">",
"       13",
"      </a>",
"      ]. Acute small bowel injury on lumiracoxib was less frequent than with naproxen plus omeprazole and similar to placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest relative protection of the COX-2 inhibitors compared with nonselective NSAIDs plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    against small bowel injury during short-term follow-up. However, the significance of mucosal breaks is unclear. As noted above, there was no difference on major lower gastrointestinal events in the large randomized study described above. Furthermore, a non-randomized cohort study found similar rates and types of small bowel injury with long-term use of COX-2 selective agents versus nonselective NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Misoprostol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    decreases the risk of small bowel lesions from NSAIDs has not been well studied. A small observational study suggested a protective benefit in patients taking enteric coated low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/20\">",
"     20",
"    </a>",
"    ]. Placebo-controlled trials are needed to confirm a potential benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an attempt to decrease gastroduodenal side effects, the use of enteric-coated, sustained-release, or slow-release nonsteroidal antiinflammatory drugs (NSAIDs) may have shifted the damage to the distal small intestine and colon. A high local concentration of an active NSAID following ingestion or biliary excretion is necessary to increase intestinal permeability, which appears to be a prerequisite for NSAID-induced enteropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/3,21\">",
"     3,21",
"    </a>",
"    ]. The latter effect, which may be associated with increased bacterial growth, is much more likely to occur with NSAIDs that undergo enterohepatic circulation; secretion of the drug in the bile leads to repeated exposure of the intestinal mucosa to the toxic drug [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/22\">",
"     22",
"    </a>",
"    ]. Studies in an animal model with two related NSAIDs found a progressive increase in epithelial permeability and intestinal ulceration only with the drug that underwent enterohepatic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NSAIDs may also exert their deleterious effect by localized mucosal injury. In support of this hypothesis are the observations that NSAID capsules have been found at the site of perforating ulcers, that areas of mucosal injury often have sharp demarcations, and that the distal small bowel and proximal colon are typically involved [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/5,23\">",
"     5,23",
"    </a>",
"    ]. At the mucosal level, postulated mechanisms of injury have included inhibition of protective prostaglandins, alterations in blood flow, and increased small intestinal permeability with subsequent invasion by luminal factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/4\">",
"     4",
"    </a>",
"    ]. The mucosal damage may lead to inflammation and ulceration, followed by reparative fibrosis and stricture formation.",
"   </p>",
"   <p>",
"    Suppression of gastric acid secretion by proton pump inhibitors is unlikely to provide protection against NSAID-induced damage to the small intestine. In fact, in animal studies, PPIs have been demonstrated to exacerbate NSAID-induced intestinal damage due to shifts in enteric microbial populations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that most nonsteroidal antiinflammatory drug (NSAID)-induced injuries are subclinical and go unrecognized. When present, symptoms and signs are nonspecific and may include iron-deficiency anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frank bleeding from ulcers; anemia, hypoalbuminemia, or malabsorption from enteropathy; intermittent or complete bowel obstruction from broad-based or diaphragm-like strictures; watery or bloody diarrhea from colitis; and acute abdomen from perforation. The typical patient is one taking an NSAID for a rheumatic condition, such as osteoarthritis or rheumatoid arthritis. The duration of NSAID use to time of diagnosis is widely variable (days to years).",
"   </p>",
"   <p>",
"    Virtually all classes of NSAIDs that block both COX-1 and COX-2 have been implicated. Whether the relative safety of the COX-2 selective inhibitors on gastroduodenal injury will be observed in the small and large bowel remains to be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intestinal diaphragms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lesion thought to be pathognomonic of NSAID injury is the diaphragm-like stricture (",
"    <a class=\"graphic graphic_picture graphicRef59412 \" href=\"UTD.htm?11/60/12226\">",
"     picture 1",
"    </a>",
"    ), which is likely a scarring reaction secondary to ulcerative injury. These lesions are thin, concentric, diaphragm-like septa with pinhole-sized lumen (",
"    <a class=\"graphic graphic_picture graphicRef74226 \" href=\"UTD.htm?20/46/21217\">",
"     picture 2",
"    </a>",
"    ). They are usually multiple, found mostly in the mid-intestine, but have also been described in the ileum and colon [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/3,5-7,25\">",
"     3,5-7,25",
"    </a>",
"    ]. They are histologically characterized by submucosal fibrosis with normal overlying epithelium, apart from tip of diaphragm, which may be ulcerated. The mucosa between diaphragms is normal. As a potential cause of subacute obstruction, these strictures are difficult to diagnose since they may appear as exaggerated plica circularis under x-ray (",
"    <a class=\"graphic graphic_picture graphicRef79919 \" href=\"UTD.htm?19/27/19889\">",
"     picture 3",
"    </a>",
"    ). At laparotomy, the surgeon should be alerted to this possibility, since the exterior aspect may look normal and the strictures difficult to palpate. In this regard, intraoperative enteroscopy is helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endoscopic and histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on capsule endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/14\">",
"     14",
"    </a>",
"    ], double-balloon enteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/26\">",
"     26",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colonoscopy may lend support to the diagnosis of NSAID-induced injury, although there is nothing endoscopically specific about NSAID-induced erosions, ulcers (",
"    <a class=\"graphic graphic_picture graphicRef72227 \" href=\"UTD.htm?1/58/1953\">",
"     picture 4",
"    </a>",
"    ), or colitis. Histology is also nonspecific. The differential diagnosis should thus include infectious etiologies (eg, Campylobacter, Yersinia, cytomegalovirus, TB), IBD, ischemia, radiation enteritis, vasculitides, and other drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    tablets) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/4,5,27\">",
"     4,5,27",
"    </a>",
"    ]. However, the right diagnosis can usually be made in conjunction with a good history and endoscopic biopsies. Furthermore, the above NSAID-induced lesions (other than strictures and diaphragms) should improve or completely resolve upon withdrawal of the drug. Endoscopic findings of cobblestoning, longitudinal ulcers, or inflammatory polyps, and histologic findings of granulomas, crypt abscesses, or crypt distortion should suggest Crohn's disease instead of NSAIDs. Similarly, the presence of vasculitis on biopsy would favor a collagen vascular disorder. As mentioned above, the diaphragm-like strictures are characteristic for NSAID injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assessment of intestinal permeability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal permeability can be assessed experimentally by measurement of urinary recovery of orally administered test probes such as 51Cr-EDTA&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/21\">",
"     21",
"    </a>",
"    ]. Similarly, localization and quantification of intestinal inflammation can be assessed by 111-Indium-labeled leukocyte scintigraphy and 111-Indium fecal excretion, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/3\">",
"     3",
"    </a>",
"    ]. Although these radionuclide tests have shed some light on the pathogenesis of NSAID-induced injury, they are of limited clinical use due to lack of availability and their expense.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of treatment for nonsteroidal antiinflammatory drug (NSAID)-induced injury is discontinuation of the NSAID. For nonstrictured ileocecal lesions, this is usually followed by prompt improvement. A repeat colonoscopy six to eight weeks later should confirm partial or complete resolution of ulcerations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colitis. Persistence or worsening of the disease should raise suspicion for Crohn's disease or other causes.",
"   </p>",
"   <p>",
"    Obstructive symptoms due to strictures are unlikely to resolve without some form of intervention. Endoscopically accessible strictures or diaphragms may be amenable to through-the-scope (TTS) balloon dilatation (",
"    <a class=\"graphic graphic_picture graphicRef50670 \" href=\"UTD.htm?19/1/19476\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the diaphragm-like strictures tend to be multiple, often requiring resection of the involved intestinal segment and, less commonly, strictureplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/29\">",
"     29",
"    </a>",
"    ]. At laparotomy, the absence of serosal abnormalities or palpable areas of transition pinpointing to the enteropathy may be problematic. In such cases, an intraoperative small-caliber enteroscope placed perorally or through a surgical enterostomy can be used to accurately localize and evaluate the extent of disease, and to better define the intestinal margins for resection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Surgery is also indicated for other NSAID-induced complications such as significant bleeding or perforation, and when carcinoma cannot be reliably excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26406/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2634900\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonsteroidal antiinflammatory drug (NSAID)-related intestinal injury is common. However, the proportion of patients who develop clinically important NSAID-induced enteropathy is relatively small. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Studies of NSAID injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      COX-2 inhibitors are not fully protective against clinically important lower gastrointestinal events and may not be more protective than some nonselective NSAIDs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'COX-2 inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies are needed to determine if",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      decreases the risk of small bowel lesions from NSAIDs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'COX-2 inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Misoprostol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most NSAID-induced injuries are subclinical. When present, symptoms and signs of NSAID injury are nonspecific and may include iron deficiency anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      frank bleeding from ulcers; anemia, hypoalbuminemia, or malabsorption from enteropathy; intermittent or complete bowel obstruction from broad-based or diaphragm-like strictures; watery or bloody diarrhea from colitis; and acute abdomen from perforation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intestinal diaphragms are pathognomonic of NSAID injury. In contrast, erosions, ulcers, or colitis may be due to NSAIDs or another etiology. However, these lesions should improve or completely resolve upon withdrawal of the drug. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intestinal diaphragms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Endoscopic and histologic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mainstay of treatment for NSAID-induced injury is discontinuation of the NSAID.",
"      <br/>",
"      <br/>",
"      For nonstrictured ileocecal lesions, discontinuation of the NSAID is usually followed by prompt improvement. A repeat colonoscopy six to eight weeks later should be performed to confirm partial or complete resolution of ulcerations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      colitis. Persistence or worsening of the disease should raise suspicion for Crohn's disease or other causes.",
"      <br/>",
"      <br/>",
"      For strictures or diaphragms causing obstructive symptoms, through-the-scope (TTS) balloon dilatation should be performed if they are endoscopically accessible. However, diaphragm-like strictures tend to be multiple, and resection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      strictureplasty of the involved intestinal segment may be required.",
"      <br/>",
"      <br/>",
"      Surgery is also indicated for other NSAID-induced complications such as significant bleeding or perforation, and when carcinoma cannot be reliably excluded. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/1\">",
"      Rampton DS. Non-steroidal anti-inflammatory drugs and the lower gastrointestinal tract. Scand J Gastroenterol 1987; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/2\">",
"      Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/3\">",
"      Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/4\">",
"      Kwo PY, Tremaine WJ. Nonsteroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature. Mayo Clin Proc 1995; 70:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/5\">",
"      Kaufman HL, Fischer AH, Carroll M, Becker JM. Colonic ulceration associated with nonsteroidal anti-inflammatory drugs. Report of three cases. Dis Colon Rectum 1996; 39:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/6\">",
"      Lang J, Price AB, Levi AJ, et al. Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol 1988; 41:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/7\">",
"      Huber T, Ruchti C, Halter F. Nonsteroidal antiinflammatory drug-induced colonic strictures: a case report. Gastroenterology 1991; 100:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/8\">",
"      Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/9\">",
"      Gibson GR, Whitacre EB, Ricotti CA. Colitis induced by nonsteroidal anti-inflammatory drugs. Report of four cases and review of the literature. Arch Intern Med 1992; 152:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/10\">",
"      Langman MJ, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J (Clin Res Ed) 1985; 290:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/11\">",
"      Matsumoto T, Kudo T, Esaki M, et al. Prevalence of non-steroidal anti-inflammatory drug-induced enteropathy determined by double-balloon endoscopy: a Japanese multicenter study. Scand J Gastroenterol 2008; 43:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/12\">",
"      Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/13\">",
"      Hawkey CJ, Ell C, Simon B, et al. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 2008; 6:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/14\">",
"      Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/15\">",
"      Maiden L, Thjodleifsson B, Theodors A, et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/16\">",
"      Maiden L, Thjodleifsson B, Seigal A, et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 2007; 5:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/17\">",
"      Smecuol E, Pinto Sanchez MI, Suarez A, et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol 2009; 7:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/18\">",
"      Laine L, Curtis SP, Langman M, et al. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac. Gastroenterology 2008; 135:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/19\">",
"      Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/20\">",
"      Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/21\">",
"      Bjarnason I, Fehilly B, Smethurst P, et al. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991; 32:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/22\">",
"      Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 1997; 112:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/23\">",
"      Day TK. Intestinal perforation associated with osmotic slow release indomethacin capsules. Br Med J (Clin Res Ed) 1983; 287:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/24\">",
"      Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/25\">",
"      Matsuhashi N, Yamada A, Hiraishi M, et al. Multiple strictures of the small intestine after long-term nonsteroidal anti-inflammatory drug therapy. Am J Gastroenterol 1992; 87:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/26\">",
"      Hayashi Y, Yamamoto H, Kita H, et al. Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy. World J Gastroenterol 2005; 11:4861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/27\">",
"      Lengeling RW, Mitros FA, Brennan JA, Schulze KS. Ulcerative ileitis encountered at ileo-colonoscopy: likely role of nonsteroidal agents. Clin Gastroenterol Hepatol 2003; 1:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/28\">",
"      Hershfield NB. Endoscopic demonstration of non-steroidal anti-inflammatory drug-induced small intestinal strictures. Gastrointest Endosc 1992; 38:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/29\">",
"      Slesser AA, Wharton R, Smith GV, Buchanan GN. Systematic review of small bowel diaphragm disease requiring surgery. Colorectal Dis 2012; 14:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/30\">",
"      Abrahamian GA, Polhamus CD, Muskat P, Karulf RE. Diaphragm-like strictures of the ileum associated with NSAID use: a rare complication. South Med J 1998; 91:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26406/abstract/31\">",
"      Achanta KK, Petros JG, Cave DR, Zinny M. Use of intraoperative enteroscopy to diagnose nonsteroidal anti-inflammatory drug injury to the small intestine. Gastrointest Endosc 1999; 49:544.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2570 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26406=[""].join("\n");
var outline_f25_50_26406=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2634900\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STUDIES OF NSAID INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Misoprostol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intestinal diaphragms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endoscopic and histologic findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assessment of intestinal permeability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2634900\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2570\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2570|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/60/12226\" title=\"picture 1\">",
"      DBE NSAID induced stricture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/46/21217\" title=\"picture 2\">",
"      NSAID induced strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/27/19889\" title=\"picture 3\">",
"      NSAID induced strictures UGI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/58/1953\" title=\"picture 4\">",
"      DBE NSAID ulcerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/1/19476\" title=\"picture 5\">",
"      Balloon dilation of an NSAID-induced ileal stricture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27530?source=related_link\">",
"      Lymphocytic and collagenous colitis (microscopic colitis)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_50_26407="M perstans life cycle";
var content_f25_50_26407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82920&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Mansonella perstans life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 452px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a blood meal, an infected midge (genus",
"    <em>",
"     Culicoides",
"    </em>",
"    ) introduces third-stage filarial larvae onto the skin of the human host, where they penetrate into the bite wound",
"    <strong>",
"     (1)",
"    </strong>",
"    . They develop into adults that reside in body cavities, most commonly the peritoneal cavity or pleural cavity, but less frequently in the pericardium",
"    <strong>",
"     (2)",
"    </strong>",
"    . The size range for female worms is 70 to 80 mm in length and 120 &mu;m in diameter, and the males measure approximately 45 mm by 60 &mu;m. Adults produce unsheathed and subperiodic microfilariae, measuring 200 by 4.5 &mu;m, which reach the blood stream",
"    <strong>",
"     (3)",
"    </strong>",
"    . A midge ingests microfilariae during a blood meal",
"    <strong>",
"     (4)",
"    </strong>",
"    . After ingestion, the microfilariae migrate from the midge's midgut through the hemocoel to the thoracic muscles of the arthropod",
"    <strong>",
"     (5)",
"    </strong>",
"    . There the microfilariae develop into first-stage larvae",
"    <strong>",
"     (6)",
"    </strong>",
"    and subsequently into third-stage infective larvae",
"    <strong>",
"     (7)",
"    </strong>",
"    . The third-stage infective larvae migrate to the midge's proboscis",
"    <strong>",
"     (8)",
"    </strong>",
"    and can infect another human when the midge takes a blood meal",
"    <strong>",
"     (1)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites: Filariasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/frames/a-f/filariasis/body_Filariasis_m_perstans.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/frames/a-f/filariasis/body_Filariasis_m_perstans.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26407=[""].join("\n");
var outline_f25_50_26407=null;
var title_f25_50_26408="Thoracic ultrasound: Indications, advantages, and technique";
var content_f25_50_26408=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thoracic ultrasound: Indications, advantages, and technique",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26408/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26408/contributors\">",
"     Peter Doelken, MD, FCCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26408/contributors\">",
"     Paul Mayo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26408/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26408/contributors\">",
"     Steven A Sahn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26408/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26408/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/50/26408/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1492226\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portable ultrasound devices are used at the bedside to evaluate pleural abnormalities and to guide thoracentesis and related procedures, such as pleural drainage catheter placement and needle aspiration biopsy of pleural or subpleural lung masses. The goals are to improve accuracy and safety in the characterization of pleural disease and performance of pleural access procedures.",
"   </p>",
"   <p>",
"    The indications, contraindications, advantages, disadvantages, and technique of ultrasound-guided thoracentesis and related procedures will be reviewed here. The diagnostic evaluation and imaging of a pleural effusion and the technique of diagnostic thoracentesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=see_link\">",
"     \"Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link\">",
"     \"Imaging of pleural effusions in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link\">",
"     \"Diagnostic thoracentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44477189\">",
"    <span class=\"h1\">",
"     ADVANTAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic ultrasound has several advantages over traditional radiographic imaging of the pleura, including absence of radiation, better portability, real-time imaging, and the ability to perform dynamic imaging.",
"   </p>",
"   <p>",
"    Ultrasound is substantially better at determining the location of pleural fluid than bedside physical examination and, in experienced hands, is associated with a lower rate of complications during thoracentesis. In addition, ultrasound guidance increases the likelihood of a successful tap compared to using physical examination for guidance. As an example, in a study of 17 patients who had a failed thoracentesis without ultrasound imaging, thoracentesis with ultrasound was successful in 15 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic thoracentesis\", section on 'Site selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ultrasound examination of the pleura is more sensitive than a plain chest radiograph at detecting the presence of pleural fluid and differentiating pleural fluid from lung consolidation. Compared with computed tomography (CT), pleural ultrasound has a 95 percent sensitivity for detection of pleural disease in patients with a &ldquo;white out&rdquo; on plain chest radiograph, but is slightly less sensitive in detecting small amounts of fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Compared with CT scanning, ultrasound may better differentiate pleural fluid from pleural thickening and pleural masses [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/4\">",
"     4",
"    </a>",
"    ]. Bedside thoracic ultrasound is also faster and less resource-demanding than transporting a critically-ill patient to the CT scanner [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrasound guidance is associated with a reduced risk of pneumothorax during thoracentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In an observational cohort study of insurance database claims for 61,261 thoracenteses, ultrasound guidance was associated with a reduced likelihood of pneumothorax (OR, 0.81; 95% CI, 0.74-0.90) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44477232\">",
"    <span class=\"h1\">",
"     DISADVANTAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic ultrasound is an operator dependent technology. Focused, supervised training is needed to ensure that the operator correctly interprets the sonographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Inadequate training may increase the risk of complications.",
"   </p>",
"   <p>",
"    Ultrasound is not as good as CT imaging for evaluation of the underlying lung parenchyma in the setting of complex pleural and lung parenchymal disease. Ultrasound guidance is not as good as guidance by CT imaging for complicated interventional procedures, such as empyema drainage with a pigtail catheter or biopsy of pleural masses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link&amp;anchor=H7#H7\">",
"     \"Imaging of pleural effusions in adults\", section on 'Ultrasonography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44477257\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for pleural ultrasound include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bedside detection of pleural fluid when the plain chest radiograph shows a &ldquo;white out&rdquo;",
"     </li>",
"     <li>",
"      Bedside detection of a pneumothorax",
"     </li>",
"     <li>",
"      Guidance for diagnostic and therapeutic thoracentesis",
"     </li>",
"     <li>",
"      Guidance for placement of thoracostomy tubes",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492233\">",
"    <span class=\"h1\">",
"     MACHINE REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of portable ultrasound machines with two-dimensional scanning capability are used for pleural ultrasonography and associated procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/4,11\">",
"     4,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346232020\">",
"    <span class=\"h2\">",
"     Transducers",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 3.5 to 5.0 MHz transducer with a convex sector design works well for pleural imaging in most instances [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/12\">",
"     12",
"    </a>",
"    ]. Cardiac transducers are particularly effective, as they are designed with a small footprint, allowing scanning between rib interspaces. An additional advantage of using a cardiac transducer is that it may be used for other ultrasound applications (eg, cardiac, lung, abdominal); this reduces equipment costs.",
"   </p>",
"   <p>",
"    Once an abnormality has been identified, a 7.5 to 10 MHz linear transducer can be used if needed to obtain more detailed images [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H346232027\">",
"    <span class=\"h2\">",
"     Image storage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many portable ultrasound machines have digital image storage and transfer capability that meets the requirements for durable image documentation. Alternatively, the machine may be equipped with a printer if the clinician prefers a hard copy of the study to place directly in the patient chart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H568796\">",
"    <span class=\"h2\">",
"     Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler is generally not required for portable thoracic ultrasound-guided procedures, although it is occasionally used by ultrasonographers to differentiate a small pleural effusion from pleural thickening and to identify blood vessels that might be in the path of a needle during a procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543573636\">",
"    <span class=\"h1\">",
"     SCANNING PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1801185\">",
"    <span class=\"h2\">",
"     Preprocedure steps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient&rsquo;s identity and planned procedure are confirmed. The results of other evaluations related to the patient&rsquo;s problem are reviewed by the ultrasonographer. In particular, the chest radiograph is reviewed before the procedure to confirm the side of the pleural abnormality and the expected location of any masses or loculated accumulations of fluid.",
"   </p>",
"   <p>",
"    Informed consent for the procedure is obtained, and clotting studies are confirmed to be adequate, if a thoracentesis or other pleural access procedure is planned.",
"   </p>",
"   <p>",
"    Acoustic gel is placed on the patient&rsquo;s skin in the area of interest to provide an airless interface, as ultrasound waves do not pass through air well. The gel also permits the ultrasound probe to slide gently over the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543573643\">",
"    <span class=\"h2\">",
"     Machine setup",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultrasound machine is positioned so the screen is easily visible from the operator&rsquo;s working position. Ambient lighting is reduced to maximize screen contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/9\">",
"     9",
"    </a>",
"    ]. Typically, the thorax is scanned using gray-scale, real-time ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/9\">",
"     9",
"    </a>",
"    ]. Dynamic noise filters are not used as they can obscure visualization of lung sliding. (See",
"    <a class=\"local\" href=\"#H1801314\">",
"     'Lung sliding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The depth setting is adjusted such that the structures of the hemithorax deep to the chest wall are imaged. Gain is adjusted to maximize the contrast between different tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain conventions are important to maintain orientation of thoracic anatomy and to standardize image acquisition. Ultrasound probes have a groove on one side that corresponds to a screen orientation marker, which appears as a white or blue dot on the screen. By convention, the dot is typically at the top or on the upper left of the screen (",
"    <a class=\"graphic graphic_movie graphicRef71825 \" href=\"UTD.htm?35/58/36768\">",
"     movie 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The transducer is held perpendicular to the skin surface with the transducer marker (groove) pointed cephalad and the scanning plane directed between adjacent ribs. Structures near the skin surface appear close to the dot and deeper structures appear lower on the screen. A depth guide is usually located along the right side of the screen, to enable estimation of the depth of a structure relative to the chest wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543573650\">",
"    <span class=\"h2\">",
"     Patient position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fluid is obedient to the law of gravity, so pleural fluid collects in the dependent portion of the thorax (unless loculated). The usual position for ultrasound examination of a pleural effusion is for the patient to sit with arms extended and resting on a firm surface that is just below the level of the shoulders. Raising the patient&rsquo;s ipsilateral arm up to or above their head widens the intercostal spaces and facilitates scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the patient is sitting, the entire back is accessible for ultrasonographic examination, so free-flowing pleural fluid is readily identified in the dependent lower thorax (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73746 \" href=\"UTD.htm?30/45/31455\">",
"     image 1",
"    </a>",
"    ). When scanning for a pneumothorax, the patient is usually positioned supine with the head of the bed elevated slightly.",
"   </p>",
"   <p>",
"    The situation is more difficult in the critically-ill patient who is in a supine position and attached to multiple support devices [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with severe respiratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemodynamic failure may be intolerant of changes in body position. We typically position critically-ill patients supine with the ipsilateral arm held across the chest towards the opposite side. If the effusion is large, it may be identified in the mid axillary line. Smaller effusions may require that the transducer be moved medially such that it is pressed into the mattress and angled upwards to visualize the effusion. This is helpful for identifying the presence of the effusion, but impractical as a means to guide thoracentesis as the transducer position cannot be duplicated by the",
"    <span class=\"nowrap\">",
"     needle/syringe",
"    </span>",
"    assembly.",
"   </p>",
"   <p>",
"    Several alternative positions may be considered in order to permit access for ultrasound guided thoracentesis. These positions include slight elevation of the head of the bed with the patient rotated towards the lateral decubitus position, a flat bed with the patient in the lateral decubitus position and the side of the expected pleural effusion up, and the supine position with the patient lying such that the side with the effusion is at the edge of the bed (",
"    <a class=\"graphic graphic_picture graphicRef79943 \" href=\"UTD.htm?27/51/28470\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10651857\">",
"    <span class=\"h2\">",
"     Scanning strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transducer is oriented to scan between the ribs, as ribs block transmission of ultrasound. This orientation yields an image where the adjacent rib shadows appear on either side of the image on the screen. By moving the transducer longitudinally from one interspace to another, multiple interspaces may be examined in a short time. A methodical scanning strategy allows a comprehensive analysis of the target effusion or other pleural pathology (",
"    <a class=\"graphic graphic_picture graphicRef60954 \" href=\"UTD.htm?25/49/26385\">",
"     picture 2",
"    </a>",
"    ). After a general examination of the thorax using multiple scan lines, the examiner may concentrate on an area of particular interest in order to correctly identify nearby landmarks and determine the best site for device insertion, if needed (",
"    <a class=\"graphic graphic_movie graphicRef71825 \" href=\"UTD.htm?35/58/36768\">",
"     movie 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1801358\">",
"    <span class=\"h1\">",
"     ULTRASOUND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terminology for thoracic ultrasound provides a description of a number of sonographic artifacts caused by air-tissue interfaces. The presence or absence of these artifacts can be used to aid in the diagnosis of pleural disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44476555\">",
"    <span class=\"h2\">",
"     A, B, and E lines",
"    </span>",
"   </p>",
"   <p>",
"    A lines are horizontal lines (roughly parallel to the chest wall) that are brightly echogenic and located between the rib shadows when the probe is positioned longitudinally [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    B lines arise at the border between aerated and compressed lung and are described as multiple ray-like, or comet-tail, vertical lines extending from the pleural line to the lower edge of the screen without fading (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71143 \" href=\"UTD.htm?13/39/13951\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/16\">",
"     16",
"    </a>",
"    ]. B lines move synchronously with the lung during respiration and tend to erase A lines (",
"    <a class=\"graphic graphic_movie graphicRef64485 \" href=\"UTD.htm?41/49/42783\">",
"     movie 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    E lines are vertical lines extending from the areas of subcutaneous emphysema deep into the chest [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/16\">",
"     16",
"    </a>",
"    ]. These sonographic artifacts can be confused with B lines and thus contribute to misidentification of a pneumothorax. The possibility of E lines should be suspected when subcutaneous emphysema can be palpated on the chest wall and when the vertical lines start at a level external to the ribs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1801314\">",
"    <span class=\"h2\">",
"     Lung sliding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sonographic effect of lung sliding (also known as lung gliding or the lung sliding sign) is created by movement of the lung relative to the chest wall during respiration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/17\">",
"     17",
"    </a>",
"    ]. The sonographic appearance is that of a thin, bright line moving horizontally along the pleural line with a wave-like pattern located above (towards the chest wall) and a granular pattern below. Lung sliding is an indirect sign indicating adherence of the visceral pleura to the parietal pleura. When air separates the two pleural layers as in a pneumothorax, the movement disappears (",
"    <a class=\"graphic graphic_movie graphicRef55433 \" href=\"UTD.htm?19/26/19885\">",
"     movie 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef64485 \" href=\"UTD.htm?41/49/42783\">",
"     movie 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Following a pleural access procedure, the disappearance of lung sliding in an area where it was previously identified is a strong indicator of a postprocedure pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H165837042\">",
"     'Identification of pneumothorax'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1801351\">",
"    <span class=\"h2\">",
"     Lung pulse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lung pulse is a vertical movement of the pleural line synchronous to the cardiac rhythm that is more commonly seen on the left hemithorax than the right. The lung pulse is caused by transmission of heart beats through consolidated, motionless lung. Intrapleural air prevents transmission of either horizontal or vertical movements to the parietal pleura. Visualization of a lung pulse excludes a pneumothorax. However, the lung pulse is only of significance if actually present; absence of a lung pulse is NOT diagnostic of a pneumothorax.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1801493\">",
"    <span class=\"h2\">",
"     Lung point",
"    </span>",
"    &nbsp;&mdash;&nbsp;A lung point is defined as a location where the lung adheres to the parietal pleura in a patient with a pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. When scanning a patient with a suspected pneumothorax, the probe is moved laterally along the rib interspaces from the area without lung sliding or B lines to search for an area where lung sliding is seen intermittently (",
"    <a class=\"graphic graphic_movie graphicRef68222 \" href=\"UTD.htm?5/56/6030\">",
"     movie 4",
"    </a>",
"    ). The presence of lung sliding in one area (ie, the lung point) and not in another is a strong indicator of a pneumothorax. However, a lung point is not always present, such as when a large pneumothorax causes such extensive lung collapse that the lung does not abut the pleura [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10024816\">",
"    <span class=\"h1\">",
"     ANATOMIC LANDMARKS AND ULTRASOUND APPEARANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the normal sonographic appearance of the chest wall, pleura, and adjacent structures guides accurate diagnosis of pleural pathology and is essential to safe needle insertion into the pleural space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165837050\">",
"    <span class=\"h2\">",
"     Chest wall and pleura",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal thoracic ultrasound has certain characteristic features [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/9,20,21\">",
"     9,20,21",
"    </a>",
"    ]. The intercostal muscles appear as hypoechoic, linear shadows of soft tissue density, containing echogenic fascial planes. The ribs appear as repeating curvilinear structures with a deeper, hypoechoic, posterior acoustic shadow that can be mistaken for pleural fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/22\">",
"     22",
"    </a>",
"    ]. The parietal and visceral pleura normally appear as a single, bright echoic line no wider than 2 mm. A high resolution ultrasound probe (7.5 to 10 MHz) is sometimes needed to differentiate parietal and visceral portions of the pleura [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/11\">",
"     11",
"    </a>",
"    ]. The change in acoustic impedance at the pleura-lung interface results in a series of echogenic parallel lines equidistant from each other just deep to the pleural line.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44476682\">",
"    <span class=\"h2\">",
"     Diaphragm and subdiaphragmatic recesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diaphragm must be positively identified before any pleural procedure to ensure that the needle insertion site and trajectory will remain above the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/4,9\">",
"     4,9",
"    </a>",
"    ]. Subdiaphragmatic insertion of a needle or catheter can be catastrophic and potentially fatal, if the liver or spleen is lacerated.",
"   </p>",
"   <p>",
"    The diaphragm typically appears as an echogenic line approximately 1 mm thick; downward (caudad) movement of the diaphragm should be seen with inspiration (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73746 \" href=\"UTD.htm?30/45/31455\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/11\">",
"     11",
"    </a>",
"    ]. As a general rule, when the patient is sitting, the diaphragm is located caudad to the 9",
"    <sup>",
"     th",
"    </sup>",
"    rib. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic thoracentesis\", section on 'Site selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to identifying the location of diaphragm, the location of the splenorenal and hepatorenal recesses should be confirmed, as the curvilinear sonographic appearance of the splenorenal and hepatorenal recesses is similar to that of the diaphragm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58325 \" href=\"UTD.htm?28/39/29311\">",
"     image 3",
"    </a>",
"    ). The splenorenal and hepatorenal recesses are identified by finding the liver or spleen craniad and the kidney caudad to the respective recess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44476689\">",
"    <span class=\"h2\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;To avoid injury to the lung during an ultrasound guided thoracentesis, the sonographer must be able to identify the appearance of air-filled, fluid-filled, or atelectatic lung. The air-filled lung has an ultrasound appearance of bright echoes. When the lung is compressed by a surrounding pleural effusion, it appears hyperechoic or tissue dense; and, in large effusions, may appear to float in the effusion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71143 \" href=\"UTD.htm?13/39/13951\">",
"     image 2",
"    </a>",
"    ). Smaller effusions cause less compressive atelectasis.",
"   </p>",
"   <p>",
"    At the border between aerated and compressed lung, multiple ray-like air artifacts termed &ldquo;B&rdquo; lines may be seen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71143 \" href=\"UTD.htm?13/39/13951\">",
"     image 2",
"    </a>",
"    ). Compressed lung frequently exhibits a characteristic flapping movement and moves with the respiratory cycle (",
"    <a class=\"graphic graphic_movie graphicRef64485 \" href=\"UTD.htm?41/49/42783\">",
"     movie 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The lung may move closer to the proposed needle path during respiratory cycling and possibly obscure the ultrasound field. Safe site selection requires that the pleural effusion space be clear throughout the respiratory cycle and that there is sufficient space between the chest wall and the visceral pleura to avoid inadvertent puncture of the lung. There is no definite rule as to the minimum allowable depth of pleural fluid at the needle insertion site. Greater than 10 mm is a reasonable estimate of a safe distance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/9\">",
"     9",
"    </a>",
"    ]. By changing transducer position and angle, the examiner selects the site that yields the greatest distance between the chest wall and the surface of the lung.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44476696\">",
"    <span class=\"h2\">",
"     Heart",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive identification of the heart is important when performing needle insertion in the left anterolateral thoracic region. The heart may be surprisingly lateral in position, particularly in supine patients or when the patient has cardiomegaly or ipsilateral mediastinal shift. Ultrasonography allows site selection that is well away from the heart. The sonographic appearance of the heart depends on the axis of viewing (",
"    <a class=\"graphic graphic_figure graphicRef59299 \" href=\"UTD.htm?1/3/1072\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef88546 \" href=\"UTD.htm?27/14/27873\">",
"     movie 5",
"    </a>",
"    ) and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14167?source=see_link\">",
"     \"Transthoracic echocardiography: Normal cardiac anatomy and tomographic views\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural loculation may cause the target effusion to be in an unusual intrathoracic position. Anteromedial loculations require the examiner to identify and avoid adjacent mediastinal structures. For parasternal needle insertion, the internal mammary artery should be looked for using color Doppler.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543573657\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF PLEURAL FLUID",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plain chest radiograph should be reviewed before the ultrasound guided procedure to confirm the expected site, size, and likelihood of loculations of the pleural effusion. By convention, the echogenicity of thoracic structures is determined relative to the liver.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44476831\">",
"    <span class=\"h2\">",
"     Characteristic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fluid usually appears as an anechoic (black), or hypoechoic compared to the liver, area surrounded by typical anatomic boundaries. Three ultrasonographic criteria must be satisfied to ensure the presence of a pleural effusion (",
"    <a class=\"graphic graphic_movie graphicRef52741 \" href=\"UTD.htm?17/4/17472\">",
"     movie 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The finding of an echo free space (appears black and without stippling) within the thoracic cavity",
"     </li>",
"     <li>",
"      The finding of typical anatomic boundaries that surround the effusion: the inside of the chest wall, the diaphragm, and the surface of the lung",
"     </li>",
"     <li>",
"      The presence of dynamic characteristics that are typical of pleural fluid, such as diaphragmatic movement, lung movement, movement of echogenic material within the fluid (septations, cellular debris, fronds), and changes in the shape of the pleural effusion with respiratory cycling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initially, the examiner should require that all of the above findings be met for identification of a pleural effusion. However, certain types of pleural effusions have variable or increased echogenicity, which can be accurately identified with advanced skill and experience. (See",
"    <a class=\"local\" href=\"#H543573664\">",
"     'Atypical appearances of pleural fluid'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unlike intraabdominal fluid, a pleural effusion is not deformable with force application to the transducer on account of the rigidity of thoracic cage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H543573664\">",
"    <span class=\"h2\">",
"     Atypical appearances of pleural fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;With experience, the examiner will recognize that some pleural effusions have an atypical appearance, which may be due to obscuration of the typical findings or may reflect the characteristic presentation of the underlying process. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Massive obesity and chest wall edema may degrade the image quality such that typical ultrasound features are not discernible.",
"     </li>",
"     <li>",
"      Complex loculated effusions may be hyperechoic and be located in a nondependent part of the thorax (",
"      <a class=\"graphic graphic_movie graphicRef52741 \" href=\"UTD.htm?17/4/17472\">",
"       movie 6",
"      </a>",
"      ). Hemothorax and empyema fluid may be isoechoic with the liver and have no dynamic changes with respiration.",
"     </li>",
"     <li>",
"      The presence of pleural or diaphragmatic thickening or nodularity, or an echogenic swirling pattern is suggestive of a malignant pleural effusion [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/9,24,25\">",
"       9,24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of air and fluid together (ie, hemopneumothorax) may present a complex sonographic picture.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the examiner is uncertain, a more experienced ultrasonographer should review the findings or an alternative imaging modality should be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1800976\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF PLEURAL MALIGNANT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morphologic characteristics used for identification of malignant pleural disease on chest computed tomography (CT) have been adapted for use in ultrasound examination of the pleura [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/9,24,26\">",
"     9,24,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link&amp;anchor=H355282026#H355282026\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\", section on 'Pleural involvement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The morphologic characteristics of pleural malignancy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diaphragmatic and parietal pleural nodule or nodules",
"     </li>",
"     <li>",
"      Pleural thickening &gt;1 cm",
"     </li>",
"     <li>",
"      Hepatic metastasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of 52 patients with suspected malignant pleural effusion, thoracic ultrasound correctly identified",
"    <span class=\"nowrap\">",
"     26/33",
"    </span>",
"    malignant effusions and",
"    <span class=\"nowrap\">",
"     19/19",
"    </span>",
"    benign effusions by using these criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/24\">",
"     24",
"    </a>",
"    ]. However, ultrasound findings alone are not sufficient to make a diagnosis of pleural malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165837042\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF PNEUMOTHORAX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portable ultrasound is used to detect a pneumothorax is several situations, such as after a pleural access procedure, in the evaluation of a patient with chest trauma in the emergency department, and following chest tube placement to assess resolution of a pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/16,27-32\">",
"     16,27-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=see_link\">",
"     \"Imaging of pneumothorax\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=see_link\">",
"     \"Primary spontaneous pneumothorax in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    As pleural air is usually located in the least dependent area, the patient is scanned in the supine position. A 3.5 to 5 MHz transducer probe is directed to the third or fourth intercoastal space between the parasternal and midclavicular lines. The first step is to identify the contiguous ribs on either side of the field. Next, the pleural line is identified between and under the ribs. For confirmation, the pleural line should be at the same depth on both sides of the chest. The four key features of a pneumothorax are the following (",
"    <a class=\"graphic graphic_movie graphicRef77394 \" href=\"UTD.htm?33/21/34141\">",
"     movie 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of lung sliding which is a horizontal movement of the lung relative to the pleural line. (See",
"      <a class=\"local\" href=\"#H1801314\">",
"       'Lung sliding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absence of B lines. The presence of B lines is strong evidence against a pneumothorax, but their absence is not a sensitive sign of a pneumothorax (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71143 \" href=\"UTD.htm?13/39/13951\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H44476555\">",
"       'A, B, and E lines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is advisable to document the presence and location of lung sliding or B-lines prior to any procedure associated with a risk of pneumothorax as the disappearance of lung sliding or B-lines after the procedure confirms the interval development of a pneumothorax. Two other signs, absence of lung pulse and identification of the lung point, have been described as consistent with a pneumothorax, but these signs are generally not used as they are less accurate than the findings of absence of lung sliding and absence of B lines [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1801351\">",
"     'Lung pulse'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1801493\">",
"     'Lung point'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a patient with COPD, the ultrasound appearance of emphysematous areas can mimic a pneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26408/abstract/33\">",
"     33",
"    </a>",
"    ]. A chest computed tomography exam may be needed to accurately identify a pneumothorax in a patient with emphysematous bullae. In addition, subcutaneous emphysema can lead to sonographic artifacts, such as E lines that are created by the subcutaneous air and mimic B lines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1492303\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Portable ultrasound is a useful technique for evaluation of the pleural abnormalities at the bedside. Pleural ultrasound improves the accuracy of the physical examination and enables a better understanding of pleural pathology than the plain chest radiograph alone. (See",
"      <a class=\"local\" href=\"#H44477189\">",
"       'Advantages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound guidance for thoracentesis has several advantages over traditional radiographic imaging of the pleura, including absence of radiation, better portability, real-time imaging, and the ability to perform dynamic imaging. (See",
"      <a class=\"local\" href=\"#H44477189\">",
"       'Advantages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of a portable ultrasound machine requires additional, focused training to ensure that the operator correctly interprets the sonographic findings. (See",
"      <a class=\"local\" href=\"#H44477232\">",
"       'Disadvantages'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The indications for pleural ultrasound include bedside detection of pleural fluid or a pneumothorax, guidance for diagnostic and therapeutic thoracentesis, and guidance for placement of thoracostomy tubes. (See",
"      <a class=\"local\" href=\"#H44477257\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A two dimensional ultrasound machine with a 3.5 to 5 MHz transducer with a convex head is typically used for thoracic ultrasound (",
"      <a class=\"graphic graphic_movie graphicRef71825 \" href=\"UTD.htm?35/58/36768\">",
"       movie 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1492233\">",
"       'Machine requirements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Terminology for thoracic ultrasound provides a description of a number of sonographic artifacts caused by air-tissue interfaces, such as A, B, and E lines, lung sliding, lung pulse, and lung point (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71143 \" href=\"UTD.htm?13/39/13951\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef64485 \" href=\"UTD.htm?41/49/42783\">",
"       movie 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef68222 \" href=\"UTD.htm?5/56/6030\">",
"       movie 4",
"      </a>",
"      ). The presence or absence of these artifacts is used in the diagnosis of pleural diseases (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef71143 \" href=\"UTD.htm?13/39/13951\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1801358\">",
"       'Ultrasound terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Knowledge of the normal sonographic appearance of the chest wall, pleura, and adjacent structures guides accurate diagnosis of pleural pathology and is essential to safe needle insertion into the pleural space. (See",
"      <a class=\"local\" href=\"#H10024816\">",
"       'Anatomic landmarks and ultrasound appearance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three ultrasonographic criteria must be satisfied to ensure the presence of a pleural effusion: (See",
"      <a class=\"local\" href=\"#H543573657\">",
"       'Identification of pleural fluid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The presence of an echo free space (appears black and without stippling) within the thoracic cavity (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73746 \" href=\"UTD.htm?30/45/31455\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef52741 \" href=\"UTD.htm?17/4/17472\">",
"       movie 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The identification of typical anatomic boundaries that surround the effusion: the inside of the chest wall, the diaphragm, and the surface of the lung (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73746 \" href=\"UTD.htm?30/45/31455\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58325 \" href=\"UTD.htm?28/39/29311\">",
"       image 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The presence of dynamic characteristics that are typical of pleural fluid, such as diaphragmatic movement, lung movement, movement of echogenic material within the fluid (septations, cellular debris, fronds), and changes in the shape of the pleural effusion with respiratory cycling (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51853 \" href=\"UTD.htm?7/17/7440\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pleural fluid may have an atypical appearance in certain situations, such as when a thick chest wall degrades the ultrasound image, when the fluid is septated (eg, complex parapneumonic effusion or empyema), when malignancy causes a nodular or thickened pleura, or when air and fluid are both present (eg, hemopneumothorax) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51853 \" href=\"UTD.htm?7/17/7440\">",
"       image 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef52741 \" href=\"UTD.htm?17/4/17472\">",
"       movie 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H543573664\">",
"       'Atypical appearances of pleural fluid'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1800976\">",
"       'Identification of pleural malignant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ultrasound characteristics that suggest the presence of pleural malignancy include: diaphragmatic and parietal pleural nodule or nodules, pleural thickening &gt;1 cm, and hepatic metastasis. (See",
"      <a class=\"local\" href=\"#H1800976\">",
"       'Identification of pleural malignant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasound signs of a pneumothorax include absence of lung sliding, absence of &ldquo;B&rdquo; lines, absence of a lung pulse, and absence of a lung point (",
"      <a class=\"graphic graphic_movie graphicRef77394 \" href=\"UTD.htm?33/21/34141\">",
"       movie 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef55433 \" href=\"UTD.htm?19/26/19885\">",
"       movie 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H165837042\">",
"       'Identification of pneumothorax'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1801358\">",
"       'Ultrasound terminology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/1\">",
"      Weingardt JP, Guico RR, Nemcek AA Jr, et al. Ultrasound findings following failed, clinically directed thoracenteses. J Clin Ultrasound 1994; 22:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/2\">",
"      Gryminski J, Krak&oacute;wka P, Lypacewicz G. The diagnosis of pleural effusion by ultrasonic and radiologic techniques. Chest 1976; 70:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/3\">",
"      Yu CJ, Yang PC, Wu HD, et al. Ultrasound study in unilateral hemithorax opacification. Image comparison with computed tomography. Am Rev Respir Dis 1993; 147:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/4\">",
"      Feller-Kopman D. Ultrasound-guided thoracentesis. Chest 2006; 129:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/5\">",
"      Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. Curr Opin Pulm Med 2007; 13:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/6\">",
"      Mercaldi CJ, Lanes SF. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis. Chest 2013; 143:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/7\">",
"      Patel PA, Ernst FR, Gunnarsson CL. Ultrasonography guidance reduces complications and costs associated with thoracentesis procedures. J Clin Ultrasound 2012; 40:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/8\">",
"      Mayo PH, Goltz HR, Tafreshi M, Doelken P. Safety of ultrasound-guided thoracentesis in patients receiving mechanical ventilation. Chest 2004; 125:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/9\">",
"      Havelock T, Teoh R, Laws D, et al. Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65 Suppl 2:ii61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/10\">",
"      Mayo PH, Beaulieu Y, Doelken P, et al. American College of Chest Physicians/La Soci&eacute;t&eacute; de R&eacute;animation de Langue Fran&ccedil;aise statement on competence in critical care ultrasonography. Chest 2009; 135:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/11\">",
"      Koh DM, Burke S, Davies N, Padley SP. Transthoracic US of the chest: clinical uses and applications. Radiographics 2002; 22:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/12\">",
"      Beckh S, B&ouml;lcskei PL, Lessnau KD. Real-time chest ultrasonography: a comprehensive review for the pulmonologist. Chest 2002; 122:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/13\">",
"      Kalokairinou-Motogna M, Maratou K, Paianid I, et al. Application of color Doppler ultrasound in the study of small pleural effusion. Med Ultrason 2010; 12:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/14\">",
"      Volpicelli G, Caramello V, Cardinale L, et al. Detection of sonographic B-lines in patients with normal lung or radiographic alveolar consolidation. Med Sci Monit 2008; 14:CR122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/15\">",
"      Bouhemad B, Zhang M, Lu Q, Rouby JJ. Clinical review: Bedside lung ultrasound in critical care practice. Crit Care 2007; 11:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/16\">",
"      Volpicelli G. Sonographic diagnosis of pneumothorax. Intensive Care Med 2011; 37:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/17\">",
"      Lichtenstein DA, Menu Y. A bedside ultrasound sign ruling out pneumothorax in the critically ill. Lung sliding. Chest 1995; 108:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/18\">",
"      Lichtenstein D, Mezi&egrave;re G, Biderman P, Gepner A. The \"lung point\": an ultrasound sign specific to pneumothorax. Intensive Care Med 2000; 26:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/19\">",
"      Lichtenstein D, Mezi&egrave;re G, Biderman P, Gepner A. The comet-tail artifact: an ultrasound sign ruling out pneumothorax. Intensive Care Med 1999; 25:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/20\">",
"      Diacon AH, Theron J, Bolliger CT. Transthoracic ultrasound for the pulmonologist. Curr Opin Pulm Med 2005; 11:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/21\">",
"      Tsai TH, Yang PC. Ultrasound in the diagnosis and management of pleural disease. Curr Opin Pulm Med 2003; 9:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/22\">",
"      Beaulieu Y, Marik PE. Bedside ultrasonography in the ICU: part 2. Chest 2005; 128:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/23\">",
"      Mayo PH, Doelken P. Pleural ultrasonography. Clin Chest Med 2006; 27:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/24\">",
"      Qureshi NR, Rahman NM, Gleeson FV. Thoracic ultrasound in the diagnosis of malignant pleural effusion. Thorax 2009; 64:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/25\">",
"      Chian CF, Su WL, Soh LH, et al. Echogenic swirling pattern as a predictor of malignant pleural effusions in patients with malignancies. Chest 2004; 126:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/26\">",
"      Bandi V, Lunn W, Ernst A, et al. Ultrasound vs. CT in detecting chest wall invasion by tumor: a prospective study. Chest 2008; 133:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/27\">",
"      Lichtenstein DA, Mezi&egrave;re G, Lascols N, et al. Ultrasound diagnosis of occult pneumothorax. Crit Care Med 2005; 33:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/28\">",
"      Reissig A, Kroegel C. Accuracy of transthoracic sonography in excluding post-interventional pneumothorax and hydropneumothorax. Comparison to chest radiography. Eur J Radiol 2005; 53:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/29\">",
"      Chun TH, Spirito A, Hern&aacute;ndez L, et al. The significance of marijuana use among alcohol-using adolescent emergency department patients. Acad Emerg Med 2010; 17:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/30\">",
"      Blaivas M, Lyon M, Duggal S. A prospective comparison of supine chest radiography and bedside ultrasound for the diagnosis of traumatic pneumothorax. Acad Emerg Med 2005; 12:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/31\">",
"      Galbois A, Ait-Oufella H, Baudel JL, et al. Pleural ultrasound compared with chest radiographic detection of pneumothorax resolution after drainage. Chest 2010; 138:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/32\">",
"      Alrajhi K, Woo MY, Vaillancourt C. Test characteristics of ultrasonography for the detection of pneumothorax: a systematic review and meta-analysis. Chest 2012; 141:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26408/abstract/33\">",
"      Slater A, Goodwin M, Anderson KE, Gleeson FV. COPD can mimic the appearance of pneumothorax on thoracic ultrasound. Chest 2006; 129:545.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14888 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-926874B457-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26408=[""].join("\n");
var outline_f25_50_26408=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1492303\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1492226\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44477189\">",
"      ADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44477232\">",
"      DISADVANTAGES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44477257\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1492233\">",
"      MACHINE REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H346232020\">",
"      Transducers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H346232027\">",
"      Image storage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H568796\">",
"      Doppler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543573636\">",
"      SCANNING PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1801185\">",
"      Preprocedure steps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543573643\">",
"      Machine setup",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543573650\">",
"      Patient position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10651857\">",
"      Scanning strategy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1801358\">",
"      ULTRASOUND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44476555\">",
"      A, B, and E lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1801314\">",
"      Lung sliding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1801351\">",
"      Lung pulse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1801493\">",
"      Lung point",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10024816\">",
"      ANATOMIC LANDMARKS AND ULTRASOUND APPEARANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165837050\">",
"      Chest wall and pleura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44476682\">",
"      Diaphragm and subdiaphragmatic recesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44476689\">",
"      Lung",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44476696\">",
"      Heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H543573657\">",
"      IDENTIFICATION OF PLEURAL FLUID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44476831\">",
"      Characteristic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H543573664\">",
"      Atypical appearances of pleural fluid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1800976\">",
"      IDENTIFICATION OF PLEURAL MALIGNANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H165837042\">",
"      IDENTIFICATION OF PNEUMOTHORAX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1492303\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/14888\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/14888|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/45/31455\" title=\"diagnostic image 1\">",
"      Pleural effusion and diaphragm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/39/13951\" title=\"diagnostic image 2\">",
"      B lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/39/29311\" title=\"diagnostic image 3\">",
"      Hepatorenal recess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/17/7440\" title=\"diagnostic image 4\">",
"      Complex pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/14888|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/3/1072\" title=\"figure 1\">",
"      2D TTE Short axis pleural effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/14888|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/51/28470\" title=\"picture 1\">",
"      Alternate patient positions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/49/26385\" title=\"picture 2\">",
"      Thoracic ultrasound transducer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/14888|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?35/58/36768\" title=\"movie 1\">",
"      Machine set up and scanning strategy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?41/49/42783\" title=\"movie 2\">",
"      B lines and lung sliding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?19/26/19885\" title=\"movie 3\">",
"      Thoracic ultrasound - Lung sliding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?5/56/6030\" title=\"movie 4\">",
"      Thoracic ultrasound - Lung point",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?27/14/27873\" title=\"movie 5\">",
"      2D TTE parasternal long axis pleural and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/4/17472\" title=\"movie 6\">",
"      Anechoic and complex pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?33/21/34141\" title=\"movie 7\">",
"      Thoracic ultrasound - Absence of lung sliding",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2632?source=related_link\">",
"      Diagnostic evaluation of pleural effusion in adults: Additional tests for undetermined etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/23/12663?source=related_link\">",
"      Diagnostic thoracentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=related_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10297?source=related_link\">",
"      Primary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14167?source=related_link\">",
"      Transthoracic echocardiography: Normal cardiac anatomy and tomographic views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_50_26409="Screening for coronary heart disease";
var content_f25_50_26409=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26409/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26409/contributors\">",
"     Frank G Yanowitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26409/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26409/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26409/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26409/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/50/26409/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although mortality from coronary heart disease (CHD) has fallen substantially over the past four decades, it remains the leading cause of death in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=see_link\">",
"     \"Epidemiology of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is considerable interest in the diagnosis of CHD when patients are still asymptomatic. An increasing number of clinicians are screening for asymptomatic CHD; in addition, many participants in wellness programs also are requesting screening for themselves because of the belief that there are legitimate screening methods for the early detection of CHD that are necessary before beginning an exercise program.",
"   </p>",
"   <p>",
"    However, critical questions remain regarding the appropriateness and cost effectiveness of screening and the optimal screening test. Efforts are underway to educate health professionals, the insurance industry, and the general public regarding the appropriate use of exercise electrocardiogram (ECG) tests in screening for CHD.",
"   </p>",
"   <p>",
"    The issues surrounding screening for CHD will be reviewed here, with particular emphasis on the exercise ECG. Other screening tests are mentioned briefly, but discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=see_link\">",
"     \"Silent myocardial ischemia: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced obstructive CHD can exist with minimal or no symptoms, and can progress rapidly. The first clinical manifestation is often catastrophic: acute myocardial infarction (MI), unstable angina, or sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/1\">",
"     1",
"    </a>",
"    ]. The rationale for early detection of CHD is that detection during the subclinical stages of disease might permit the reliable identification of subjects at increased risk of an adverse cardiac event and that appropriate therapy (eg, lipid lowering) might improve the prognosis of those at high risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Identifying patients at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to identifying patients at risk, data from more than 10,000 subjects who participated in the Multiple Risk Factor Intervention Trial (MRFIT) and the Lipid Research Clinic's Coronary Primary Prevention Trial (LRCPPT) found that the presence of asymptomatic ischemia detected during baseline treadmill exercise testing predicted an increased risk of coronary events and cardiac death at 7 to 10 year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A similar relationship has been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. However, exercise capacity, rather than ST segment changes, may have the strongest association with outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative risk of an abnormal exercise test is greatest in patients with underlying risk factors for CHD, such as smoking, hypertension, hypercholesterolemia, and diabetes (",
"    <a class=\"graphic graphic_figure graphicRef65130 \" href=\"UTD.htm?38/24/39309\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56398 \" href=\"UTD.htm?21/39/22141\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'High-risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Diabetes mellitus is considered a CHD risk equivalent. The magnitude of the increase in risk for silent ischemia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link&amp;anchor=H3#H3\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Diabetes as a CHD equivalent'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Silent ischemia and infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intervening in patients at risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although screening appears to identify patients at increased risk, there is a paucity of evidence that such screening actually improves outcomes.",
"   </p>",
"   <p>",
"    Some data suggest that medical therapy or revascularization in selected patients with silent ischemia may improve outcomes. MRFIT and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     Atenolol",
"    </a>",
"    in Silent Ischemia Study demonstrated benefit from risk factor reduction and atenolol, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A benefit from revascularization was suggested by results from the NIH-sponsored Asymptomatic Cardiac Ischemia Pilot (ACIP) trial, which randomly assigned 558 patients to one of three treatment strategies: angina-guided medical therapy; ischemia-guided medical therapy; or revascularization with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). At two years, total mortality was significantly lower with revascularization compared to ischemia-guided or angina-guided medical therapy (1.1 versus 4.4 and 6.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/12\">",
"     12",
"    </a>",
"    ]. The composite end point of death, MI, or recurrent cardiac hospitalization was also reduced.",
"   </p>",
"   <p>",
"    The only appropriate indication for revascularization in asymptomatic patients is to improve prognosis since revascularization cannot improve symptoms. The choice of revascularization and of the procedure is dependent upon coronary anatomy, left ventricular function, and the presence or absence of diabetes. These factors were taken into account in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA/SCAI",
"    </span>",
"    guideline update on PCI and the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline update on CABG in patients with asymptomatic myocardial ischemia (",
"    <a class=\"graphic graphic_table graphicRef69950 \" href=\"UTD.htm?10/44/10956\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXERCISE ECG TESTING IN ASYMPTOMATIC INDIVIDUALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise ECG testing has evolved into a modality of considerable importance in the evaluation of patients with known or suspected CHD, and in the assessment of the therapeutic effects of cardiac drugs. The exercise ECG test also provides significant prognostic information concerning patients with known CHD. However, there is a great deal of controversy regarding the use of exercise ECG testing in screening asymptomatic individuals without known coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/2\">",
"     2",
"    </a>",
"    ]. The major source of controversy concerns the predictive value of exercise ECG testing and its relation to the prior probability of disease in the population being tested. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link&amp;anchor=H17#H17\">",
"     \"Evaluating diagnostic tests\", section on 'Disease prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Probability theory",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is necessary to understand the theory of conditional probability (Bayes' theorem) as applied to medical decision making in order to evaluate the utility of exercise ECG testing for the diagnosis of CHD in asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link&amp;anchor=H2#H2\">",
"     \"Stress testing for the diagnosis of coronary heart disease\", section on 'Pretest probability'",
"    </a>",
"    .) According to this theory, the predictive value of positive or negative exercise tests can be determined if one knows three variables:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pretest probability of disease or prevalence, P(CHD), in the person being tested.",
"     </li>",
"     <li>",
"      The sensitivity or true-positive rate, that is, the probability of a positive test in patients with significant CHD. The false-negative rate is defined as \"100 percent minus sensitivity.\"",
"     </li>",
"     <li>",
"      The specificity or true-negative rate, that is, the probability of a negative test in non-diseased individuals. The false-positive rate (FP) is defined as \"100 percent minus specificity.\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both sensitivity and specificity can be combined to define the predictive accuracy, which is the percentage of test responses which are true. Predictive accuracy can be positive or negative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive predictive value reflects the percentage of individuals with positive results who truly have the disease",
"     </li>",
"     <li>",
"      Negative predictive value is the percentage of negative tests associated with the absence of disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to Bayes' theorem, the predictive value of a positive test in a person being screened for CHD (PV+) is calculated by the following formula:",
"   </p>",
"   <p>",
"    PV(+) = [P(CHD) x sensitivity] &divide; [P(CHD) x sensitivity + P(noCHD) x FP]",
"   </p>",
"   <p>",
"    where P(noCHD) is \"100 percent minus P(CHD).\"",
"   </p>",
"   <p>",
"    The pretest likelihood of CHD in a population with certain characteristics influences the posttest risk of having CHD (",
"    <a class=\"graphic graphic_figure graphicRef81630 \" href=\"UTD.htm?1/0/1037\">",
"     figure 3",
"    </a>",
"    ). A positive result on ECG testing is likely to be a true positive result (ie, a low false positive rate) in a population with a high pretest risk for CHD, while a negative test is likely to be falsely negative (",
"    <a class=\"graphic graphic_figure graphicRef50189 \" href=\"UTD.htm?2/19/2367\">",
"     figure 4",
"    </a>",
"    ). Conversely, in a population with a low pretest risk for CHD, a positive exercise test that uses abnormal electrocardiographic ST segment criteria is only weakly correlated with the presence of CHD (ie, has a high false-positive rate), while a negative test is highly predictive of the absence of CHD. Thus, the probability of CHD following a treadmill test is directly related to the specific population evaluated and the results of the exercise test.",
"   </p>",
"   <p>",
"    An extensive meta-analysis involving 24,000 patients attempted to define reasonable estimates for the diagnostic sensitivity and specificity of the exercise ECG test [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/16\">",
"     16",
"    </a>",
"    ]. There was a wide variation in values of these parameters; the mean sensitivity was 68 percent but ranged from 23 to 100 percent, and the mean specificity was 77 percent but ranged from 17 to 100 percent. This wide range reflected different criteria for a positive test and the fact that there was bias in patient selection in most of the published literature. Nevertheless, when a positive test was defined as &ge;1 mm horizontal or downsloping ST segment depression, the mean sensitivity and specificity was approximately 60 and 90 percent, respectively.",
"   </p>",
"   <p>",
"    According to the Framingham risk factor prediction charts, in which points are given for age, gender, HDL-cholesterol, LDL-cholesterol, systolic blood pressure, diabetes, and smoking, multiple risk factors need to be present to be associated with a five year probability of developing CHD that is over 10 percent. It is unlikely that asymptomatic individuals have a pretest probability of more than 20 to 30 percent based upon risk factors; higher pretest probabilities are usually found in symptomatic people [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of patient selection was illustrated in a 1989 cost-effective analysis, which concluded that screening would increase the life expectancy of a 60 year old man at average risk for CHD by at most 12 days [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/18\">",
"     18",
"    </a>",
"    ]. The same age man with no risk factors, younger men, and women would derive even less benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clinical example",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of the relatively high specificity of exercise testing, Bayes' theorem suggests that a positive test in an asymptomatic person with a low pretest probability of CHD is far more likely to be a false-positive than a true-positive. As an example, an asymptomatic 45 year-old man, nonsmoker, nondiabetic, has the following laboratory findings:",
"   </p>",
"   <p>",
"    &nbsp;HDL-cholesterol = 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.04",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;LDL-cholesterol = 160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.50",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Systolic blood pressure = 150 mmHg",
"   </p>",
"   <p>",
"    &nbsp;Diastolic blood pressure = 90 mmHg",
"   </p>",
"   <p>",
"    Using the Framingham risk factor prediction charts, this patient has an approximately 5 percent probability of developing symptomatic CHD over the next 10 years. Assuming that his P(CHD) is 5 percent, the predictive value of a positive exercise ECG test, calculated from Bayes' theorem, is:",
"   </p>",
"   <p>",
"    PV(+) = 5 x 50 &divide; [(5 x 50) + (95 x 10)] = 250 &divide;1295 = 19 percent",
"   </p>",
"   <p>",
"    Thus, this individual has an 81 percent likelihood that the positive exercise ECG test is a false-positive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link&amp;anchor=H9#H9\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Framingham risk scores'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A positive exercise test in an asymptomatic person often results in referral for unnecessary, expensive, and invasive procedures in an attempt to identify coronary disease. This can lead to considerable anxiety on the part of the patient and family. In addition, disease in an asymptomatic individual is more likely to be single vessel than multivessel or left main disease. Nevertheless, there is often the irresistible urge of the cardiologist to intervene with revascularization, although there are no data to support such an approach. A more prudent course of action might be to avoid exercise testing in asymptomatic patients, and to manage the risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal exercise ECG in an asymptomatic person appears to predict increased cardiovascular risk, at least in men (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Rationale for screening'",
"    </a>",
"    above)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. However, this does not mean that exercise testing reduces mortality or is cost-effective in unselected patients. This issue was addressed in a study in which screening exercise treadmill tests were performed in 4334 adults, 89 percent of whom were male, with a median age of 51 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/19\">",
"     19",
"    </a>",
"    ]. An abnormal test was noted in 15 percent; the most common abnormalities were ischemic ST segment changes in 9.7 percent, and failure to reach &ge;85 percent of the age predicted maximum heart rate in 4.1 percent. After a 2.5 year follow-up, the mortality was similar in subjects with and without ST segment depression (2.1 versus 1.8 percent). Coronary angiography was performed in 126 patients with an abnormal test; 19 had severe coronary disease, representing 0.44 percent of the original cohort.",
"   </p>",
"   <p>",
"    The estimated cost of screening exercise testing to identify one patient with severe coronary disease for which surgery may provide a survival benefit was $39,623, and the estimated cost per life saved was at least $55,274. The authors concluded that this negative result may have been due in part to the low-risk population that was selected and the failure to incorporate pretest variables into post-test clinical decision making.",
"   </p>",
"   <p>",
"    The prognostic value of exercise testing in women appears to be related to measures of cardiovascular fitness but may be",
"    <strong>",
"     unrelated",
"    </strong>",
"    to ECG findings suggestive of ischemia. This was demonstrated in an analysis from a Lipid Research Clinics study of 2994 asymptomatic women who underwent exercise testing at study entry and were then followed for 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/20\">",
"     20",
"    </a>",
"    ]. There were 427 deaths (14 percent), of which 147 (5 percent) were due to cardiovascular causes. Exercise-induced ST segment depression (&ge;1.0 mm) did not increase the risk of cardiovascular death (age-adjusted hazard ratio 1.02). In contrast, women who were below the median for either exercise capacity or heart rate recovery, both of which were considered measures of fitness, were at increased risk. Those below the median for both variables were at highest risk (multivariable-adjusted hazard ratio 3.5 compared to those above the median for both variables).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Before an exercise program",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening has often been recommended for people who are sedentary but are considering a vigorous exercise program. The efficacy of this approach was addressed in another analysis from the Lipid Research Clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/21\">",
"     21",
"    </a>",
"    ]. Among 3617 asymptomatic, hypercholesterolemic men, the cumulative incidence of activity-related acute cardiac events was only 2 percent during a mean follow-up of 7.4 years. Furthermore, although the risk of a cardiac event was increased 2.6-fold in patients with clinically silent, exercised induced ST-segment changes during submaximal ETT at study entry, only 11 of the 62 men who experienced an activity-related event had a positive ETT at entry (sensitivity 18 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     High-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictive value of an abnormal exercise test is affected by the presence or absence of conventional risk factors for CHD, including hypertension, hypercholesterolemia, smoking, a family history of premature CHD, and diabetes mellitus (",
"    <a class=\"graphic graphic_figure graphicRef65130 \" href=\"UTD.htm?38/24/39309\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56398 \" href=\"UTD.htm?21/39/22141\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/5,8,20,22-25\">",
"     5,8,20,22-25",
"    </a>",
"    ]. Based upon the 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    practice guidelines, both diabetes mellitus and chronic kidney disease are considered CHD equivalents for the purpose of assessing the risk of CHD events [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of risk factors was illustrated in a report cited above of almost 26,000 healthy men (mean age 43) who were followed for an average of 8.4 years after a screening maximal exercise test [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/5\">",
"     5",
"    </a>",
"    ]. The age-adjusted relative risk of an abnormal exercise test for coronary death increased progressively with underlying risk, ranging from 21 in men with no risk factors to 27, 54, and 80 in those with one, two, or three or more risk factors, respectively.",
"   </p>",
"   <p>",
"    The specific findings on the exercise test may provide additional information to the Framingham risk score which, as noted above, estimates the probability of developing symptomatic CHD over the next 10 years. The different exercise test variables are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=see_link\">",
"     \"Electrocardiographic changes during exercise ECG testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report from the Framingham Heart Study, 3043 individuals (mean age 45 years) underwent an exercise stress test and were followed for up to 18 years [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/23\">",
"       23",
"      </a>",
"      ]. After adjusting for age and Framingham risk score, the risk of developing CHD was significantly increased in men with ST segment depression &ge;1 mm (hazard ratio 1.88) or failure to achieve the target heart rate of 85 percent predicted maximum (hazard ratio 1.70). The increase in risk was greater in men with a baseline 10-year predicted CHD risk &ge;20 percent. On the other hand, a greater exercise capacity predicted a lower CHD risk (hazard ratio 0.94 per MET). Similar hazard ratios were noted in women but were not significant due to the small number of events.",
"     </li>",
"     <li>",
"      The prognostic significance of exercise capacity, as well as other exercise test variables such as maximum heart rate increase, heart rate recovery, and test cessation for dyspnea, has been noted in other studies of asymptomatic individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/20,24,25,27\">",
"       20,24,25,27",
"      </a>",
"      ]. In an asymptomatic cohort of 6126 men and women who were followed prospectively for 20 years, 91 percent of the 246 cardiovascular deaths occurred in individuals who were below the median for both exercise capacity and heart rate recovery (adjusted hazard ratio compared to individuals above the median for both parameters 3.53 and men and 8.51 in women) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/24\">",
"       24",
"      </a>",
"      ]. It was suggested that exercise testing might be useful in men with a Framingham risk score of 10 to 19 percent and women with a score of 6 to 19 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prognostic significance of exercise capacity or fitness is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\", section on 'Relation to fitness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A similar approach of combining the predictive value of exercise testing with that of risk factor analysis was performed using the SCORE risk system, which is a European system analogous to the Framingham risk score [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link&amp;anchor=H10#H10\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'SCORE'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective cohort study, 3554 asymptomatic adults (ages 50 to 75) underwent exercise stress testing and calculation of both Framingham and SCORE risk estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/28\">",
"     28",
"    </a>",
"    ]. At a mean of eight years, 114 patients (3 percent) died. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise test data predictive of death included impaired functional capacity and heart rate variability, but not ST segment changes.",
"     </li>",
"     <li>",
"      The SCORE risk estimate but not the Framingham risk estimate was predictive of death.",
"     </li>",
"     <li>",
"      Patients with a SCORE result in the top tertile of predicted risk plus an abnormal exercise test had a markedly higher mortality at eight years than those in the bottom tertile with a normal exercise test (9 versus 1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other tests that have been considered for screening for coronary disease include the resting ECG, ambulatory ECG, nuclear and echocardiographic studies, electron beam computed tomography, high resolution ultrasound, and coronary angiography. However, none of these studies is ideal for screening patients for CHD for a variety of reasons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Resting ECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic persons with resting ECG abnormalities such as ST depression, T wave inversion, left ventricular hypertrophy or strain, and premature ventricular contractions have a 2 to 10-fold increased risk of CHD compared to those with a normal ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In different epidemiologic studies, the presence of variably defined ECG abnormalities has increased the adjusted relative risk for cardiovascular mortality and morbidity by 1.5 to 2.5 fold (",
"    <a class=\"graphic graphic_figure graphicRef54801 \" href=\"UTD.htm?9/37/9822\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the utility of these findings for screening is limited for the following reasons. Approximately, one-third to one-half of individuals with a normal coronary arteriogram have ECG abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/32\">",
"     32",
"    </a>",
"    ], approximately 30 percent of individuals with angiographically proven CHD have a normal resting ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/33\">",
"     33",
"    </a>",
"    ], and most coronary events occur in individuals without resting ECG abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ambulatory monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia detected by ambulatory monitoring does not necessarily correlate with the presence and extent of ischemia as determined by radionuclide myocardial perfusion imaging with thallium or sestamibi. In one study, for example, the concordance for normalcy or abnormalcy between these tests was only 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=see_link\">",
"     \"Silent myocardial ischemia: Diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nuclear imaging and stress echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise ECG testing can only be performed in patients who are able to exercise and who do not have baseline ECG abnormalities that can interfere with interpretation. These include preexcitation (Wolff-Parkinson-White) syndrome, complete left bundle branch block, more than 1 mm ST depression at rest, and a paced ventricular rhythm. Stress radionuclide myocardial perfusion imaging and stress echocardiography are alternative approaches to exercise ECG testing in such patients. However, these techniques are expensive and have not been demonstrated to be beneficial in improving outcomes when used for screening purposes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential value of exercise thallium scanning compared to exercise ECG testing was illustrated in a study of 264 asymptomatic individuals under age 60 (average age 46) who had a sibling with documented CHD before age 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/36\">",
"     36",
"    </a>",
"    ]. Over a mean of 6.2 years, 19 (7.2 percent) developed clinical CHD. The frequency of an abnormal baseline exercise ECG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thallium scan varied with age and gender: 45 percent in men &ge;45 years of age compared to 3 percent of women under age 45. An abnormal thallium scan was more predictive of developing CHD: relative risk 4.7 after adjustment for age, gender, and the exercise ECG. The relative risk increased to 14.5 in the 12 patients in whom both tests were abnormal; all were men over age 45 and the absolute risk of developing CHD within five years was 64 percent. Such patients are likely to have severe coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electron beam or multidetector row computed tomography (EBCT and MDCT) can noninvasively detect and quantify coronary artery calcification (CAC) using serial thin section (3 mm) tomograms from the aorta through the apex of the heart. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct relationships have been established between coronary calcium as measured by EBCT or MDCT and histologic, ultrasonographic, and angiographic measures of coronary disease. These observations provide the rationale for the use of CAC scanning to screen for CHD in asymptomatic adults suspected of having or being at risk for coronary disease.",
"   </p>",
"   <p>",
"    In both men and women, CAC detected by EBCT is highly sensitive for the presence of &ge;50 percent angiographic stenosis but only moderately specific [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Both sensitivity and specificity vary with the degree of CAC. The magnitude of this effect was illustrated in a study of 1764 patients with suspected CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/38\">",
"     38",
"    </a>",
"    ]. As the Agatston CAC score varied from &gt;20th percentile to &gt;75th percentile for age, the sensitivity fell from 97 to 81 percent in men and from 98 to 76 percent in women but the specificity increased up to 77 percent. Patients with no CAC had a probability of stenosis of less than 1 percent.",
"   </p>",
"   <p>",
"    The CAC score provides additional prognostic information to the Framingham risk score. However, it is not clear how to act upon a positive test. Studies evaluating the effect of statins and other therapies on CAC progression or clinical outcomes have not provided clear evidence of benefit. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    Expert Consensus Document coronary artery calcium scoring concluded it",
"    <strong>",
"     cannot be recommended",
"    </strong>",
"    as a screening tool for the diagnosis of obstructive CHD because of its low specificity, with a resulting high false positive rate when the test is applied to low risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/40\">",
"     40",
"    </a>",
"    ]. The panel did feel that selective use of coronary calcium scores in patients at intermediate risk may be appropriate.",
"   </p>",
"   <p>",
"    Although not recommended, CAC scanning by CT is available without clinician referral at many centers. As a result, many asymptomatic individuals undergo CAC scanning and then present to their health care providers for a discussion of abnormal test results. In such patients,",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines published in 2003 concluded that the efficacy of exercise ECG testing is not well established for asymptomatic patients with CAC. Since the pretest probability for significant CHD is low, a negative exercise test confirms the low likelihood of disease and a positive test may not sufficiently increase disease probability to make a clinical difference. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless, exercise ECG testing might be warranted in patients with severe calcification, defined as a calcium score above the 75th percentile for age and gender. Exercise perfusion imaging and echocardiography are alternatives in patients who have baseline ECG abnormalities that interfere with interpretation. Stress perfusion imaging or echocardiography can be performed in those who are unable to exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary angiography has been considered to be the best test for the detection of CHD, with more than 50 percent luminal narrowing of a coronary artery being considered evidence of significant CHD. However, the clinical usefulness of identifying high grade obstructive lesions in predicting the future risk of coronary events is uncertain because arteriography does not necessarily assess the functional significance of a lesion. One study, for example, found that angiographic findings frequently did",
"    <strong>",
"     not",
"    </strong>",
"    accurately predict the site of lesions that led to subsequent coronary artery thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FROM MAJOR SOCIETIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations still vary regarding the optimal approach to screening for CHD. This can be illustrated by the following recommendations from major groups.",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) made two recommendations in 2012 regarding the use of the resting or exercise ECG testing for screening for CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They recommended against routine screening in adults at",
"      <strong>",
"       low risk",
"      </strong>",
"      for CHD events.",
"     </li>",
"     <li>",
"      They concluded that there was insufficient evidence to recommend for or against routine screening in adults at",
"      <strong>",
"       increased risk",
"      </strong>",
"      for CHD events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The USPSTF did not recommend an approach to risk assessment, but did note that many clinicians ascertain a person's overall risk for CHD events by screening for cardiac risk factors and incorporating that information into risk prediction equations derived from the Framingham (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?43/28/44482?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/63/10226?source=see_link\">",
"     calculator 2",
"    </a>",
"    ) or other cohort studies. The USPSTF clinical practice guideline for screening for coronary heart disease, as well as other USPSTF guidelines, can be accessed through the website for the Agency for Healthcare Research and Quality at",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     www.ahrq.gov/clinic/uspstfix.htm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The 2002 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines for exercise testing reached a similar conclusion that there is little evidence to support routine testing in asymptomatic adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/43\">",
"     43",
"    </a>",
"    ]. They did identify the following subgroups that might benefit from screening:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The guidelines concluded that the weight of evidence favors evaluation of asymptomatic patients with diabetes who plan to begin a vigorous exercise program. This is consistent with the conclusion that diabetes is a CHD equivalent, since diabetic patients without an MI have the same risk for coronary mortality as nondiabetic patients with an MI (",
"      <a class=\"graphic graphic_figure graphicRef80251 \" href=\"UTD.htm?34/1/34845\">",
"       figure 6",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link&amp;anchor=H3#H3\">",
"       \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\", section on 'Diabetes as a CHD equivalent'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other evidence that diabetes is a CHD equivalent comes from the Heart Protection Study, in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    therapy reduced the risk of major vascular events in diabetic patients, including those with no known history of MI, and those with a normal baseline serum LDL concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise testing can also be considered (although the weight of evidence is less clear) in patients with multiple risk factors for CHD as a guide to risk reduction therapy, in men over age 45 and women over age 55 who plan to start a vigorous exercise program or who are involved in occupations that impair public safety, or in patients who are at high risk for CHD due to other diseases (eg, peripheral vascular disease and chronic renal failure).",
"     </li>",
"     <li>",
"      Exercise testing can also be considered in patients who have undergone EBCT and have a coronary calcium score above the 75th percentile [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/43\">",
"       43",
"      </a>",
"      ]. As noted above, however, EBCT is not recommended as a screening test for CHD in low-risk asymptomatic subjects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other groups have also made recommendations for screening for CHD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The American College of Physicians does not recommend ETT as a routine screening procedure in asymptomatic adults.",
"     </li>",
"     <li>",
"      The American Academy of Family Physicians recommends ETT for those people who have jobs that are linked to public safety (eg, pilots, air traffic controllers) or that require high cardiovascular performance (eg, police officers, firefighters).",
"     </li>",
"     <li>",
"      The American College of Sports Medicine recommends ETT for men over age 40, women over age 50, and other asymptomatic people with multiple cardiac risk factors prior to beginning a vigorous exercise program.",
"     </li>",
"     <li>",
"      The American Diabetes Association does not recommend routine screening for CHD in patients with diabetes as screening has not been shown to improve outcomes compared with aggressively treating risk factors alone [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=see_link\">",
"       \"Screening for coronary heart disease in patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       \"Patient information: Coronary heart disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=see_link\">",
"       \"Patient information: Nuclear heart testing (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       \"Patient information: Sudden cardiac arrest (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While there is general consensus that screening is not necessary for asymptomatic patients at low risk for CHD, there may be certain groups in which screening is warranted. Although the available data are not strong enough to reach consensus on the identity of these special groups, many clinicians perform periodic exercise ECG tests in asymptomatic individuals with multiple coronary risk factors including total cholesterol greater than 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    systolic blood pressure greater than 140 mmHg, diastolic blood pressure greater than 90 mmHg, smoking, diabetes, and a history of premature MI or sudden cardiac death in a first-degree relative under age 60. A positive test in such patients is associated with an increased risk of subsequent myocardial infarction and death [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the decision is made to screen, no single test is ideal. However, it seems reasonable to conclude, based upon the available data, easy accessibility, and cost considerations, that initial screening with exercise ECG testing is the most prudent approach in high-risk individuals who can exercise and who do not have ECG abnormalities that can limit the detection of ischemic changes. Additionally, an exercise test provides information about the exercise capacity, which may be more predictive of outcome than ST segment changes [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to screening for CHD in patients with diabetes mellitus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=see_link\">",
"     \"Screening for coronary heart disease in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Evaluation of a positive test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent evaluation of those with positive findings on the exercise test should be based upon consideration of the patient's risk factors, occupation, cost-effectiveness, and clinical justification for any intervention that might be recommended as a result of the findings on further testing. Although the majority of positive exercise tests in asymptomatic individuals are false-positives (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical example'",
"    </a>",
"    above), a subset of patients are at increased risk and may benefit from further diagnostic testing.",
"   </p>",
"   <p>",
"    The predictive value of an abnormal screening exercise test is determined by the presence or absence of risk factors for CHD (",
"    <a class=\"graphic graphic_figure graphicRef65130 \" href=\"UTD.htm?38/24/39309\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/5,37\">",
"     5,37",
"    </a>",
"    ]. In addition, treadmill scores have been devised to estimate patient prognosis according to test results [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. The most popular validated treadmill score comes from Duke University and is based upon data from 2758 consecutive patients with chest pain a median age of 49 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Duke treadmill score uses three exercise parameters:",
"   </p>",
"   <p>",
"    &nbsp;Duke prognostic treadmill score =",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Exercise time (minutes based on the Bruce protocol) -",
"    <br/>",
"    &nbsp; &nbsp;(5 x maximum ST segment deviation in mm) - (4 x exercise angina [0 = none, 1 = nonlimiting, and 2 = exercise limiting])",
"   </p>",
"   <p>",
"    Patients are classified as low, moderate, or high risk according to the score:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low-risk &ndash; score &ge;+5",
"     </li>",
"     <li>",
"      Moderate-risk &ndash; score from -10 to +4",
"     </li>",
"     <li>",
"      High-risk &ndash; score &lt;-11",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, asymptomatic patients were",
"    <strong>",
"     excluded",
"    </strong>",
"    from these studies. As a result, there are no data applying the results of the Duke treadmill score to asymptomatic patients who are screened for CHD. In addition, even among symptomatic patients, the score has limited prognostic utility in patients &ge;75 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H11#H11\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Duke treadmill score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2002",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines suggested that exercise radionuclide myocardial perfusion imaging or exercise echocardiography has potential use as a second test in asymptomatic patients who have an intermediate or high risk Duke treadmill score on exercise ECG testing even though the score has not been evaluated in asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26409/abstract/50\">",
"     50",
"    </a>",
"    ]. Since positive tests in asymptomatic patients are often false-positives, this can be confirmed by a negative stress image. On the other hand, patients with a positive stress image and an intermediate or high risk Duke treadmill score may benefit from coronary arteriography and revascularization, if appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/1\">",
"      Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/2\">",
"      Greenland P, Gaziano JM. Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. N Engl J Med 2003; 349:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/3\">",
"      Rautaharju PM, Prineas RJ, Eifler WJ, et al. Prognostic value of exercise electrocardiogram in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial experience. J Am Coll Cardiol 1986; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/4\">",
"      Ekelund LG, Suchindran CM, McMahon RP, et al. Coronary heart disease morbidity and mortality in hypercholesterolemic men predicted from an exercise test: the Lipid Research Clinics Coronary Primary Prevention Trial. J Am Coll Cardiol 1989; 14:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/5\">",
"      Gibbons LW, Mitchell TL, Wei M, et al. Maximal exercise test as a predictor of risk for mortality from coronary heart disease in asymptomatic men. Am J Cardiol 2000; 86:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/6\">",
"      Rywik TM, Zink RC, Gittings NS, et al. Independent prognostic significance of ischemic ST-segment response limited to recovery from treadmill exercise in asymptomatic subjects. Circulation 1998; 97:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/7\">",
"      Roger VL, Jacobsen SJ, Pellikka PA, et al. Prognostic value of treadmill exercise testing: a population-based study in Olmsted County, Minnesota. Circulation 1998; 98:2836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/8\">",
"      Laukkanen JA, Kurl S, Lakka TA, et al. Exercise-induced silent myocardial ischemia and coronary morbidity and mortality in middle-aged men. J Am Coll Cardiol 2001; 38:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/9\">",
"      Deedwania PC. Silent ischemia predicts poor outcome in high-risk healthy men. J Am Coll Cardiol 2001; 38:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/10\">",
"      Exercise electrocardiogram and coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Am J Cardiol 1985; 55:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/11\">",
"      Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994; 90:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/12\">",
"      Bourassa MG, Pepine CJ, Forman SA, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: effects of coronary angioplasty and coronary artery bypass graft surgery on recurrent angina and ischemia. The ACIP investigators. J Am Coll Cardiol 1995; 26:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/13\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (accessed September 18, 2007) www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/15\">",
"      Diamond GA, Hirsch M, Forrester JS, et al. Application of information theory to clinical diagnostic testing. The electrocardiographic stress test. Circulation 1981; 63:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/16\">",
"      Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. Circulation 1989; 80:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/17\">",
"      Califf RM, Armstrong PW, Carver JR, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 1996; 27:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/18\">",
"      Sox HC Jr, Littenberg B, Garber AM. The role of exercise testing in screening for coronary artery disease. Ann Intern Med 1989; 110:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/19\">",
"      Pilote L, Pashkow F, Thomas JD, et al. Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults. Am J Cardiol 1998; 81:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/20\">",
"      Mora S, Redberg RF, Cui Y, et al. Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study. JAMA 2003; 290:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/21\">",
"      Siscovick DS, Ekelund LG, Johnson JL, et al. Sensitivity of exercise electrocardiography for acute cardiac events during moderate and strenuous physical activity. The Lipid Research Clinics Coronary Primary Prevention Trial. Arch Intern Med 1991; 151:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/22\">",
"      Conroy RM, Py&ouml;r&auml;l&auml; K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/23\">",
"      Balady GJ, Larson MG, Vasan RS, et al. Usefulness of exercise testing in the prediction of coronary disease risk among asymptomatic persons as a function of the Framingham risk score. Circulation 2004; 110:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/24\">",
"      Mora S, Redberg RF, Sharrett AR, Blumenthal RS. Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores. Circulation 2005; 112:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/25\">",
"      Jouven X, Empana JP, Schwartz PJ, et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005; 352:1951.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/27\">",
"      Bodegard J, Erikssen G, Bj&oslash;rnholt JV, et al. Reasons for terminating an exercise test provide independent prognostic information: 2014 apparently healthy men followed for 26 years. Eur Heart J 2005; 26:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/28\">",
"      Aktas MK, Ozduran V, Pothier CE, et al. Global risk scores and exercise testing for predicting all-cause mortality in a preventive medicine program. JAMA 2004; 292:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/29\">",
"      Daviglus ML, Liao Y, Greenland P, et al. Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study. JAMA 1999; 281:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/30\">",
"      De Bacquer D, De Backer G, Kornitzer M, et al. Prognostic value of ischemic electrocardiographic findings for cardiovascular mortality in men and women. J Am Coll Cardiol 1998; 32:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/31\">",
"      Chou R, Arora B, Dana T, et al. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011; 155:375.",
"     </a>",
"    </li>",
"    <li>",
"     Guide to Clinical Preventive Services, 2d ed. Williams &amp; Wilkins; United States Preventive Services Task Force, Baltimore, MD 1996, p. 4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/33\">",
"      Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. Circulation 1983; 68:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/34\">",
"      Rose G, Baxter PJ, Reid DD, McCartney P. Prevalence and prognosis of electrocardiographic findings in middle-aged men. Br Heart J 1978; 40:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/35\">",
"      Mahmarian JJ, Steingart RM, Forman S, et al. Relation between ambulatory electrocardiographic monitoring and myocardial perfusion imaging to detect coronary artery disease and myocardial ischemia: an ACIP ancillary study. The Asymptomatic Cardiac Ischemia Pilot (ACIP) Investigators. J Am Coll Cardiol 1997; 29:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/36\">",
"      Blumenthal RS, Becker DM, Moy TF, et al. Exercise thallium tomography predicts future clinically manifest coronary heart disease in a high-risk asymptomatic population. Circulation 1996; 93:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/37\">",
"      Blumenthal RS, Becker DM, Yanek LR, et al. Detecting occult coronary disease in a high-risk asymptomatic population. Circulation 2003; 107:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/38\">",
"      Haberl R, Becker A, Leber A, et al. Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol 2001; 37:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/39\">",
"      Nallamothu BK, Saint S, Bielak LF, et al. Electron-beam computed tomography in the diagnosis of coronary artery disease: a meta-analysis. Arch Intern Med 2001; 161:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/40\">",
"      Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2007; 49:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/41\">",
"      Little WC. Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction. Am J Cardiol 1990; 66:44G.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/42\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/43\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol 2002; 40:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/44\">",
"      Haffner SM, Lehto S, R&ouml;nnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/45\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/46\">",
"      Mark DB, Hlatky MA, Harrell FE Jr, et al. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med 1987; 106:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/47\">",
"      Shaw LJ, Peterson ED, Shaw LK, et al. Use of a prognostic treadmill score in identifying diagnostic coronary disease subgroups. Circulation 1998; 98:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/48\">",
"      McNeer JF, Margolis JR, Lee KL, et al. The role of the exercise test in the evaluation of patients for ischemic heart disease. Circulation 1978; 57:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26409/abstract/49\">",
"      Kwok JM, Miller TD, Hodge DO, Gibbons RJ. Prognostic value of the Duke treadmill score in the elderly. J Am Coll Cardiol 2002; 39:1475.",
"     </a>",
"    </li>",
"    <li>",
"     Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1519 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-A1721555EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26409=[""].join("\n");
var outline_f25_50_26409=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Identifying patients at risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intervening in patients at risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXERCISE ECG TESTING IN ASYMPTOMATIC INDIVIDUALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Probability theory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clinical example",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Before an exercise program",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - High-risk patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Resting ECG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ambulatory monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nuclear imaging and stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      RECOMMENDATIONS FROM MAJOR SOCIETIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Evaluation of a positive test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1519\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1519|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/24/39309\" title=\"figure 1\">",
"      Prognosis ETT asymptomatic men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/39/22141\" title=\"figure 2\">",
"      Silent ischemia CHD mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/0/1037\" title=\"figure 3\">",
"      Positive predict value ETT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/19/2367\" title=\"figure 4\">",
"      Value ETT Bayes theorem",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/37/9822\" title=\"figure 5\">",
"      ECG abnormalities outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/1/34845\" title=\"figure 6\">",
"      Diabetes increases coronary mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1519|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/44/10956\" title=\"table 1\">",
"      ACC AHA CABG asx CAD mild AP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?43/28/44482?source=related_link\" title=\"calculator 1\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in men (2008 paper)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/63/10226?source=related_link\" title=\"calculator 2\">",
"      Calculator: Framingham 10 year risk of general cardiovascular disease in women (2008 paper)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11017?source=related_link\">",
"      Electrocardiographic changes during exercise ECG testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=related_link\">",
"      Evaluating diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=related_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=related_link\">",
"      Screening for coronary heart disease in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28180?source=related_link\">",
"      Silent myocardial ischemia: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_50_26410="Nonoccupational exposure to HIV in adults";
var content_f25_50_26410=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonoccupational exposure to HIV in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26410/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26410/contributors\">",
"     Judith A Aberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26410/contributors\">",
"     Demetre Daskalakis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26410/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26410/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/50/26410/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/50/26410/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/50/26410/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9053130\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare personnel who are potentially exposed to HIV infection through a needlestick injury are offered counseling and postexposure prophylaxis (PEP) for HIV with antiretroviral medications. Some evidence of the efficacy of this approach in the occupational setting prompted experts to suggest that a similar management approach should be adopted for persons exposed to HIV through sexual or needle-sharing behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of infection and the management of adults with nonoccupational HIV exposure are reviewed here. The management of healthcare personnel exposed to HIV and the risk related to transfusion of blood products are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=see_link\">",
"     \"Management of healthcare personnel exposed to HIV\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=see_link\">",
"     \"Transfusion transmitted HIV infection and AIDS\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9053137\">",
"    <span class=\"h1\">",
"     RISK OF TRANSMISSION OF HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four distinct risk groups have been considered in studies of nonoccupational exposure to HIV infection, including men who have sex with men (MSM), injection drug users (IDUs), male and female heterosexuals, and persons exposed to HIV through other routes (eg, human bites). Estimates of exposure risk are based on observational studies and are difficult to quantify since transmission risk also depends on other cofactors that greatly enhance the probability of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], as discussed below (",
"    <a class=\"graphic graphic_table graphicRef60145 \" href=\"UTD.htm?31/59/32700\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9053145\">",
"    <span class=\"h2\">",
"     Sexual exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact risk of transmission of HIV with sexual exposure is incompletely defined [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, the data do suggest that risk of HIV acquisition varies by type of exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/1,8-14\">",
"     1,8-14",
"    </a>",
"    ]. For example, receptive anal intercourse, which can lead to mucosal disruption and rectal bleeding, is associated with higher risk compared with other types of sexual exposures, such as oral sex [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among MSM, approximate risk of HIV varies as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Receptive anal intercourse &ndash; One transmission per 200 sex acts",
"     </li>",
"     <li>",
"      Insertive anal intercourse &ndash; Six transmissions per 10,000 sex acts",
"     </li>",
"     <li>",
"      Receptive oral sex &ndash; One transmission per 10,000 sex acts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approximate risk of HIV transmission from a male to female also varies according to sexual exposure history. One meta-analysis demonstrated that infectivity estimates were very heterogeneous, ranging from zero transmissions after more than 100 penile-vaginal contacts in some serodiscordant couples to one transmission for every three episodes of heterosexual anal intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/15\">",
"     15",
"    </a>",
"    ]. Estimates of risk are listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Receptive anal intercourse &ndash; One transmission per 200 sex acts",
"     </li>",
"     <li>",
"      Receptive vaginal intercourse &ndash; One transmission per 1000 sex acts",
"     </li>",
"     <li>",
"      Insertive vaginal intercourse &ndash; Five transmissions per 10,000 sex acts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, as seen in most sexually transmitted diseases, male to female transmission is more common than female to male transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/16\">",
"     16",
"    </a>",
"    ]. The relative risk of male to female compared with female to male HIV transmission was well illustrated in one study of 563 HIV discordant couples (comprised of 156 HIV-seropositive males and 400 HIV-seropositive males), where 19 male partners and 82 female partners seroconverted for HIV during the course of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/17\">",
"     17",
"    </a>",
"    ]. This study suggested that male to female transmission was 1.9 times more efficient (95% CI 1.1-33) than female to male transmission.",
"   </p>",
"   <p>",
"    Differences in infectivity are also strongly influenced by the presence of other cofactors, such as concomitant genital ulcerative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, using a single value for assessing risk of HIV transmission based on route of sexual exposure fails to reflect the variation associated with other important cofactors. (See",
"    <a class=\"local\" href=\"#H8055455\">",
"     'Other factors affecting risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4626318\">",
"    <span class=\"h2\">",
"     Needle and trauma exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of other routes of HIV exposure is listed below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Needle or syringe sharing &ndash; 0.67 percent per needle-sharing contact [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mucous membrane exposure to blood (eg, splash to eye) &ndash; 0.1 percent per exposure",
"     </li>",
"     <li>",
"      Other exposure (eg, human bite) &ndash; 0.004 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79887584\">",
"    <span class=\"h2\">",
"     HIV status of the source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often the HIV status of the sex or injecting partner is unknown. The probability of HIV acquisition from a source whose HIV status is unknown is approximated by estimating the likelihood that the source is HIV-positive multiplied by the likelihood of transmission (as listed above). As an example, the prevalence of HIV infection in men aged 18 to 39 in the NHANES study (2003 to 2006) was 0.43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, the estimated risk of transmission following a single episode of receptive vaginal intercourse would be approximated by multiplying 0.0043 times 0.001 for an estimate of 0.0000043 (ie, 1 in ~233,000). However, specific information about the source may increase the likelihood that the he or she is HIV-seropositive (eg, a history of injection drug use).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8055455\">",
"    <span class=\"h2\">",
"     Other factors affecting risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimates of risk are also influenced by other cofactors that may affect infectivity, defined as the probability of transmission during a single contact between an infected and uninfected individual [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/15\">",
"     15",
"    </a>",
"    ]. These cofactors should be evaluated in every person who is potentially exposed to HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/15,20\">",
"     15,20",
"    </a>",
"    ]. The effects of these cofactors have been evaluated with regard to cumulative HIV incidence; there are little data regarding the effect of cofactors on &ldquo;per contact&rdquo; risk of HIV acquisition [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/15\">",
"     15",
"    </a>",
"    ]. One meta-analysis concluded that there were insufficient data to analyze the margin of effect that these variables conferred on individual risk [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10218897\">",
"    <span class=\"h3\">",
"     HIV viral load",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectiousness is influenced by the height of the viral load, which will vary greatly depending on whether the source is taking antiretroviral therapy (ART) and on the stage of HIV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/15,21\">",
"     15,21",
"    </a>",
"    ]. For example, the viral load can be very high in patients with acute HIV infection or in those with advanced untreated AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/22\">",
"     22",
"    </a>",
"    ]. Studies in heterosexual discordant couples have shown a 2.5-fold increase in the risk of transmission for each log increase in viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/23\">",
"     23",
"    </a>",
"    ]; in contrast, persons with viral suppression on antiretroviral therapy (ART) rarely transmit infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/21,24\">",
"     21,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10218904\">",
"    <span class=\"h3\">",
"     Mucosal integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of sexual transmission is also increased by traumatic injury (eg, nonconsensual sex) and the presence of genital lesions (in the exposed person or the source) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/13,22,25\">",
"     13,22,25",
"    </a>",
"    ]. Genital ulcers have also been associated with increased risk of sexual acquisition of hepatitis C virus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"     \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10218911\">",
"    <span class=\"h3\">",
"     Circumcision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of female to male transmission of HIV is reduced with circumcision, but there is no evidence that male circumcision protects against male to female transmission. Controlled studies of male circumcision have not been conducted among men who have sex with men. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"     \"Prevention of sexually transmitted infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10218930\">",
"    <span class=\"h3\">",
"     Sexual assault",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of acquiring HIV after rape by an unknown assailant depends on many factors specific to the assault. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10218863\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of sex act strongly influences level of risk; anal intercourse, particularly with a history of rectal bleeding, is associated with increased risk of HIV exposure compared with other sexual exposures. However, other cofactors, which may affect risk of exposure, must be assessed as well. For example, some models suggest that rates of HIV transmission may be as high as one transmission event for every three episodes of penile-anal sex between a male source with late-stage disease and a susceptible female with genital ulcerative disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/26\">",
"     26",
"    </a>",
"    ]. Clinicians need to be aware that estimates of risk are often based on studies of monogamous couples where risk is cumulative; there are scant data on per contact risk of exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9053166\">",
"    <span class=\"h1\">",
"     PREEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although research is ongoing, there is no available HIV vaccine to date. In the meantime, clinical trials are evaluating whether regular or preexposure use of antiretroviral therapy provides additional protection for HIV-seronegative persons at high risk of infection who are offered standard preventive care, including HIV testing, counseling, condoms, and management of sexually transmitted infections",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Data regarding the use of antiretroviral medications to prevent HIV transmission are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1413672\">",
"    <span class=\"h1\">",
"     DATA ON POSTEXPOSURE PROPHYLAXIS TO PREVENT HIV TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antiretroviral therapy (ART) in preventing HIV infection was first evaluated in pregnant women to decrease the risk of mother to child transmission (MTCT) and among healthcare personnel who had accidental needlestick exposures. The risk of HIV transmission has been better defined in MTCT than in exposures among healthcare personnel. These limited data form the basis for the current recommendations for postexposure prophylaxis after sexual or injection drug use exposures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556853\">",
"    <span class=\"h2\">",
"     General background",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1994, a clinical trial of the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    was performed among 477 pregnant women in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/28\">",
"     28",
"    </a>",
"    ]. Thirteen infants in the zidovudine group and 40 in the placebo group became HIV infected. The proportions of infants infected at 18 months of follow-up were significantly lower in the zidovudine group (8 percent versus 26 percent).",
"   </p>",
"   <p>",
"    The major risk factor for perinatal HIV transmission is related to the height of the maternal viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/29\">",
"     29",
"    </a>",
"    ]. In one observational study of HIV-infected women who took",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    during pregnancy, there were no cases of infant HIV transmission if the viral load was suppressed to &lt;500",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    In fact, in resource-rich settings, the risk of perinatal transmission has been reduced from 25 percent to less than 1 percent with three-drug combination regimens, which are more effective than monotherapy in suppressing HIV replication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the 1990s there have been efforts to study the risk of HIV transmission among healthcare personnel with needlestick injuries. In one prospective surveillance project conducted by the Centers for Disease Control (CDC), the estimated risk of HIV transmission from a needlestick was 0.36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/30\">",
"     30",
"    </a>",
"    ]. A case control study in 1997 showed that healthcare personnel who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    after a needlestick exposure were 81 percent less likely to undergo seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/31\">",
"     31",
"    </a>",
"    ]. Limitations of the study included its retrospective design, small numbers of case patients, and lack of a uniform ART protocol. Enrollment was never completed in one placebo-controlled trial that had been designed to evaluate the effectiveness of zidovudine monotherapy after needlestick injury in healthcare personnel.",
"   </p>",
"   <p>",
"    Despite these data limitations, no further studies have been planned in light of the expense of conducting such a trial and the low per exposure seroconversion rates that have been observed. In 2005, the CDC recommended postexposure prophylaxis (PEP) following needlestick injuries among healthcare personnel based on the limited data presented above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556898\">",
"    <span class=\"h2\">",
"     Data in nonoccupational HIV exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the difficulties in completing the PEP trial in healthcare personnel, the Centers for Disease Control and Prevention (CDC) stated that for ethical and logistic reasons, a randomized, placebo-controlled clinical trial of PEP would not be performed for nonoccupational HIV exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, the data supporting ART for postexposure prophylaxis in nonoccupational exposures is limited to animal studies, observational studies, and clinical data in other patient populations, such as healthcare personnel (as noted above). Although the data on the efficacy of ART as PEP for nonoccupational HIV exposures is limited, there is more extensive data on the frequency of compliance and side effects. The data related to sexual exposures are discussed below; there are scant data on the use of PEP for injection drug users.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556905\">",
"    <span class=\"h3\">",
"     Animal data",
"    </span>",
"    &nbsp;&mdash;&nbsp;A macaque study, which was designed to assess the effectiveness of PEP, found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    protected all eight animals when the drug was administered within 12 to 36 hours after vaginal exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/32\">",
"     32",
"    </a>",
"    ]. Three of four animals treated 72 hours after exposure were also protected; the fourth animal had delayed seroconversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H556943\">",
"    <span class=\"h3\">",
"     Observational studies of nonoccupational PEP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462340\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies of patients who were offered PEP for HIV prevention after sexual exposure have suggested possible benefit, although conclusions are limited because of the observational design of the studies and sample sizes have been too small to be conclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/33-38\">",
"     33-38",
"    </a>",
"    ]. A few examples of representative studies are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 200 men who have sex with men (MSM) and bisexual men, a supply of PEP (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ) was given to all study participants with instructions to take the medications within 96 hours of a self-identified high-risk exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/33\">",
"       33",
"      </a>",
"      ]. Approximately one-third of the participants took PEP. Over a median of 24 months there were 11 HIV seroconversions (10 among non-PEP users and 1 on PEP). The most common reason for not taking PEP for a high-risk exposure was sex with a steady partner.",
"     </li>",
"     <li>",
"      A trial to assess the feasibility of offering individualized PEP was conducted in San Francisco among 401 persons with eligible sexual and injection drug use exposures [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/34\">",
"       34",
"      </a>",
"      ]. No seroconversions were observed among those who completed PEP (n = 309), those who interrupted PEP (n = 37), or those who decided not to take PEP at all (n = 55). Among sexual exposures, receptive or insertive anal intercourse was the most common sexual exposure. Of those who did consent to take PEP, 97 percent of participants were treated with dual nucleoside reverse transcriptase inhibitors and 78 percent completed the four-week treatment. Side effects were not reported.",
"     </li>",
"     <li>",
"      In a retrospective study from Amsterdam, a higher incidence of HIV was observed in 355 MSM who used PEP (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"       zidovudine-lamivudine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      ) than in 728 who did not (6.4 versus 1.6 seroconversions per 100 person years) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/35\">",
"       35",
"      </a>",
"      ]. The higher incidence of seroconversion in those who were prescribed and used PEP may reflect higher risk behavior in that group. Of note, 8 of the 11 PEP users who were infected with HIV seroconverted more than three months following PEP use, suggesting that their infections were not related to PEP failure, but continued high-risk exposure. The use of a PEP regimen not widely prescribed in the US is an additional limitation of this study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462347\">",
"    <span class=\"h4\">",
"     Completion rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of limited efficacy data, selected medications are generally chosen based on side effect profiles and completion rates, which are variably reported in studies of patients who receive PEP. Several examples are discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a clinical trial of 200 patients randomized to",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"        zidovudine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"        lamivudine",
"       </a>",
"      </span>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"       lopinavir-ritonavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      for PEP, rates of discontinuation at 28 days for any reason (36 percent) were similar between the two groups [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/38\">",
"       38",
"      </a>",
"      ]. The proportion of patients reporting adverse effects (46 percent) and discontinuing PEP because of adverse effects (16 percent) were also similar between the two groups.",
"     </li>",
"     <li>",
"      In the study from Amsterdam, 86 percent of the 355 MSM who used PEP reported adverse effects, but 94 percent still completed the PEP course [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/35\">",
"       35",
"      </a>",
"      ]. A separate evaluation of this study population compared the adherence to and side effects with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"       zidovudine-lamivudine",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"      (regimen 1 provided from 2000 to 2005) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      (regimen 2 provided from 2005 to 2007) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/37\">",
"       37",
"      </a>",
"      ]. More patients reported adverse effects, predominantly diarrhea, with regimen 1 (92 versus 82 percent with regimen 2), but completion rates were comparable between the two groups (about 90 percent). These PEP regimens are not widely prescribed in the US.",
"     </li>",
"     <li>",
"      In a study of 100 patients using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      for PEP, 85 percent took all or most of the PEP regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/36\">",
"       36",
"      </a>",
"      ]. Side effects were common (nausea or vomiting 27 percent, diarrhea 21 percent, headache 21 percent, fatigue 14 percent), but all were mild and did not result in drug discontinuation. Side effects were significantly less common and completion rates higher than those historically observed with protease inhibitor-based regimens with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"       zidovudine-lamivudine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95794100\">",
"    <span class=\"h4\">",
"     Relevance of data in other patient populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experts in the field have suggested that management of occupational exposures to HIV is relevant to other types of exposures, such as unprotected sex. However, major differences between nonoccupational and occupational exposures include [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/6,7,39-41\">",
"     6,7,39-41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The serologic status of the source is often difficult or impossible to determine compared with the hospital setting, thus necessitating more overall use.",
"     </li>",
"     <li>",
"      The delay from exposure to treatment is usually greater among exposed persons in the community compared with healthcare personnel, which may compromise efficacy.",
"     </li>",
"     <li>",
"      Medical expenses for nonoccupational exposures must usually be assumed by the exposed person, unlike occupational exposures, which are covered by workers' compensation in the United States.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, with sexual exposures, there is often the risk of pregnancy or acquiring other sexually transmitted diseases, which require additional testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69156515\">",
"    <span class=\"h1\">",
"     GUIDELINE CRITERIA FOR POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are wide-ranging recommendations for the use of postexposure prophylaxis (PEP) in nonoccupational settings [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/2,42\">",
"     2,42",
"    </a>",
"    ]. The following criteria have been suggested by some experts in the field:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure to a source known to be HIV infected or to be in a high-risk category (eg, men who have sex with men [MSM], injection drug users, sex workers)",
"     </li>",
"     <li>",
"      Unprotected receptive or insertive vaginal or anal intercourse",
"     </li>",
"     <li>",
"      Presentation for medical care within 72 hours of exposure",
"     </li>",
"     <li>",
"      History of a single exposure with commitment to prevent recurrence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines from the Centers from Disease Control and Prevention (CDC) recommend PEP for a somewhat broader group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/5\">",
"     5",
"    </a>",
"    ]. PEP is recommended when all the following conditions are met and the source patient is known to be HIV infected (",
"    <a class=\"graphic graphic_algorithm graphicRef73394 \" href=\"UTD.htm?14/21/14672\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure of vagina, rectum, eye, mouth, or other mucous membrane, nonintact skin, or percutaneous exposures (eg, injection drug use)",
"     </li>",
"     <li>",
"      Exposure to blood, or any body fluid that is visibly contaminated with blood, semen, vaginal secretions, rectal secretions, or breast milk",
"     </li>",
"     <li>",
"      Exposure within 72 hours of presentation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following the 2005 CDC guidelines would lead to PEP in patients who are probably at very low risk for contracting HIV, such as in a patient who performs oral-genital contact on a woman who is not menstruating. (See",
"    <a class=\"local\" href=\"#H9053173\">",
"     'Postexposure management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additionally, the CDC guidelines recommend a case-by-case determination of the need for PEP when the above conditions are met, but the HIV status of the source is unknown. The guidelines recommend against prophylaxis when the patient presents after 72 hours; when the exposure is to intact skin; or when certain exposure fluids, such as urine, nasal secretions, saliva, sweat, or tears, are not visibly contaminated with blood.",
"   </p>",
"   <p>",
"    Guidelines from the American Academy of Pediatrics (AAP) address the issue of percutaneous exposures from human bites and needles found in public places (eg, \"found needles\") [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/4\">",
"     4",
"    </a>",
"    ]. The guidelines recommend against routine PEP for an injury from a found needle; some experts recommend considering PEP if the needle or syringe have visible blood and the source is known to be HIV infected. The AAP guidelines recommend against routine PEP in the injured person after bite wounds, unless the saliva contains blood. If there is transmission of blood, the guidelines recommend consideration of PEP for the exposed person (whether it is the person bitten or the person biting). An alternative approach offered by some experts would be prophylaxis for a bite by or in an HIV-infected person when the skin is no longer intact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9053173\">",
"    <span class=\"h1\">",
"     POSTEXPOSURE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After exposure to HIV through sexual contact or injection drug use, postexposure prophylaxis (PEP) may be administered to prevent HIV infection. As noted above, efficacy data supporting PEP for nonoccupational exposures are scant, but limited efficacy, feasibility, and safety data in other populations (eg, healthcare personnel) have led to widespread acceptance of this practice, which has been advanced by expert guideline committees. The most updated versions of the Centers for Disease Control and Prevention (CDC) guidelines are available at:",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/\">",
"     file://aidsinfo.nih.gov",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/5\">",
"     5",
"    </a>",
"    ]. Clinicians may also seek expert telephone advice through the National",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    Clinician&rsquo;s Consultation Center, 24 hours a day (1-888-448-4911).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95794772\">",
"    <span class=\"h2\">",
"     Determining the HIV status of the exposed person",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2005 DHHS guidelines",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/5\">",
"     5",
"    </a>",
"    ]",
"    <strong>",
"    </strong>",
"    and expert opinion",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/40\">",
"     40",
"    </a>",
"    ]",
"    <strong>",
"    </strong>",
"    recommend that rapid HIV testing should be performed on all persons seeking evaluation for potential nonoccupational HIV exposure. However, if rapid testing is not available, an initial treatment decision should be made based on the assumption that the potentially exposed patient is not infected, pending standard antibody test results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4625581\">",
"    <span class=\"h2\">",
"     Determining the HIV status of the source",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the source is known and is willing to be tested, a negative rapid HIV test negates the need for prophylaxis. If testing is delayed, it is prudent to initiate PEP while awaiting the results of HIV testing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/40\">",
"     40",
"    </a>",
"    ]. If the source is willing, testing for hepatitis B (eg, hepatitis B surface antigen) and hepatitis C infection (eg, HCV antibody) is also prudent.",
"   </p>",
"   <p>",
"    If possible, it is desirable to interview the source to determine his or her HIV treatment history and most recent viral load testing results, because this information may provide guidance for ART selection. For example, if the source had a history of drug resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , alternative agents should be considered.",
"   </p>",
"   <p>",
"    Usually the source is not available for testing, so decisions to initiate PEP are usually based on epidemiologic and other various factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4625650\">",
"    <span class=\"h2\">",
"     Assessing exposure risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history must be obtained from the patient to determine the patient&rsquo;s exposure risk (eg, route of exposure and other cofactors that heighten risk of transmission). The exposure may be through sex, injection drug use, or a traumatic route (eg, human bite). (See",
"    <a class=\"local\" href=\"#H9053137\">",
"     'Risk of transmission of HIV'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4625673\">",
"    <span class=\"h2\">",
"     Should postexposure prophylaxis be offered?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to initiate PEP is complicated and depends on several factors that vary from case to case.",
"   </p>",
"   <p>",
"    The risk of HIV acquisition and the risk of experiencing an adverse event related to PEP need to be weighed on an individual basis. For example, a person with a history of rectal sex and genital ulcerative disease with a known HIV seropositive partner has a greater estimated risk of HIV acquisition than a person with a history of oral sex with a person of unknown HIV status. In contrast, if the source is HIV infected, but has attained viral suppression on an antiretroviral regimen, the risk of sexual transmission is likely very low [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=see_link\">",
"     \"HIV treatment as prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of time that has elapsed from the exposure must also be assessed. (See",
"    <a class=\"local\" href=\"#H79887868\">",
"     'Timing of HIV prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Experts in PEP have suggested that PEP should be considered if the risk of exposure is estimated to be at least 0.1 percent from a source patient who is known to be HIV-seropositive or is at high risk for HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/40\">",
"     40",
"    </a>",
"    ]. Clinicians can also call the National Clinician&rsquo;s Post-Exposure Prophylaxis Hotline at 888-448-4911 for expert advice 24 hours a day.",
"   </p>",
"   <p>",
"    When postexposure prophylaxis is being considered, patients should be counseled regarding data limitations supporting the use of PEP and the potential of drug toxicity. Patients untroubled by potential toxicity who place a high value on preventing HIV acquisition are likely to choose PEP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108470559\">",
"    <span class=\"h3\">",
"     Persons with repeated exposures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain individuals might repeatedly present with exposures that could qualify for PEP; however, PEP should not be offered to persons who repeatedly engage in high-risk behaviors that would require sequential courses of antiretroviral medications (eg, discordant sex partners who rarely use condoms or injection drug users who often share injection equipment). In addition, limited resources can restrict availability, particularly to those who are uninsured [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/44\">",
"     44",
"    </a>",
"    ]. In select patients with repeated exposures to HIV, preexposure prophylaxis may be an effective option for reducing the risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79887644\">",
"    <span class=\"h2\">",
"     How many medications should be given?",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of chronic HIV infection generally involves three-drug combination therapy for maximal viral suppression and to decrease the risk of drug resistance. This typically includes the use of two nucleoside reverse transcriptase inhibitors (NRTIs) as the &ldquo;backbone&rdquo; and either a protease inhibitor (PI), a nonnucleoside reverse transcriptase inhibitor (NNRTI), or an integrase inhibitor as the base. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend a three-drug regimen for nonoccupational PEP because of efficacy in patients with chronic HIV infection, reduced number of pills, and demonstrated safety. This is consistent with the Department of Health and Human Services guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/5,45\">",
"     5,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the past, many clinicians would choose between a two- or three-drug PEP based on level of exposure risk. The three-drug therapy was often given for persons with a history of anal intercourse, which is associated with the highest risk of HIV transmission compared with other sexual exposures. Two-drug therapy was offered to persons with low-risk exposures, such as vaginal intercourse. One mathematical model suggested that when balancing side effects, efficacy, and cost, a dual nucleoside regimen was preferable to a three-drug regimen for HIV prophylaxis, unless the background rate of viral resistance in the community exceeds 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/46\">",
"     46",
"    </a>",
"    ]. However, newer drugs have a more favorable side effect profile and data on the local prevalence of HIV drug resistance are usually not available to make rapid decisions regarding prophylaxis. Thus, most experts no longer use a two-drug regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9053187\">",
"    <span class=\"h2\">",
"     Potential choices in ART regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since there are no data on the most efficacious PEP regimens for persons with nonoccupational exposure to HIV, selected medications are chosen based on side effect profiles, patient convenience (eg, pill burden and dosing frequencies), and completion rates. The classes of antiretroviral medications that are available for PEP include the NRTIs, NNRTIs, PIs, and integrase strand transfer inhibitors (INSTIs).",
"   </p>",
"   <p>",
"    For the NRTI backbone, we prefer the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    (coformulated as Truvada) because it is well tolerated and only requires once-daily dosing. The main concern with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    is renal toxicity, which usually occurs with long-term administration of tenofovir. Other NRTI coformulations may be associated with hypersensitivity reactions (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/4/3141?source=see_link\">",
"     abacavir-lamivudine",
"    </a>",
"    , coformulated as Epzicom) or anemia (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/901?source=see_link\">",
"     zidovudine-lamivudine",
"    </a>",
"    , coformulated as Combivir) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/47\">",
"     47",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    also requires twice-daily dosing and may not be as well tolerated.",
"   </p>",
"   <p>",
"    As noted above, we prefer a three-drug regimen for all PEP, with dual NRTI therapy paired with an integrase inhibitor, a PI, or nonefavirenz NNRTI (",
"    <a class=\"graphic graphic_table graphicRef83598 \" href=\"UTD.htm?26/58/27563\">",
"     table 2",
"    </a>",
"    ). Since the PEP guidelines were published in 2005, many more anti-HIV agents have become available for the treatment of chronic HIV infection. The integrase inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    is well tolerated and has few drug-drug interactions. Raltegravir also achieves higher concentrations in the male and female genital tract than do PIs and NNRTIs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/48\">",
"     48",
"    </a>",
"    ]. These characteristics make it a desirable choice for the third agent in a PEP regimen despite its required twice-daily dosing. In 2012, the New York Department of Health AIDS Institute released revisions of its occupational PEP guidelines that support the use of raltegravir with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    as the NRTI backbone [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/49\">",
"     49",
"    </a>",
"    ]. Many experts expect that other occupational and nonoccupational PEP guidelines will follow suit.",
"   </p>",
"   <p>",
"    The newer PIs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    , are well tolerated and less likely to result in substantial lipid abnormalities seen more commonly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20378?source=see_link\">",
"     lopinavir-ritonavir",
"    </a>",
"    (eg, hypertriglyceridemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/40\">",
"     40",
"    </a>",
"    ]. If selected, atazanavir and darunavir should be given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , which boosts the serum levels of the parent drug. These PIs also afford the same convenience of single daily dosing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=see_link\">",
"     \"HIV protease inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     Efavirenz",
"    </a>",
"    (an NNRTI) can be given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    as a single pill once daily, coformulated as Atripla, for patient convenience. However, efavirenz can be associated with rash, headache, and dizziness. Additionally, efavirenz is pregnancy category D, potentially limiting its utility in females of child-bearing age. Side effects can lead to early medication discontinuation and potential failure of prophylaxis. Since many of these symptoms with Atripla are particularly common during the first month of administration, we prefer other antiretroviral medications as the third agent for PEP. Furthermore, the barrier to resistance to NNRTIs is not as high as that to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PIs, and in some locations, reported rates of transmitted resistance to efavirenz range between 9 and 21 percent, depending on the phase of infection that resistance testing was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/50\">",
"     50",
"    </a>",
"    ]. Although still included in older guidelines as a reasonable choice for PEP, these issues make efavirenz and efavirenz-containing fixed-dose combinations less desirable choices for first-line PEP regimens.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    (an NNRTI) can also be given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    as a single pill once daily, coformulated as Complera. This combination is less likely than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    -based therapy to have central nervous system side effects and sleep disturbance, though there remains a risk of rash. There is no published experience with this combination as PEP, although its benign side effect profile and dosing convenience may offer some advantages. However, the relatively low barrier to resistance observed in treatment studies is a shortcoming. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link&amp;anchor=H658623#H658623\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\", section on 'Efavirenz versus rilpivirine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, for patients who are offered PEP following a nonoccupational exposure to HIV, we recommend the following regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       Tenofovir-emtricitabine",
"      </a>",
"      (coformulated as Truvada) PLUS",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      OR",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       Tenofovir-emtricitabine",
"      </a>",
"      (coformulated as Truvada) PLUS",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      or ritonavir-boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts recommend giving the exposed individual the same regimen for PEP as the source patient is taking for chronic HIV infection or using resistance data from the source patient to guide drug selection. This approach is logical if the following conditions are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The source is willing to share such medical information.",
"     </li>",
"     <li>",
"      The source has attained viral suppression on",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      current regimen.",
"     </li>",
"     <li>",
"      The ART regimen does not include medications with unacceptable toxicity profiles for PEP use.",
"     </li>",
"     <li>",
"      Obtaining the necessary data does not delay the initiation of PEP in the exposed individual.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4626494\">",
"    <span class=\"h2\">",
"     Medication adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;All people taking PEP should be informed about drug side effects, drug interactions, and proper timing of doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4626513\">",
"    <span class=\"h2\">",
"     Duration of ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 28-day course of ART is recommended for persons with a significant HIV exposure, although the optimal duration of prophylaxis is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79887838\">",
"    <span class=\"h2\">",
"     Drugs that should not be given for PEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    should be given for PEP. Nevirapine, which is another drug within the NNRTI class, has been associated with severe hepatotoxicity in patients receiving PEP and is contraindicated for this purpose. The NRTI, abacavir, is associated with a hypersensitivity syndrome. Testing for genetic risk for this clinical syndrome is not practical when rapid initiation of therapy is warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=see_link\">",
"     \"Pharmacology of non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69157609\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC CONSIDERATIONS IN SEXUAL EXPOSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various antiretroviral medications attain lower drug concentrations in the male and female genital tract relative to blood plasma concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Penetration into the genital compartment is strongly influenced by the degree of protein binding [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/54\">",
"     54",
"    </a>",
"    ]. Highly protein-bound drugs are recovered in lower concentrations in genital tract secretions compared with plasma. This is an important issue, since maximal suppression of viral replication in the genital tract is believed to be essential to prevent evolution and transmission of drug-resistant virus from this compartment during antiretroviral therapy (ART).",
"   </p>",
"   <p>",
"    The degree of protein binding varies by drug and drug class. Male and female genital concentrations of protease inhibitors tend to be less than 10 to 50 percent of plasma, respectively, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    concentrations are low to negligible [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/52\">",
"     52",
"    </a>",
"    ]. In contrast, most nucleoside reverse transcriptase inhibitors (NRTIs) have limited protein binding and thus attain genital tract concentrations that are two- to sixfold higher than plasma concentrations.",
"   </p>",
"   <p>",
"    Pharmacokinetic studies of chronically-infected women have shown that certain drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    attain higher levels in cervicovaginal fluid than in blood plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/53\">",
"     53",
"    </a>",
"    ]. Concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    in the genital tract also appear to be excellent with a favorable genital to blood concentration ratio in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/55\">",
"     55",
"    </a>",
"    ]. In contrast, cervicovaginal to blood plasma ratios for other medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , lopinavir, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    are very low [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Nevertheless, the risk of HIV RNA detection in cervicovaginal fluid is low in patients with ongoing viral suppression in plasma.",
"   </p>",
"   <p>",
"    The extrapolation of these data to persons taking postexposure prophylaxis (PEP) is somewhat limited by the time it takes for antiretroviral medications to reach steady state drug concentrations. However, these data have several important implications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viral replication in the genital tract can be suppressed even when all components of an ART regimen do not achieve adequate concentrations.",
"     </li>",
"     <li>",
"      The excellent accumulation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      in the genital tract supports their use in postexposure prophylaxis regimens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79887868\">",
"    <span class=\"h1\">",
"     TIMING OF HIV PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of HIV pathogenesis suggest that HIV prophylaxis should be given as soon as possible and within 72 hours. In studies of the biology of a closely related virus, simian immunodeficiency virus (SIV), SIV RNA was detected in lymph nodes of macaques within 18 hours of infection. These data suggest that there is a small window of opportunity to interrupt HIV dissemination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4625819\">",
"    <span class=\"h1\">",
"     RISKS ASSOCIATED WITH POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providers need to have a detailed discussion with patients about the potential risks and benefits of postexposure prophylaxis (PEP). The",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    ratio of PEP rises in patients with lower risk exposures (eg, fellatio versus anal intercourse) so patients must be aware of potential medication side effects and toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/5,40\">",
"     5,40",
"    </a>",
"    ]. In addition, antiretroviral medications are costly and all patients taking antiretroviral therapy must have laboratory and clinical monitoring while taking PEP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4625866\">",
"    <span class=\"h2\">",
"     Increased behavioral risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conflicting data have been published as to whether PEP may increase high-risk sexual behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/33,52,56,57\">",
"     33,52,56,57",
"    </a>",
"    ]. In a study of 397 adults who received PEP for high-risk sexual or drug-use exposures, most participants (73 percent) reported a decrease in high-risk sexual acts within the subsequent 12 months, while 14 percent reported an increase [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/58\">",
"     58",
"    </a>",
"    ]. Other data suggest that the availability of potent ART may be associated with increased risk-taking behaviors, as evidenced by higher rates of sexually transmitted diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/33,56\">",
"     33,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4625873\">",
"    <span class=\"h2\">",
"     Potential failure of prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be informed that there are instances of prophylaxis failure [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/59\">",
"     59",
"    </a>",
"    ]. Reasons for failure may include poor adherence to the PEP regimen, suboptimal treatment regimen, delay in initiation, or ongoing HIV exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/60\">",
"     60",
"    </a>",
"    ]. In instances where PEP may fail, selection of resistant virus by drug exposure is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79887882\">",
"    <span class=\"h1\">",
"     TREATMENT COMPLETION AND ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Completion of postexposure prophylaxis has been variable, ranging from 24 to 78 percent of participants [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/7\">",
"     7",
"    </a>",
"    ]. Toxicity has been the main reason for treatment discontinuation. As noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    are well-tolerated nucleoside reverse transcriptase inhibitors. Rates of adverse reactions are generally higher in persons receiving triple-drug therapy as compared with two-drug therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69157132\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV testing should be performed at baseline, four to six weeks, twelve weeks, and six months following the exposure and at any time the patient develops symptoms consistent with HIV seroconversion disease (",
"    <a class=\"graphic graphic_table graphicRef66128 \" href=\"UTD.htm?8/25/8605\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/40\">",
"     40",
"    </a>",
"    ]. In patients who become acutely infected with hepatitis C virus (HCV) after exposure to an",
"    <span class=\"nowrap\">",
"     HIV/HCV-coinfected",
"    </span>",
"    source, the Centers for Disease Control and Prevention recommend that HIV serology additionally be performed after 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine monitoring of HIV RNA in an attempt to detect early infection should generally not be performed because of the risk of a false positive test result. However, such testing is appropriate in patients who have symptoms suggestive of the acute HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H69157020\">",
"     'Symptoms of HIV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Regular contact with the patient, either in person or by telephone or email, is recommended to improve adherence to prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/34\">",
"     34",
"    </a>",
"    ]. Patients should be monitored for potential drug side effects including rash or symptoms and signs of hepatotoxicity (ie, nausea, vomiting, right upper quadrant pain). Laboratory monitoring consists of a complete blood count with differential count, blood urea nitrogen (BUN), and creatinine and liver function tests (",
"    <a class=\"graphic graphic_table graphicRef66128 \" href=\"UTD.htm?8/25/8605\">",
"     table 3",
"    </a>",
"    ). Additional studies may be indicated when specific antiretrovirals are used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link\">",
"     \"Patient monitoring during HIV antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women of childbearing potential, a pregnancy test should be performed at the baseline visit. If positive, an antiretroviral regimen should be chosen following consultation with an obstetrician specializing in high-risk pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9053215\">",
"    <span class=\"h1\">",
"     PATIENT COUNSELING AND EDUCATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare personnel need to be well educated about the factors that influence HIV transmission so appropriate counseling can take place. Postexposure prophylaxis (PEP) is also viewed as an opportunity to reach at-risk patient populations for HIV counseling and testing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important factor in PEP acceptance is the support of the provider who is dispensing medications. In a prospective study of 386 adolescent sexual assault victims in Canada, only 43 percent accepted and one-third completed the 28-day course of PEP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/62\">",
"     62",
"    </a>",
"    ]. One of the major factors associated with PEP acceptance was the strength of the recommendation by the examining healthcare provider (OR 5.86, 95% CI 3.06-11.25). Risk of HIV exposure is often conveyed as",
"    <span class=\"nowrap\">",
"     1/1000",
"    </span>",
"    episode of intercourse, which can lead some victims to conclude that they are at negligible risk; however, each exposure should be evaluated individually based on factors that may increase risk of HIV acquisition (eg, rectal tearing) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have been traumatized by a sexual assault should have a follow-up visit within a few days of starting antiretroviral therapy for a more comprehensive discussion of PEP [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69157013\">",
"    <span class=\"h2\">",
"     What to do to avoid secondary transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;People potentially exposed to HIV should be advised to use the following measures to prevent secondary transmission during the follow-up period, especially during the first 6 to 12 weeks after exposure when most HIV-infected persons are expected to seroconvert:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use condoms, or practice sexual abstinence, to prevent sexual transmission and to avoid pregnancy.",
"     </li>",
"     <li>",
"      Refrain from donating blood, plasma, organs, tissue, or semen. The usual duration for this precaution is two months.",
"     </li>",
"     <li>",
"      Breastfeeding women in resource-rich settings should discuss the risks and benefits of continuing breastfeeding while taking ART. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"       \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69157020\">",
"    <span class=\"h2\">",
"     Symptoms of HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;People potentially exposed to HIV should also be advised to seek medical attention if they develop symptoms consistent with primary HIV infection, often described as a \"mononucleosis-like syndrome\". The most common findings are fever, lymphadenopathy, sore throat, mucocutaneous lesions,",
"    <span class=\"nowrap\">",
"     myalgia/arthralgia,",
"    </span>",
"    diarrhea, headache,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    and weight loss. The usual time from HIV exposure to the development of symptoms is two to four weeks, although incubation periods as long as 10 months have been seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=see_link\">",
"     \"Acute and early HIV infection: Pathogenesis and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who develop a syndrome concerning for primary HIV infection should undergo HIV RNA testing. (See",
"    <a class=\"local\" href=\"#H69157132\">",
"     'Patient monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9053229\">",
"    <span class=\"h1\">",
"     OTHER TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sexual exposures to HIV should be offered testing for other sexually transmitted infections, such as gonorrhea, chlamydia, and syphilis, and empiric treatment should be considered. Pregnancy testing and emergency contraception should also be offered (",
"    <a class=\"graphic graphic_table graphicRef66128 \" href=\"UTD.htm?8/25/8605\">",
"     table 3",
"    </a>",
"    ). A high frequency of sexually transmitted infections has been found in men who have sex with men who were provided postexposure prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/63\">",
"     63",
"    </a>",
"    ]. All patients with nonoccupational exposures should be offered testing for hepatitis B and C; immunization for hepatitis B should be offered if the patient is nonimmune and hepatitis B immunoglobulin offered to individuals exposed to a source with active hepatitis B infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=see_link\">",
"     \"Screening for sexually transmitted infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\", section on 'Postexposure prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional evaluation and management of rape victims is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=see_link\">",
"     \"Evaluation and management of adult sexual assault victims\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69157301\">",
"    <span class=\"h1\">",
"     BARRIERS TO POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postexposure prophylaxis (PEP) is an episode-driven intervention following a particularly high-risk event that is oftentimes limited. However, many individuals may not be aware of the possibility of PEP, and this lack of awareness may be a barrier to initiation. Several studies have assessed the feasibility and acceptance of antiretroviral therapy for nonoccupational exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/34,57,64,65\">",
"     34,57,64,65",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    As an example, in a study that followed 4295 men who have sex with men (MSM) from six cities in the United States over four years, 48 percent of participants reported awareness of PEP, only 2 percent utilized PEP prior to enrollment, and 6 percent utilized PEP at least once during the study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/66\">",
"     66",
"    </a>",
"    ]. Similarly, in a separate study of 554 MSM surveyed at two New York City bathhouses, only 36 percent of men were aware of PEP or preexposure prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/67\">",
"     67",
"    </a>",
"    ]. Furthermore, less than half of the men reported having disclosed MSM behavior to their primary care provider, and this lack of disclosure also likely serves as a barrier to PEP use. Nevertheless, awareness and use of PEP may be increasing over time [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/64,65,68\">",
"     64,65,68",
"    </a>",
"    ]. In a survey of MSM in Australia, awareness of PEP increased from 23 percent of surveyed men in 2001 to 64 percent in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/68\">",
"     68",
"    </a>",
"    ]. PEP use also increased from 2.3 percent to 3.9 percent over that time period.",
"   </p>",
"   <p>",
"    PEP awareness and use has been associated with high-risk behavior, including multiple sexual partners, unprotected receptive and insertive anal sex with HIV-infected partners and partners with unknown HIV status, and illicit drug use [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. However, many people with high-risk exposures who have been seen in an emergency department are not offered PEP and many persons continue to decline PEP when offered [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/57\">",
"     57",
"    </a>",
"    ]. Furthermore, it is unknown whether such high-risk behavior may limit the utility of episodic prophylaxis over the long term. Preexposure prophylaxis may be an option for certain individuals with high-risk behavior. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link\">",
"     \"Pre-exposure prophylaxis against HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The availability of PEP for nonoccupational exposure also remains a problem in the United States. A 2007 survey in Los Angeles revealed that only 15 percent of health care venues were able to offer PEP services and only 9 percent of these venues were able to provide PEP to noninsured persons [",
"    <a class=\"abstract\" href=\"UTD.htm?25/50/26410/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H95794884\">",
"    <span class=\"h1\">",
"     COST EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One issue that is specific to postexposure prophylaxis (PEP) outside of the occupational setting is cost. While the cost of medications for PEP in occupational exposures is not generally an issue in the United States, cost may be a significant concern for PEP of nonoccupational exposures. In the US, PEP with a two-drug regimen for four weeks can be expected to cost about $750, and a three-drug regimen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    and coformulated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    for 28 days can be expected to cost about $2000. Monitoring for toxicity will further increase the cost.",
"   </p>",
"   <p>",
"    One review concluded that postexposure prophylaxis following nonoccupational exposure to HIV on a one-time basis was cost-effective for the following persons [24]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men who have unprotected receptive anal intercourse with men, whether the source partner is known to be HIV-positive or not.",
"     </li>",
"     <li>",
"      Heterosexuals after unprotected receptive anal intercourse.",
"     </li>",
"     <li>",
"      Intravenous drug users sharing needles with a known HIV-positive person.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=see_link\">",
"       \"Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=see_link\">",
"       \"Patient information: Care after sexual assault (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9053264\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall risk of contracting HIV from any single exposure to body fluids from an HIV-infected patient from nonoccupational exposures is low. However, individual risk may be influenced by many variables. (See",
"      <a class=\"local\" href=\"#H9053137\">",
"       'Risk of transmission of HIV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to determine the exact nature of the HIV exposure (eg, unprotected sexual intercourse or injection drug use), which may confer varying levels of risk. For example, receptive anal intercourse carries a higher risk of HIV acquisition than other exposures, such as vaginal intercourse. However, additional risk factors may augment HIV exposure risk significantly, such as the level of viremia in the source patient and the presence of genital lesions in the source or the exposed patient. (See",
"      <a class=\"local\" href=\"#H4625819\">",
"       'Risks associated with postexposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no placebo-controlled, randomized trials evaluating the role of antiretroviral prophylaxis in nonoccupational exposures to HIV. The use of postexposure prophylaxis has been extrapolated from randomized controlled trials showing the effectiveness of antiretroviral prophylaxis in the prevention of mother-to-child transmission (MTCT) of HIV and limited observational data in persons with occupational and nonoccupational exposures to HIV. (See",
"      <a class=\"local\" href=\"#H1413672\">",
"       'Data on postexposure prophylaxis to prevent HIV transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Baseline HIV testing should be performed on all persons seeking evaluation for prophylaxis after a nonoccupational HIV exposure. (See",
"      <a class=\"local\" href=\"#H9053173\">",
"       'Postexposure management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before offering postexposure prophylaxis, patients should also be evaluated for the following criteria: the nature of the exposure; whether the HIV status of the source is known; whether the exposure occurred within 72 hours prior to presentation; and whether the patient is committed to future risk reduction. (See",
"      <a class=\"local\" href=\"#H69156515\">",
"       'Guideline criteria for postexposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Providers need to have a detailed discussion with patients about the potential risks and benefits of postexposure prophylaxis. The",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      ratio of postexposure prophylaxis rises in patients with lower risk exposures (eg, fellatio versus anal intercourse) so patients must be aware of potential medication side effects and toxicity concerns. Patients also need to be counseled regarding the risk of drug-resistant HIV if prophylaxis should fail. (See",
"      <a class=\"local\" href=\"#H4625819\">",
"       'Risks associated with postexposure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest postexposure prophylaxis for patients who report high-risk nonoccupational exposures to HIV (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). An example of high-risk exposure would include receptive anal intercourse with an untreated HIV-infected individual.",
"     </li>",
"     <li>",
"      If the decision is made to administer postexposure prophylaxis, it should be started as early as possible after an exposure and should be continued for 28 days. PEP is not indicated if the patient presents for care more than 72 hours after an exposure. Decisions about offering postexposure prophylaxis should also weigh patient values and preferences. Patients who are untroubled by drug toxicity and place a high value on preventing HIV acquisition are likely to choose postexposure prophylaxis and vice versa. (See",
"      <a class=\"local\" href=\"#H79887868\">",
"       'Timing of HIV prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9053173\">",
"       'Postexposure management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are offered postexposure prophylaxis following a nonoccupational HIV exposure, we prefer a three-drug regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"       tenofovir-emtricitabine",
"      </a>",
"      (coformulated as Truvada) PLUS",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      . Alternative regimens are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"       emtricitabine",
"      </a>",
"      (coformulated as Truvada) PLUS either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      -boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      or ritonavir-boosted",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       darunavir",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H79887644\">",
"       'How many medications should be given?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postexposure prophylaxis for an episode of injection drug use is reasonable if the event was isolated and if the patient is committed to future risk aversion. (See",
"      <a class=\"local\" href=\"#H9053215\">",
"       'Patient counseling and education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV testing should be performed at baseline, 6 and 12 weeks, and at six months after exposure. The vast majority of individuals who seroconvert will do so within the first three months. (See",
"      <a class=\"local\" href=\"#H69157132\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As many users of PEP have high-risk behavior, referral to risk-reduction counseling should be considered for individuals after an episode of PEP. Preexposure prophylaxis may be a consideration for certain high-risk individuals. (See",
"      <a class=\"local\" href=\"#H4625819\">",
"       'Risks associated with postexposure prophylaxis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H108470559\">",
"       'Persons with repeated exposures'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=see_link\">",
"       \"Pre-exposure prophylaxis against HIV infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/1\">",
"      Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997; 336:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/2\">",
"      Katz MH, Gerberding JL. The care of persons with recent sexual exposure to HIV. Ann Intern Med 1998; 128:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/3\">",
"      Tolle MA, Schwarzwald HL. Postexposure prophylaxis against human immunodeficiency virus. Am Fam Physician 2010; 82:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/4\">",
"      Havens PL, American Academy of Pediatrics Committee on Pediatric AIDS. Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. Pediatrics 2003; 111:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/5\">",
"      Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/6\">",
"      Roland ME. Postexposure prophylaxis after sexual exposure to HIV. Curr Opin Infect Dis 2007; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/7\">",
"      Bryant J, Baxter L, Hird S. Non-occupational postexposure prophylaxis for HIV: a systematic review. Health Technol Assess 2009; 13:iii, ix.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/8\">",
"      Pinkerton SD, Martin JN, Roland ME, et al. Cost-effectiveness of postexposure prophylaxis after sexual or injection-drug exposure to human immunodeficiency virus. Arch Intern Med 2004; 164:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/9\">",
"      Pinkerton SD, Martin JN, Roland ME, et al. Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. AIDS 2004; 18:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/10\">",
"      Vittinghoff E, Douglas J, Judson F, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/11\">",
"      Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr 1992; 5:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/12\">",
"      Rozenbaum W, Gharakhanian S, Cardon B, et al. HIV transmission by oral sex. Lancet 1988; 1:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/13\">",
"      Lazzarin A, Saracco A, Musicco M, Nicolosi A. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1991; 151:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/14\">",
"      Seidlin M, Vogler M, Lee E, et al. Heterosexual transmission of HIV in a cohort of couples in New York City. AIDS 1993; 7:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/15\">",
"      Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/16\">",
"      Nicolosi A, Corr&ecirc;a Leite ML, Musicco M, et al. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 1994; 5:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/17\">",
"      Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV. BMJ 1992; 304:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/18\">",
"      Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/19\">",
"      McQuillan GM, Kruszon-Moran D, Granade T, Feldman JW. Seroprevalence of Human Immunodeficiency Virus in the US Household Population Aged 18-49 Years: The National Health and Nutrition Examination Surveys, 1999-2006. J Acquir Immune Defic Syndr 2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/20\">",
"      Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/21\">",
"      Attia S, Egger M, M&uuml;ller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/22\">",
"      Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/23\">",
"      Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/24\">",
"      Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/25\">",
"      Cohen MS, Pilcher CD. Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis 2005; 191:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/26\">",
"      Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/27\">",
"      Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis. Clin Infect Dis 2010; 50 Suppl 3:S96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/28\">",
"      Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/29\">",
"      Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999; 341:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/30\">",
"      Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. The CDC Cooperative Needlestick Surveillance Group. Ann Intern Med 1993; 118:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/31\">",
"      Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/32\">",
"      Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol 2000; 74:9771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/33\">",
"      Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004; 35:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/34\">",
"      Kahn JO, Martin JN, Roland ME, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001; 183:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/35\">",
"      Heuker J, Sonder GJ, Stolte I, et al. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour. AIDS 2012; 26:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/36\">",
"      Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr 2012; 59:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/37\">",
"      Sonder GJ, Prins JM, Regez RM, et al. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance. Sex Transm Dis 2010; 37:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/38\">",
"      Diaz-Brito V, Le&oacute;n A, Knobel H, et al. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther 2012; 17:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/39\">",
"      Landovitz RJ. Occupational and nonoccupational postexposure prophylaxis for HIV in 2009. Top HIV Med 2009; 17:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/40\">",
"      Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med 2009; 361:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/41\">",
"      Chin RL. Postexposure prophylaxis for HIV. Emerg Med Clin North Am 2010; 28:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/42\">",
"      Bamberger JD, Waldo CR, Gerberding JL, Katz MH. Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault. Am J Med 1999; 106:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/43\">",
"      Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/44\">",
"      Landovitz RJ, Combs KB, Currier JS. Availability of HIV postexposure prophylaxis services in Los Angeles County. Clin Infect Dis 2009; 48:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/45\">",
"      Cohen MS. HIV postexposure prophylaxis after sexual assault: why is it so hard to accomplish? Sex Transm Dis 2008; 35:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/46\">",
"      Bassett IV, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis 2004; 39:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/47\">",
"      Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/48\">",
"      Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011; 16:1149.",
"     </a>",
"    </li>",
"    <li>",
"     HIV Prophylaxis Following Occupational Exposure. NYS DOH AIDS Institute. www.hivguidelines.org (Accessed on November 09, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/50\">",
"      Yanik EL, Napravnik S, Hurt CB, et al. Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/51\">",
"      Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72:4265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/52\">",
"      Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/53\">",
"      Dumond JB, Yeh RF, Patterson KB, et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007; 21:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/54\">",
"      Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46:719.",
"     </a>",
"    </li>",
"    <li>",
"     Dobson E, Luque A, Aslam F, et al. Comparing raltegravir genital tract distribution in HIV-infected men and women. 52nd Interscience Conference on Antimicrobials and Chemotherapy (ICAAC). September 9-12, 2012. San Francisco. Abstract A-1252.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/56\">",
"      Scheer S, Chu PL, Klausner JD, et al. Effect of highly active antiretroviral therapy on diagnoses of sexually transmitted diseases in people with AIDS. Lancet 2001; 357:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/57\">",
"      Merchant RC, Mayer KH, Becker BM, et al. Predictors of the initiation of HIV postexposure prophylaxis in Rhode Island emergency departments. AIDS Patient Care STDS 2008; 22:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/58\">",
"      Martin JN, Roland ME, Neilands TB, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004; 18:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/59\">",
"      Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/60\">",
"      Cohen MS, Kashuba AD, Gay C. HIV antiretroviral postexposure prophylaxis: a cautionary note. Clin Infect Dis 2005; 41:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/61\">",
"      Panlilio AL, Cardo DM, Grohskopf LA, et al. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/62\">",
"      Du Mont J, Myhr TL, Husson H, et al. HIV postexposure prophylaxis use among Ontario female adolescent sexual assault victims: a prospective analysis. Sex Transm Dis 2008; 35:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/63\">",
"      Hamlyn E, McAllister J, Winston A, et al. Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile? Sex Transm Infect 2006; 82:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/64\">",
"      Poynten IM, Jin F, Mao L, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS 2009; 23:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/65\">",
"      Lunding S, Katzenstein TL, Kronborg G, et al. The Danish PEP registry: experience with the use of postexposure prophylaxis (PEP) following sexual exposure to HIV from 1998 to 2006. Sex Transm Dis 2010; 37:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/66\">",
"      Donnell D, Mimiaga MJ, Mayer K, et al. Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trial. AIDS Behav 2010; 14:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/67\">",
"      Mehta SA, Silvera R, Bernstein K, et al. Awareness of post-exposure HIV prophylaxis in high-risk men who have sex with men in New York City. Sex Transm Infect 2011; 87:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/68\">",
"      Zablotska IB, Prestage G, Holt M, et al. Australian gay men who have taken nonoccupational postexposure prophylaxis for HIV are in need of effective HIV prevention methods. J Acquir Immune Defic Syndr 2011; 58:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/50/26410/abstract/69\">",
"      Golub SA, Rosenthal L, Cohen DE, Mayer KH. Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection. AIDS Behav 2008; 12:852.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3768 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26410=[""].join("\n");
var outline_f25_50_26410=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9053264\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9053130\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9053137\">",
"      RISK OF TRANSMISSION OF HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9053145\">",
"      Sexual exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4626318\">",
"      Needle and trauma exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79887584\">",
"      HIV status of the source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8055455\">",
"      Other factors affecting risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10218897\">",
"      - HIV viral load",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10218904\">",
"      - Mucosal integrity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10218911\">",
"      - Circumcision",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10218930\">",
"      - Sexual assault",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10218863\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9053166\">",
"      PREEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1413672\">",
"      DATA ON POSTEXPOSURE PROPHYLAXIS TO PREVENT HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H556853\">",
"      General background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H556898\">",
"      Data in nonoccupational HIV exposures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H556905\">",
"      - Animal data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H556943\">",
"      - Observational studies of nonoccupational PEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H462340\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H462347\">",
"      Completion rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H95794100\">",
"      Relevance of data in other patient populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69156515\">",
"      GUIDELINE CRITERIA FOR POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9053173\">",
"      POSTEXPOSURE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H95794772\">",
"      Determining the HIV status of the exposed person",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4625581\">",
"      Determining the HIV status of the source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4625650\">",
"      Assessing exposure risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4625673\">",
"      Should postexposure prophylaxis be offered?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108470559\">",
"      - Persons with repeated exposures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79887644\">",
"      How many medications should be given?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9053187\">",
"      Potential choices in ART regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4626494\">",
"      Medication adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4626513\">",
"      Duration of ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79887838\">",
"      Drugs that should not be given for PEP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69157609\">",
"      PHARMACOLOGIC CONSIDERATIONS IN SEXUAL EXPOSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79887868\">",
"      TIMING OF HIV PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4625819\">",
"      RISKS ASSOCIATED WITH POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4625866\">",
"      Increased behavioral risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4625873\">",
"      Potential failure of prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H79887882\">",
"      TREATMENT COMPLETION AND ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69157132\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9053215\">",
"      PATIENT COUNSELING AND EDUCATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69157013\">",
"      What to do to avoid secondary transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69157020\">",
"      Symptoms of HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9053229\">",
"      OTHER TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69157301\">",
"      BARRIERS TO POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H95794884\">",
"      COST EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9053264\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3768\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3768|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/21/14672\" title=\"algorithm 1\">",
"      Nonoccupation HIV PEP algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3768|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/59/32700\" title=\"table 1\">",
"      Per act risk of HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/58/27563\" title=\"table 2\">",
"      ART for PEP after nonoccupational exposure to HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/25/8605\" title=\"table 3\">",
"      Nonoccupat HIV exposure labs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18151?source=related_link\">",
"      Acute and early HIV infection: Pathogenesis and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20601?source=related_link\">",
"      Evaluation and management of adult sexual assault victims",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40458?source=related_link\">",
"      HIV protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19848?source=related_link\">",
"      HIV treatment as prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/30/1509?source=related_link\">",
"      Patient information: Care after sexual assault (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/35/31282?source=related_link\">",
"      Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37162?source=related_link\">",
"      Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34041?source=related_link\">",
"      Pre-exposure prophylaxis against HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=related_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/30/490?source=related_link\">",
"      Screening for sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31175?source=related_link\">",
"      Transfusion transmitted HIV infection and AIDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_50_26411="Diagnostic criteria P vera";
var content_f25_50_26411=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F62788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F62788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The Polycythemia Vera Study Group diagnostic criteria for polycythemia vera",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Increased red cell mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Males: &ge;36 mL/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Females: &ge;32 mL/kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial oxygen saturation &ge;92 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet count &gt;400,000/microL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White blood cell count &gt;12,000/microL*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocyte alkaline phosphatase score",
"&gt;100*&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum vitamin B12 &gt;900 pg/mL",
"        <strong>",
"         or",
"        </strong>",
"        serum unbound B12",
"binding capacity &gt;2,200 pg/mL&bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagnosis of polycythemia vera requires the presence of all three major criteria or the presence of the first two major criteria and any two minor criteria.",
"    <div class=\"footnotes\">",
"     * In the absence of fever or infection.",
"     <br>",
"      &bull; Editor's note: These two minor criteria are not commonly used at the present time for making the diagnosis of polycythemia vera.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26411=[""].join("\n");
var outline_f25_50_26411=null;
var title_f25_50_26412="Vitamin intake in CKD";
var content_f25_50_26412=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended vitamin intake for patients with chronic kidney and end-stage renal disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Vitamins",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic kidney disease*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Maintenance hemodialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        Diets to be supplemented with the following quantities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiamin, mg/day",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        1.1-1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Riboflavin, mg/day",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"       <td>",
"        1.1-1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pantothenic acid, mg/day",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Niacin, mg/day",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        14-16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyridoxine, mg/day",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin B12, &micro;g/day",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin C, mg/day",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        75-90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Folic acid mg, day",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin A",
"       </td>",
"       <td>",
"        No addition",
"       </td>",
"       <td>",
"        No addition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin D",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin E, IU/day",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        400-800",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin K",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The nutritional intake is adjusted based upon individual patient needs.",
"    <div class=\"footnotes\">",
"     * GFR &lt;70 mL/min/1.73m2 with evidence for progression.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Vitamin D, given as calcitriol, is adjusted according to phosphate and calcium balance.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Ahmed, K, Kopple, J. Nutritional management of renal disease. In: Primer on Kidney Diseases, Greenberg, A (Ed). Academic Press, San Diego, CA, 1994, p. 289.",
"       </li>",
"       <li>",
"        Tattersall, J, Martin-Malo, A, Pedrini, L, et al. European Best Practice Guidelines on Haenodialysis. Nephrol Dial Transplant 2007; 22(Suppl 2):62.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26412=[""].join("\n");
var outline_f25_50_26412=null;
var title_f25_50_26413="TmHCO3 without volume expansion";
var content_f25_50_26413=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Maximum bicarbonate reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bicarbonate titration curves obtained from a patient with a GFR of 37 mL/min studied under conditions of minimized (circles) and exaggerated (triangles) expansion of the extracellular fluid volume. Minimizing volume expansion increased maximum bicarbonate reabsorptive capacity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Slatopolsky, E, Hoffsten, P, Purkerson, M, Bricker, NS, J Clin Invest 1970; 49:988, by copyright permission of the American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26413=[""].join("\n");
var outline_f25_50_26413=null;
var title_f25_50_26414="Contents: Hospital medicine calculators";
var content_f25_50_26414=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/37/606\">",
"       Calculators",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hospital medicine calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hospital medicine calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/8/3205\">",
"           Calculator: APACHE II scoring system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33796\">",
"           Calculator: CIWA-Ar Clinical Institute Withdrawal Assessment for Alcohol scale",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/19/14642\">",
"           Calculator: Clinical indicators for malignant hyperthermia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/42/44705\">",
"           Calculator: Community-acquired pneumonia severity index (PSI) for adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1505\">",
"           Calculator: DVT probability: Wells score system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/35/4656\">",
"           Calculator: Diagnosis of endocarditis - Duke criteria for definite endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/36/40513\">",
"           Calculator: Pressure ulcer risk stratification (Braden score)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/35/40496\">",
"           Calculator: Pulmonary embolism Wells score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/53/28497\">",
"           Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for ST elevation acute myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/34/5665\">",
"           Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/0/34818\">",
"           Calculator: Venous clinical severity score",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/51/31539\">",
"           Calculator: A-a gradient (alveolar-arterial gradient; AaG)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/1/12305\">",
"           Calculator: Absolute neutrophil count",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34337\">",
"           Calculator: Adult burn injury fluid resuscitation (Parkland crystalloid estimate)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/27/4529\">",
"           Calculator: Body Surface Area (Mosteller, square root method)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/41/40593\">",
"           Calculator: Body mass index (BMI; Quetelet's index)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/35/17969\">",
"           Calculator: Calcium correction in hypoalbuminemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/51/15153\">",
"           Calculator: Calcium correction in hypoalbuminemia (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/62/25570\">",
"           Calculator: Cardiac Output",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/19/42288\">",
"           Calculator: Corticosteroid Medication Dosing Conversions (glucocorticoid effect)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/8/16513\">",
"           Calculator: Creatinine clearance (measured)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/57/30609\">",
"           Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/22/19809\">",
"           Calculator: Creatinine clearance estimate by Cockcroft-Gault equation (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/13/25809\">",
"           Calculator: Fractional excretion of sodium",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/28/25025\">",
"           Calculator: Fractional excretion of sodium (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/40/24193\">",
"           Calculator: Glomerular filtration rate estimate by Schwartz formula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10194\">",
"           Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/7/34928\">",
"           Calculator: Nasal Canula Oxygen Fractional Inspired O2 (FIO2) Estimate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/49/14098\">",
"           Calculator: Oxygenation index",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/9/14481\">",
"           Calculator: Peak Expiratory Flow Prediction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28593\">",
"           Calculator: Pulmonary Vascular Resistance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/48/7937\">",
"           Calculator: QT Interval Correction (EKG)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/45/28370\">",
"           Calculator: Serum osmolal gap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/19/20786\">",
"           Calculator: Serum osmolal gap (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/56/26497\">",
"           Calculator: Systemic Vascular Resistance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/18/16673\">",
"           Calculator: Urinary protein excretion estimation",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-5E682EEA44-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_50_26414=[""].join("\n");
var outline_f25_50_26414=null;
var title_f25_50_26415="Endoscopic image after gastric plication";
var content_f25_50_26415=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic image after gastric plication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 293px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAElAboDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiloAMVPY2c99dx21qhkmkbaqjqTSWdtNeXMdvbI0ksh2qqjJNfU/wAEfhlD4ds11bWoEfUXGY1bnYD/AFrKtWjSjc2oUZVpWR5lafs++Lbm1in+16NF5ihtkk0oYZ9cRkU6T9nvxUhw2o6F/wB/5f8A41X1K0wUEnpWPqN0FbJY/SvFqZlVjtY9qnldJ7nzUfgN4nBIOoaJ/wB/pf8A43T1+AXilhkX+ifjNL/8br6HgJllGScVfZwo61gs1rvqvuOh5Th+l/vPmg/APxQP+X/RP+/0v/xuo3+BPiZOt/ov/f6X/wCN19JSTD+9WfczEk8nFDzXELa33GkMmw73v9587yfBHxGnW+0f/v8ASf8Axuq0nwe16Prf6QfpLJ/8br3m9uwCVyfzrJmk39Kj+1sT3X3HXDIcI1d3+88VPwn1wdbzS/8Av7J/8RUD/DDWVODd6b+Ej/8AxFezSscVVZueaazXEeX3Gj4fwfRP7zyD/hWesf8AP1p3/fx//iKRvhrq4/5etP8A+/j/APxFetSOAOtVZpeOKpZpiH2+4zlkWDXR/eeVN8PNVHW5sP8Avt//AImkHw91U/8ALzYf99v/APE16VJJToss3FV/aWI7r7jJ5NhNrP7zzUfDrVj0ubD/AL7f/wCJqaP4Y61IfludP/GR/wD4ivVbePJFalvFgCpeaYhdV9xcciwj6P7zx9PhNrr9LvTP+/kn/wARUw+D3iA/8vmlf9/ZP/iK9qgBBq9HUPN8R5fcbLIMH2f3nh1t8FfEVxMka32jqWOAWlkx/wCi6ST4LeIo5Wja80kMDj/WyYP/AJDr363yGBXhgcg+9alvbf2rZGJRtvYGz/vjrVRzXES6r7jmq5LhKbu07ep84w/BDxJKflvtHH1mk/8AjdWLf4DeJ57lIFv9FDP0JmlwP/Ide8xkwzlJAUYHkela0ExEyPDguDxmtaeZ1m/eaMKmT4ezcE/vPEB+y142OMap4cI/6+Jv/jNZGvfs9+KtEaNbvUtBZn6COeY4+uYhX2Lp+sI8CecNrgZIJ5rz7xZqEmq6xcsCRDENirn8M111Mwko3ieVhsuc6vLNaHzK/wAGPESxK5vNJ2t0/eyf/EVE3we8QL1u9L/7+yf/ABFfR+rwmK105cY2qc+/Wst1JrhlmtdPdfce3DJcLJXs/vPAf+FQ6/8A8/el/wDf2T/4ik/4VHr3/P3pn/f2T/4ivd3BqNxgUlmtfuvuK/sPC9n954SfhPro63Wm/wDfx/8A4ioX+F+tJ1udO/7+P/8AEV7nMcDpVGbk1SzSv5fcQ8lwy6P7zxVvhtrC9bmw/wC/j/8AxNRt8O9WXrcWH/fb/wDxNexSj2qjNnJrSOY131X3GbyfDLo/vPJm8A6ovWey/wC+2/8AiahbwTqS9ZrT/vtv/ia9VkBxVKVa0WPreRk8qw67/eeYv4Sv06y23/fTf/E0z/hF73ODLbD6s3+FeizJxVCePnitFjarIlllBdH95xo8I3x6TWv/AH03/wATTv8AhD9Q/wCe1r/303/xNdlD0FXI0yKv63UMv7Po+ZwP/CHah/z2tP8Avpv/AImmnwhfj/lran6M3/xNeiGI1BJGR1pLGzvqDy6j0PLtQ0q5sH2zhfYqSQaokYr1LULKO8tzHIo9j6V59qunyWMxSQcdj6120MQqmj3POxOF9n8Jm0UpGKSuk4QooopgFFFFIAooooAKKKWnYAqSKNpJERASzHAApgBJwOa+gfgp8LJnS31nVrdG8zmGOQcKPU1lWqqlG7NaVN1JWNX4MfDePQ0i1vW4wb11zDE/8Oe9evy3eXwpxnt6VHpkVodRnOoSv5URKRlehx3rPllRriVom3IGIBr53FV3J3Z9NgqEVpFFu7vzEvLCsdJWupix6VBfFnkH1qSFvJQ44Jryp1LnswoWNKORYxx1qCW6BLZNZs1wcnmqssjNzUKZusPctT36rnrms241FjnrUcrn61VkFPnNVQsQyzl2JY1C8mKJe9VJpMUJtmqXKhZZuarPNzUUklV3frWyRlKdiSSQnNQO2aaz0wOCcVrGJy1KomCzYFXbSIhhkVFCgLCti0h4GaHoZwd2WbWMY5XNaEKdOKZCgAxVuNaxkzvhEljQdqtRKMUyMVMlYs0asTR9sVat5XgnWaFirj071XSp4xVJtHPUSaszWvYI9ZtRdWwCXif6xP71ZMEjR5yMMnUelT29xNa3SzQnBHUetNvZBPcPMqBWYfMB3rTnUtTkjCULxW39aHceEdOjvYjdz8nptrH8faXDp95Dc2pVFn+VovX3/Sq9tr8+nzMLAYieMfK3Zqyb24udQvBc3rbiv3R2FdrrU1Dl6nlwwuI9v7S9olS+Mk8CGRt0iNhQOm2qzDjpV6TGMiqj9685u7PcgrKyKci1A44q1JVeU+lUiilNVGbGavS9/SqU2Oa2iTJFKY4FUZeSavyiqcowTW0DGSKsg4NUpQcn0q+/Sq8iitUzCSM+RCRVG4jNaz8VQn6mtEzGSKcQwcVfgHFUejVftjkCtdznaJ8cVHIuasAcUjLUNCZRkj9Ky9W0yO/gZGADjoa3nSqrpzVQk4O6MakFJanlOo2UlpMySKRg9fWqNena1piX0DKQA3Y153fWclrO0cgwQa9mhWVRa7niYrDuDutipRS0ldBxBRRRQAUUUUAL2pyruOBSAEnAGT7V7R8GvhlJqNzHq2u24FggDxxt1c571FWrGlG7N6FCVeXLE1vgT8LoL24t9b8Rr/oQw0cRXBb619S2sFvqq+Vap5NnFhQqDHFcdAEiRYoVCRKMKo6AVu6RrcWlWEu4FppGxGg7mvFeJ9rL3tj2q2BdKCdPcTxbp1tYxNKigEjaq9q4MblG1Mcmu41fzdSuraO7YYAyy+9c1r6QQ3cdvahcR8sV9a4MW09Ud+XKUWoy3MjBX73JqGR+1WJSeaqSH1ry2fRQVxh5PNRSHFOdwKpXE3HBqbHTGNxLmQKKzZ5jnrRcSlskmqE0nPWtIwCTsOlmyTzVGaXNJK/JqrK5INbxgcs5iSS471A8vvTHaoJHreMDhqTJTIT3pA5zmq4YnpVi3jaRgK0ehzc3MzW04NkMw4retwCoIrLtIsKoNa1uMCueTOqmi9CvFX4kqlAa0ITxWTO+DHqtTKOKaBTlqGht3JUqZWqFaUdalmTVyfNTRQSSQyyqv7uMZY1WB4q1FMwt5IgxCMMsB3pGM7paDYwGwa2/D9lZ3dndXN/IFSIkBScVl28IVYZJpFEcikgDqDUcjKISgzgnnnrWkHbVnPWi6q5YOxXwMPg5G44+meKryVYYgIcVVlakddNWRXmqnKasytk9apzNgGrRTK05qjMamuJMVnyTcmtoIhiSN1zVOVxSzzDB5qjJLya2SMZMez1C7ZqJ5ucZphfI9qtI55MVjVO4HNWSagl5Bq0zJ6lFutXbQ8CqjjmrlovArZMwkXR0p3amgHFOApEkTCoJFGatkVBIKCbFVgO9Y2v6TFfwErxKOhralQ4qo+RmtKU3B3Mq0FONmeW3du8ErI6kEHvVY8V3uv6Yt5FvTiVRx71xE8TRuVZcEV7FGqpo8HEUHB3IKKU0lbHKLTgvpSKMmvT/AIQ/Dm48UajHe36mLSYWy5Yf6z2FTOpGnHmZrRpSqvlii78GvhtLrt3HqurIY9OiIZFI5lI6fhX0mu2KJYYkVIUGEVegFJb28FjaxWlmgS3iG1FHYVJszXzeKxLrSPqsHhY0IeYxOtKk3kyLLtDOn3c9qUrgVSu5QvHc1xuXKd0YqbsPfUJhK7li0je9U1h2F3dizucnNTRQj7zdaiuHIzXPOTe50Rik7RKc3U1QnOM1Pczcmsy4lPPNYNnpUYNjJ5ODzWXcT471JdTHBrJnmFXBXOuVoodLOeapyye9RyTVWaTJrqhE4KkyR5OetQs3BpjOc1G78HmuiMDhqVBkrcGqrNRPJwaqlzWyiedVqaluJhkAd617OMjawFZGmIZJsnoK6mziGBWc0XR1Llqp4rSjUYyagt0AFWtvycVyyR6UETQsoNX4HXisVW2uB61ehfgVBtF2NUEGpFFUUkPFW0kBFS0WTClBxUe6jdnpUNCsS5zUkZIqAHmpVNTYiSJM+vbpUcshp2eaY+MUCSIml9aRjGUYlsGmSDmq0hAHNVEsZMQMmqE75J5qaeUVm3E2M8itUhMgu3ABrJmlHPNTXk3Bwax558d62gjKciaeQYPNUJZsE81WurzaPvVQ89pG610qFzknUNESZbrUwNVbccDNWlFVYwcrjs0xjwaXpUcjAKTTSJuU2YNIQOtaFpkDkVk2+XnY9s1t2w4FWYyLSjiingcUhxQiSNzUD1O3eq8hxmgGQSNgVUlbrU8hzmqslWkZyZXkIBz3rntd09bnMsY/ed/etyY1SlPUVvTk4O6OerBTVjg5kKMQwwQairf8R26CJJ1wGL7SB9D/AIVgV6tOXNG54VeHJNxOz+E/hP8A4TDxclg5xBDEbiY5x8gZR/NhX2Dp9jbadYRWdhEsNtEoVVUY6dzXzZ+y+M+PtQ/7Bkn/AKNir6eBwMV5OYVJc/L0PcyuCVLn6kXlZpcBRUtRTHivHloeqm3oV7iQKpqnDCZGLt07VZ8oyyc/dFSTbYkwKxbubqXKrLcqTMFHFZN1J1q3dzgGsi6mHNYyZ34emypPJljWfcNwealnl5OKzrqbFR1PXpx5VcqXcmAayJpeatXk2azJGOa6acTmr1Ads96jLCmM1Rlq6oxPNqTJGaoZDwaC1RO2RWyRxVJFWc8GqpbJqxOQFOaoxtuuFUd62S0PPm9To9HiKhePvV09ouAKydMjXalbUS1hUOvDsvQVb7VUhGMVYLYFc0kelGRXlBEqk9BUqTYah8MPeq7DDVDiaRmjSSbOKtxSkiseJzmr0UnFQ0aJmh5vFPibIJrNeYDvU0F0pGO9S0WmaIPNSK3NUUmyasLJSsJonJpjvikLcVXkY+tTYSQsr9aozSAA9amkfjmqM74zVJAU7qbANY93cgZ5q/eNwcVh3p4OK2iRIq3NyOeaxb68CqfWrF2zHNYt6jGuqlBN6nHVlZFSW4MjmrtnyOax2JWTnpWvp7ArXc4qx5sqjbNmEfKKtgDFVYCNoqznisWilIRqzdRl2xMo4LcVdlcAcmsJ7j7VqXlD7qdcVUYEuZp6fF+6TPWteFMCqdouAKvx9KGJO5KtNc04GmP0qRkZbiq03WppDgVTlfnrQSxkhqnKamkf3qpM4pq5LRXmPNUpTViZuapzuBXRHUyloYviI5tk/wCug/ka5+tzXX3wLjpvH8jWHXp4dWgeHjf4p7D+y8ceP9Q/7Bkn/o2Kvp+vl/8AZe/5H+//AOwZJ/6Nir6h7V42ZP8AensZZ/A+bEyAKhKmRiAOKl2F+lPx5Y968yR6N7bFd8RIc1l3s/vVu9ckHFYd2Sc81zSl0O3D07u7Kl3Nz1rLnkyTVm45qlKh5rLc9yjBJFK4fANZVy5Oa2mt9+cmsq/g8skVcY6m9SWmhjTtlqquauTLzVSRRXXE82pqV2IxULsAKllQgZqtIcda6IHFUQ0yUx5Rg1FM3Bqm8h55rogrnHVQ+eXINVtOO7UFz0FRSyZBqvbymO4DZ5rZROCe56BYyYxW/atuUHtXCWd8emetbVrqjxhVJ+UVy1Is66Mkjrg4UUNKKyE1KCQLhxk1I1wG+6Qa53E6+cvefzin79wrPiYk1OkgJ4NKwKZbTrUudoqsj4709mzUOJvGZIXzRFLscCoRmkbrWdjeMjVSUE5Bq1HNWRbvirSy470rFcxqCTNNkORVJZyO/FO+0Amlyi5iSTkVn3IPerckq461UnYEZppBzGZcjrWPdgkmtmfms6dAc1tFESkc/cryay7xDtPFb9zEOazLuP5TxXTTZxVdTlLtdr1a0+XaMUmopjNULWXa2Ca74+9E8uorM6uCYbRUpuOOKxorkBetOluQFJ3DP1qOUlTJdUv1hhPPzHoKzfDgZp5JHHzN3qjdv9ouVLH5R2rd0xFRRsrV6RsK92dDbfdHFWkqlbPwM1ZV65pGqJ2bFQSPxSO/FVZJMcUrFXCWTrVKV+adNMMdaz5rhd3WqUSWx8svJqnPPTJ7pVPWs6e43dDWsYGcpE81zx1qhNOWzzUcjljQsTN1BreMVE55SuUNVJMC5/vf0NZVbWsRFLRWI/jA/Q1i13UfhPHxf8Q9i/ZbGfH+of8AYLk/9GxV9RBcmvl/9lgZ+IOoD/qFyf8Ao2GvqQ4WvEzL+N8j2Mtf7m3mKMItUbmXGTU88vy1kXcx5ryatQ9WjT5mRXU2RWTcNyasTSHBqjKxINc2569GFinMctVaY8VYk+9VaWmj0oFdnxVC7G+rslVZulaQLm9DFuI+uKzpVINbky5zmqNzGNvAroizhkjLmPyVm3DjNaU4IBFZN0OSRXRA4qpWnfg1mzy4PWrFwxGaybl+tdlKNzzqsrCyS9earGUhveonf3qtJJz1rsjTPLq1LHQWF6EI3nmuitbiKYAhhXn8Evz4zWlbuxb5WII9DUTok08QdyuB0xU0Vy8bdciuUsryVWw7EjpWzBcbhnNckqR3KvdHSwXRbcVOFC5PNWbWXOM1z9q5LcGtiyx361zShY6Kc+Y11arKjiqcZ5q4nQVizqiOpMU+gDNZtHRFiDinq9MYUzJpJF3LG+jfzUAcilDinYVydmz3qvK3FKWqFm4pJCbIpSapSnirj9KqSCtUiGzPnHNZ92vy9K1JlqhdD5TW0TCTOY1GP5W4rm5H2ORXXXyZVhXGXWROw969HD6nnYkmWdscGpFLP1JNVY6vWy5xW0lY4VIFiOa1tOkZGUN0qsqVMgxWUjRM6COVexp/n4HBrHikKr1xUc2oqg+9WPJc1UjVmvMVSnusAsTisS51QsSEFVGmlmHzEkelaRpNbg5mhc6gxBCkVReeRzwaWG3LHnpV+3tAOSM1dlEhybM7ypJOuTUiWTEdK2khHoKeI8DpRzENGOlkcjIq3Ha4PNXhH7U/ZU8wcpzfiuIJpUZA/wCWwH/jrVyVdn4zGNLi/wCuw/8AQWrjK9DDawPHxqtVPZP2Vzj4g6h/2C5P/RsNfT0z9a+Yf2WBn4g6h/2C5P8A0bDX1BNH1rxM1f709bLLeyM+aSsyc5zWhcDBIrPmHWvFlds+gopFKaqcnSr0ik1XaM5pHoQaRQkU9arSKa13h46VUkh5p2OmFVGRMMVUcVrzRDoaqSQj0qlobN8yuZMo5qpKhxWpLD3qu6YHStkzmmjn7yFsnArGnQ5Oa6e64B4rBul5Jrops4qsTHubcOjYPIFc3dnDEHrXUTvtJ9K53VUXzSRxmvRw7PJxJkSPyaqSOQxq1MOaoydTXpwR8/iJNMVZSGzV+0vPLcE81lZ5p6Ng1pKCZyxrWZ18MoYBh3rStpQFJPauQtLwxKFJ4rZt7nzI/lPBrjqUzvpV7nW6ZIJhlTkCt+z6iuF0K8FtdFZD8jV2ljKDyOhrzq0bHr4eSZtwjkVejFUYDnGK0Ivu1xSPSih4WjGKkBpDzUGoxlyKjZMVOKQ4NAyo4xUTPtq26CqkyAGqsTcb53amNIMVC/GajLU1ElyJi/HWq8rc0heo3bPWqUSXIjkOapXHI5qzI3WqNw+Ac1okYykZF/wDXF33Nw5rrNVnVImLHrwK4y6f5ySepr0cLE8zEzHI3Iq5DLs6VlhuetKrnPU11uB5/PqdAt5Cq/M3NQzaiP8AlkpNZkYyASasKgrJxSNFIk+1zydyBQI2Y5JNKgAIqYFaXoUpjIoAeozVqOIL2FQiQA1IJM0FXLiKKsx4rOWQ5qzFLwKzky0XhTwBUUTZHNSrWTHYcFoIpw6UpFFx2Ob8bDGlxf8AXYf+gtXFV2/jf/kFRf8AXcf+gtXEV6mF/hniY7+Ke0fspDPxD1H/ALBUn/o6GvqK44yK+X/2T+fiJqX/AGCpP/R0NfT12CGOa8nMo3qnp5Z/DMm56mqci1fmXJ6VXdOOleJJWZ9BTlYoMopAgIqy8ftTFTAqbHQp6Fd0qrLHWi68VA6ZFVY1hMyZoTVOaPBrYkT2qjNGeaTR20qhlyQ5BqlNFhTWyUqjdJwRTRrKzRz9zCCCe1Yt5DjIxXVzQ/J0rIvLb2rWEjkqx0OKvkZGPHFc9qTZ69a7zULLcDgVxus2jRTfdJBr08NNXszx8VT7HPSDrVOda05Y6oToea9amz57E0ynilHBoPWkrpPKkrEgNaukzkOI+xrIBxVi1co+4duazmro0pzszqJo8AMOorp/DV/58QRz+8Xg1zVlKs9spPWrFtMbO7jkjGRnBFedWhpY9vDVT0q1kziteBvl5rntMlEyI6ng1txtha8qpGx7lKdy2XFN3VX30rScVhY3uT78UgkGaoPPg1C12BnJrSMRORptIDVaZs1mSarFEDvasq78SW6AhWLNWig3sZSqI1rhyuTms+S62nrWFNrs0xPlxmqE9/dt/BWsaTMZVTqhfKRzTWvUz1rjZb+4XquKrHVpy3CVrGg2YyrHYzXy9jzVC5voiDl1GPeualv52GRxWdO8rEkk1tChfcwlXNvX/MFjb3SoWtZSVEn8OfTNcvcHJ5rsPB0g1ayuvDVywIuQZbQn+GUc4/HH61yt9DLb3EttdRmO4hYo6n1FdtOChojzqtTmKf0oU5wRV/RdPi1O7khmuUtgkbOGbuR2qoifKCK2OW7uSREk1ejjLAelVbdfmHFakQAFYyN4IYsJIp4tjVmPG2pkArJyNlEp/ZjUiWxq+qinhR6VDkaKJREBFTxQnirCqM1Mijis2y0hsSYwDU6jilVelPxxUsoRRRTsU00hHO+OP+QVF/13H/oLVw9dv43/AOQVD/12H/oLVxFephf4Z4mO/intv7JIz8R9SH/UJk/9HQ19T38BIyBXy3+yIM/EnUv+wTL/AOjoa+t5o9w5FcONhzTZ1YGpyRRyrxtnkVBIvNdDPaZPArPntME8c149Sg1qe3TrpmQUqNkrQeEjtULx47Vg42OqNQounFRFKuumahdcVJtGRQlUZNUpU5NaUo61SkFS2ddORRkXmqksYOc1fkqs4oR2wZmTRYzVC4hB6itmUZqjOoq4imjn7q3BJ4rGvLJGB3puHeupuU61m3EddNOVjiqU7nB6noSMrPanDf3DXLXNq6EhlORXp9zD8xIHNZN3YpKdzIMjvXoUsTy7nlYjCKSPM7iEpnII+tVzxXf3umxTDEiD2PpXI6pp7WkuOqHoa9OjiIz0PnMXhJQ1RnDrViEfKagK4NTwVvI4YJ3NjSnKLtzXQW8QljOa53T0Z2GBXYWMGYhng159Y9jDpl3wlemMSW0p+Zc4Ndhby74xXDR2hinMsbbWHP1rf0bUfPhy4KuDgivNqq7uezSlZHQZpjvxRE4dQRSSLkVz2OpSKNxKeayriV8GtiaLINUJoMZ4q4kyZzl6Hkzmq9tp4Jyy1tyQZbpUkUOMcV0RZyyZVhslVfu0kkCrnitFhhaqz4xVJGUmYN7Gpzis3yRmtW9IGao5FbxRzyZCYRioJoRgjFW94pGXdWq0MWzJhkm07ULe7tSRNA4kU+4Oa3fF/wDxOoIfEQVQ077LgL2YY5rMuoxiuh+F62d5rsuhau+2z1OMxRlj8qS4wp/PFbxlcwqI42GygfTWuHlzOZdqxjrj1pywegrQ1LSpdJ1S7sLuPZc2shjYeo7GlROO1OUiYRRVih2/WrKripVSn7KycjZRI1zU8bYoEdDLgVmy0WEep0Oaz1YjrVmOQY61DNEWTUsY4FQK4NTowPeoKLKgYoqINilLZpWAeTUZNBNRyOAtFho5/wAasDpkQ/6bD/0Fq4uus8XPusI/+uo/ka5OvVwv8M8TH/xj3H9kL/kpWpf9gmX/ANHQ19dtzXyH+yJ/yUnUv+wTL/6Ohr65LVz4n4zTCr3BrgVUmjBqwxqJjXHKKZ3QujNlhxniqkkR5rYkAPaqkqDFck6R2U6jMoxgHJFVJxWtKgxVCda5Z07HbSndmZKKpyKa0ZF61TlU81zuJ305FCVaqSCr8i1TmXGaVrHdTZUdc1UnjyavlfWoZFppmrVzLlj7VQnhHpW3IoqnNHkdK0jKxlOJgy24J6VSmtvat+WMZ6VUljA5xmtVI5pwML7FFIzCTgAda5XxDYh4nCrkryK7e4wN3HWsW+j3duK7KFRpnm4rDqUTyqZCrEHrU1smSK1/EtgLe7BUYVxmqNpHg5r2faXhc+ceHcZ2N7RYQq89TXU2ifKOK5nTW2sNxrrtOAbGelcFWR6NKnYljj+ccDFJJC6XQKjCegrWSAHBAp7QZHSuKTOuCsFpIeBV/qtUYYyrYrQUfKKzaOlMhkTiqVwnWtGTpVKbmmhPUy3T58GlAxU0vWoHbArSLMZoinYjpWNqN1s4J5qzql8tvGxJ5PQVyV1ctMxJJNdMIXOWcrE9zdbiearNOegqudx5zSqjDkVuo2OeUizHngk1ZVh61nvceWuSOlV21E9FWrUWzO5cu5BkjNVVRzIjxOUkQhlYHBU+tMjZpm55rQtoju5pr3WS9To/EM/9u6TFrb/NqEGIbvHUgdG/nWBDtPI6dq1dHmS0vlExza3A8uVT0+tZ93aHT9Vms2JIQ7kb+8tEmEVYeF4pG61Mq8USL3rJs2QijIFKUB7UqdKfnFK4FeSPjIqI5WrTciqz8Zp7hcVJqmjnA5rOclaiacg8Ucg+Y2xcrjrQbpR3rn3uT61GJ3Peq5Bc5vyXwHQ1Wkuy5xms1HJ6mplH51LjYakVvEs7PpkUZUYEoO7v0NcxXQ+ISfsKf9dB/I1z1d+G+A8bHfxT279kf/kpGpf9gmT/ANHQ19bsa+SP2SP+Skal/wBgmT/0dDX1oxrmxPxnThF+7GsetRMacx61C5rlZ3RQjPxUMjUrVE5rGRvGJFM3FUJjnNXZelUpRXPJXOuloU5ByaqSrV2TrVeQVhKJ3QZQkTmqUq81pyLxVGZeazlE7acio2BUEgB6VZdarMuKhLU6L6FWUVC68GrMoGartVolsozJgmqM/Ga05e9Ztz156VSM5GTcnkis6YZrSuh8xqhKOD61vTZy1NUct4yi/wBFtJP9rbXNxHaxArofGM7COCHPAO7FcxE2XOa9ilrA8CvZVDZtZcMtddpM/A3GuGhfBHNbtheFcc8VjUiaU5HoUEqlQAasKwPeuc0+6BUEmtWK4BArilE6FI0Ywu6pt2KorMKeLhcdazszXmRK7g96quRTJJwAaz7rUI4lYswGPWtI02yHUSJrhgATWPf3qxqSDWPqXiIZZYTmsGa+kuG+duvauqFE5p1kWL+6a5kYk8Z4qtGmetMQgnmrEddEY2OSUrjljH0qdVAHSmKaUvgU2iSCZFLAMPlJ5qle28cN9shO6MgHNW5pOtUlbfMKqOhEjU0y0eaeOOCPe7HgDvVzaUmcMu1gcEelR6bNJbSpLE2106GpN/mSszdWOTWcnqEQYBiAe9XJYm1TSnuEcC6sThgerL/kVUOOuajtbtrXVUP/ACxm/dv+NC1B6EsTiRFK9COKWQcUzXbKfQdXmsLhTHgCRM/3T0qob5cDJFHKXGZYEgXrR53pWfLPk5BqGScgcGmoj5zUabFVJrjAPNZ73TetV3mZquNMlzLEtwT3qHex71EMnrUyrV2SErsBk9aljHHNIq+tTKKhstRHIMVIDUdGagdilrxzZp/10H8jWDW3rZ/0RP8AfH8jWJXdh/gPIxv8U9t/ZJOPiPqP/YJk/wDR0NfWjdK+Sf2TDj4jaj/2CpP/AEdDX1oz8VyYr4zrwa/djH71Ew6092qFnrlbO+KZG3FQSNUrNVaU81jI6IIbI3FVJDU8jZFVXPWsmdNNEDnmoXqVu9RuwrK1zqiVpBVSVc1dkIqs4qHE6abKTrVeRKuSCoX6VnY6k9DPlQE1Vdea0JBzVWRetFhMoyr1rNuk61rSjOazrlTg0EsxrgcGs2fAFatypBOaybkZzitIPUwqbHnviKVpb98nheBWUrYrZ163dbp3K4zWC5x2r36NnBHzOKbU7llZcdKuW90QRzWQHx0pwkOauVO5jHEWOptdSKEfPW/baqhQfPzXm5lPrTluZE+65rF4a5f1k9TXVEAyXH51RvvFltbZUDcw9K86a6mPWRvzqBiWOSc0RwivqTPFPodfe+MppciGPaPWsK81a5uzmWQ49KzRkClreNKMdkc8q8mTrKT1NSLLz1qpTlPNU4ohVJF9ZiOlTrcEDGaz1apA1ZuJqqly8t0R3pTcn1qiWzTd1Ty3H7QsTTE96ZDIA4NRIjSxyOCNqdc1Er4FWoEuob0EwxwasLIM5zXOrcFelS/bmqHTuNVDdknx3rPup+DtIDAhh9RVBrl370nL9TSULblOR2Os6lL4r0wX96d19BCse8DkhcCuXRrV7GTzDILg/wCrwOPxrS8LytFeGAOEhkUhyfSoNS00297IkDBom5BHSqukJJszA7AdaCzNVn7BN6VLFYvn5hSckWoNlARknmpFh9a10sDTxpwY/NmpdQ0VJmQqAU8KK1/7LUD7xoGmoP4jUOojZUjLVTTgPatMWWOnNJ9jIqectUzOxSVom2x1FMMA9KXOkHIzB1kYtV/3x/I1i10XiKPZZIcf8tB/I1ztehh3eB4WPVqx7V+ydx8RdRyQB/ZUnX/rtDX1eWU/8tI/++hX59eGtPi1TWoLS4Z1idXJKEA/KjMOoPcVYk0ZBM6o7bVYgEkf4VjWpxlU1ZthZzVP3Vdep99PjH30/wC+hURH+2n/AH0K+DI9DRjgu35//Wq1F4aibrK/5j/CoeDT+0dMcTU/l/E+45Bx95f++hVSTPdl/wC+hXxgnhOFsfvZfzH+FTp4MgbrNN/30P8ACpeBT+1+BrHGVI/Y/H/gH2E/+8v/AH0Khb3ZfzFfJKeB4G/5bT/99D/CnHwRZqcPPcD/AIEv+FN5Z/e/AtZlNfY/H/gH1bIAejL/AN9CoGUDqyj8RXyZqXhzSLKPP2ud5OyB1z/6DXNz2QSQgblXsGOTUf2Z/e/D/gj/ALYnH/l3+P8AwD7ScDGd6f8AfQqu5X++n/fQr4yjtUc43GhrMA43GpeVr+b8P+CUs9kv+Xf4/wDAPsZ9v95P++hUDlP76f8AfQr5GXTgRkvikaxRTyzH6VDypfz/AIf8E0XEE/8An3+P/APrGQj+8n/fQqBwCD8yf99CvlI2a9i341G1sF6k0llkP5/w/wCCV/rDP/n1+P8AwD6lkAB+8v8A30KpThSfvL+dfMnk0hiHvVf2XH+b8P8Agkf6wz/59/j/AMA+jbmFXzhl/OsW6tt2cZwPSvCnQKuR619HG3UDYBxisquDVBJ3udOGzGeNk4uNred/0OF1WySaNty89BXBahbNBcMjDoa9X1S2KEntmua1jSUuY2aNf3mPzp4avyuzHi8NzxujgDxSZq7PaSRMQ6kH3quyYr1FJPY8CdGSZGDRQRiimRawtLim5ozQV6jsUhozQaBWCjOKQUUAySMk5pwNRA46U4NSaJTJN3PWkJpope1Kw7iEnPBIHp60lLSgc0xasAuakWI46UqLipkPFQ2axiMCAY4qRV9BUqRFjwKvW9k7ckGs5SOiFK4mlxfOXxWu0O9fpTIbby1AFXYIyBXNOZ1QpFJIyCRipo4M1eFtu5FSJDjisnM6I0yokHNTfZquRwjNSFQM1LmWqZntCAKiaL0FaEi9qgZalSL9mVdnFNKVY2801l7Uc4cpWZM1G8XtVormmkUXuS0cz4sXGnx/9dR/I1yldj4xGNNi/wCuw/k1cdXr4P8AhnzeZfx36I3PBcgi8SWzt0Cy/wDotq6EwZZuOpzXP+CoVn8T2cbnCtvz/wB8NXqy6faxrwma0lS553DDTSpteZx0NsQcVp21meM1tGG3VvljFCxlm+ReK3VJmntUiC3tlrVtNO81k2jIbpWvBols9oJixzjkA1jXaOJStmXVQeDW0aJm8QiXUDa6dGWuHVAo9a4HW/Ec07tHYREJ03kda7K4tftsAiuoiz9NxrG11bLw/GIbqNZJ5BlAv8NRUTiioz5jhY98bM8isznnJqGRGkYllPNdOl3aSbQU+Y+tXRZW8kYZAOa8+daUWaxppnIwW8SsofIz1PpVm5jgRitujyqP4sV0gsIB1QU5reJVwqio+sNlvDnGXgd8eWjJjtTo122pEit5uRjjtW3eWRYnZxVUWEq8l93tW6lzIxdFoy5HUggdqquM9Kvz2jKSdpUVFHbMzYx1qfhEkVNnrUTjmtOW0dULEcDvUMccW3LMAaamS4ozp1IjGRjmvpOQYGe9fON/jaMdM19KOoIxXLjX7ifqepky/eT+X6mPeQl0YEbgecVhyQ4YjB4rrpEGeBWPdW/zk4ryFo7n0XLdWOUvdMjuA2V5rFn8NuSTF+td4YPRaaYR6V0QxEo7HJUwsXrY8zu9AuYwTtz9BWbNYSx9VP5V608A7iqlxaoRgxKfwrphi31OGpgIvVHk7xsvUUzpXfalocMqsUTaxrltQ0mW1ycFl9QK66deMzz6uElDYys0ZzTjGQaNhArfQ5bNbiAc0Yp4BFJt5pXFYQUAU8LS7ec0XCwKtPCGnKMVKAcVDZUY3K+w04LU3ln0qeC2Mh4FS52NYU7lZVJOBV60s2kcDBwav2umA4NbVtbBFAxzWE6q6HZTola105EAzyavrbhRwKnRKnSPOK5pVDrjSKog5zipUhA7VaWKpFj56Vk5m0aZAsfHAqRIeeRU6xmpAhqHI1UCtsIppXmrRSmFCDSuPkKrJmoZIqvlajZeKLj5TP8ALpjR89KvlOelMZRnpQpCcSlspjpVtl9qidapMzlE5TxoMaZF/wBdh/6C1cZXbeNxjS4v+uw/9BauJr2sH/CPl8z/AI79Edx8FNGbxB8TdG0tGCNP5+Ce22CRv/Za+kLn4bNpsz/apkcD+EV85fA/UZdJ+KOi3sBxJH5+PxgkX+tfTWr+I5p4vNmYhupOetepQjdXZ5zqOKsh+lfDLTr2w+2GbHzYKnsKsTfDvTLUBkm356CuVHim4jQrBMwU9QKlPiq5Kfuy28Dg1vZLcScpF1/Dlv5zRLNsUHpVxvDum28O6SVCR1rj31C/lneRy2W61T1PVJLC2N1ezYgQ5YE8t7CnzxRSpSNjxw+naD4Tk1UIMOfLhB/jb2r5wmubjUb9prly7k5GTnb7V1nxG8a3XjS7tY4kMGl2oC28OMc+pxWFY6VOSzKu4jk+1c1azR00myzp9sC/zenH1rctrcpF1+b0rPsI2jlVpB07VrzOu9dgIyK8qrY9CDHW0e9W39abJAAcA05HK0jbiRiuCWjOuMrohMHNSrbRlOVGavQ2hdA3XND27KcAVrCrYmUbmNd2kZVsoOe9YF7ZGPDwN8w7V2d4ka2xaZT7VipYSSQyzSsI06qD6V1RqKRzygc9qOqNJYLCY1Qr1I71z+/3rRlTzrh0HzAGqE8ZRyMYrWNjkqRaEuGDQDH94fyNfTDDtXzLMpEAyO9fT5SuDMNIx+Z7GSL35+i/UhxVO7iHpWmqetV7hBury2z6NGWIeKY0FX/LpfLyKyuNq5kvFUDQ5bmthoM1EbbFUpGbgYdzCMHism5tFfJKg11U0GQazriDAPFb06lmc9SimcBq2kbSZYxx3FYUkRUkEV6VcQAo2VBrlNV08qWcLx7V6FKvfRnl18L1RzhWk21eS13Ng5Apz2RBwDkV0+0RwexZQx7U4Kc9K0I7QnjbVmLTieuKl1UNUWZSISauQwk1qR6WMc1dt9OA61nKqjWFEy4bIv16VpWdkE7VpxWYUcCrUUGO1c86uh006WpXhgVR0qxHFzVlYalSH2rnczrjTIUhqVIjmrscHyipVi9qzczojTKqRcdKkEWOlWQnHpS7ajmNFAr+X608R8VPs4pwjouUolYx1G0dWyhzTGWi4WKjJiomSrhWo2WhMTRVZOKgdcVdK1BIKZDRUZeKhZatsvFQMMHmqizNo5Px4uNKh/67j/0Fq4Su+8f/APIIh/67j/0Fq4GvcwX8I+VzVWxD9EdB4DvY9O8V2N1O22OPzMn6xsP616jefEPTW/cu7FfYV4tYIJLuNGOFOc/lW5NDYpE0cEbPIf4zXowm4xscEYc2p6A/j/S4V/cwO7e9VW+I7txb2u30yK4KK23HG39K6Oy0TyrT7TMMDsDWU6rR1Qpmv/wmWtXPKIqr9KwfEN/f6wVW7mbYv8A6Guo0zS5Xt1kZAFPatFdGttu+WMVySxDOiNK5wFlaSMiAp92tm1EsbEb2UHqPWuwh0mDaDGoANXE0aIIWlCgDvWEsU2axopHM2kMZALAE1baPcMRxr+VaEkUAJWFBx3p8Fn5nQ4FcsqzZ0xpow2hbdwOasxQYTLDFbP8AZhU5BzVa4tpwQgXKt6Vjz3NVGxNYqBGfLIPFRMnzljSww3VmGOzdHVCW+MkmFGOeaauJlm9MAhDSgbVrltWnN6HggBQfzFdPcW63NmY0YGRuvtVZdHVIQuDvx1FbQbRhI4r7JFBH93D+tZGoIBJ04rr9XsrqwZWZPOhbsByKxdRFvcwfuwUlHY12wbZhOJy9+cwqAOhr6eIyx+tfMOoE+WFK4Ib86+qY4sqK5sw+CPzO/Jv4s/RfqVQpqG4j/OtLysdqq3K8147Z9Ityh5ZpdhqcilC5PSs7spog2e1RyJ7Vd2cVE6UXFYzpI/QVSuI613XmqtxHntVxdhOJhXEYweKxb6AOGBHBrqJos9qzp7cZ6VtGpY5507nEXlkYj8o4qtErqeRXW31ruGay5LUDtXRCtdanFOgirAoJ6VejiB6CoooCrA4rRgSqdQy9kNii46VetoPanQxAir9vFwKz5zSNIjWAelSxwe1XUiyOlWI4R6VnKZvCmUVg46VKlv04q+IsDpT1j6cVlzm/IVlhwOlBi9quhPajZSbLUTPaM0BParxjzSeXU3LSKypx0pdtWNnFIVFHMJorFfaoyntVwqKjKUXFYpuntULLV51qvIOtUmS0VHWq8i8VcYVAwq0ZtFNhVeQ81dcAVRvJEgRnkYKoGSTWkVd2RjUmoK7OW8fn/iUQj/puP/QWrga6DxRq/wDaEgjj/wBSjZHufWufr3sLBwppM+QzCqqtZyRc0lDJqEKjqc/yNdd5dvDCY0G+X19K5PRQx1OHa204bn/gJrp4Dubci5PrW7lZCw8OZDbeGbzfmQBM5zXRm3nu4kVZQABwtZQFy/3VGKt29vdrhskVzzlc7FTaOhS6u7GBFYAheOlTJeXV1H9wbepwKr2lwDCqzjLDuauW86hwIU3ewrkcHJmi0LFszgfNuAFNvL196qZMITgitWGxvL8BnURRjtig+G0uLpAWLRLyx96pYY0UiK2hgZB+8QZHrWhBZMgDAgg1ZfQrNI+GCgeprKu5hprqPtQaLPSlLD6G0ZFx43LBFBLHpinLBcRKcx5PuKhi8RmOINaW+4dyaWTxNdSj5bPBrn+rsvmIUgubmdjcHy407dqoXNpbCR5AVx1JFR6ne6lLFI8gMUZHT1rD0nTL+8DMXYIT0rSNFozbJ7K6jhmlYtwTxmtaLUoCnLKTUX/CP7V/eZrJutAkDtJas2V5K1qqZi2a1xJHOMnGK5jxDpEcy+dD8rgdu9Xo1lXG8mor138tueMV0wjYym9DzjW42jQBx827/Gvq1UAHHSvljxIcgHvv/oa+riuAR6Vx5j8Mfmd2TfxZ+i/UrMMmqs0YzV8L7VBImSeK8WTPporqZ5izTxFgVY2c0u0VncqxUZagkFW5FwarSg9qaFYquOaikWp2HNRkUxFGVOelU5YiTxWpIPaq7JzzSTE4mPNBkHNZs1uN3Aro5Ywaoywc9K1izKcDH8nnpU0cPPStDyeOlKIsVpzmHIRwx8Vft4+lRRJV+BOlLmGokiJU8S805UqaJOaiTNEhFWn7alVKfsrM0SIAgpdgxVgJS7KLlFRk4phSrjJUbqKVxFQik2cVPtFGKYiuU4pjLVo1HIOKaEU5BzVdxVqRearsODVollSTiqztjNWZutUZ2CKzMcAc1cVd2MZz5VcguJliVnkIVR1JrznxVrpvZWhgbECn86n8W68bl3t7clYh1PrXIMcmvZwmG5fekfNZhjm3yRBjk02lpK9E8Nu4UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an endoscopic image of a greater curve plication procedure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_50_26415=[""].join("\n");
var outline_f25_50_26415=null;
